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Colorectal cancer is the second most common malignancy in the Western world after 
non-melanoma skin cancer.1 In Europe, colorectal cancer has an annual incidence of 
450,000 cases.2 In the Netherlands, over 15,500 patients were diagnosed with colorectal 
cancer and over 5,000 patients with colorectal cancer died in 2015.3 Most cases of 
colorectal cancer are sporadic, with hereditary forms being 3-5% of all cases.4, 5 
As in many other solid cancers, the extent of disease progression is a very important 
determinant of prognosis in colorectal cancer. The most commonly used staging 
system is the TNM classification of malignant tumours (TNM), developed and 
maintained by the Union for International Cancer Control (UICC). In the Netherlands, 
the 5th version of the TNM classification is used for colorectal cancer.6 The T category 
indicates the invasiveness of the primary tumour into the bowel wall, while the N 
category indicates the number of regional lymph nodes containing cancerous cells. 
The M stage indicates the absence or presence of distant dissemination to other 
organs. These three indicators are combined into a tumour stage ranging from stage 
I to stage IV (Table 1). 
Tumour stage is also used to determine the treatment approach. Patients with stage 
I-III colorectal cancer (i.e. no distant metastases) should be considered for treatment 
with curative intent by radical resection of the primary tumour with en-bloc resection 
of the draining lymph nodes. In rectal cancer, surgery is preceded by (chemo)
radiotherapy for patients with an intermediate or high risk carcinoma and is not 
followed by systemic therapy.7 In colon cancer, the focus of this thesis, adjuvant 
systemic therapy may be considered in patients with stage III or high risk stage II 
disease.8-10 However, to date it has not been established convincingly which individual 
TABLE 1. THE 5TH TNM CLASSIFICATION FOR COLORECTAL CANCER
Stage T N M
0 Tis N0 M0
1 T1 N0 M0
T2 N0 M0
2 T3 N0 M0
T4 N0 M0
3 Tis-T4 N1-2 M0
4 Tis-T4 N0-2 M1
Tis=the tumour has not grown beyond the mucosa; T1=the tumour is confined to the submucosa; T2=the 
tumour has grown into (but not through) the muscularis propria; T3=the tumour has grown into (but not 
through) the serosa; T4=the tumour has penetrated through the serosa and the peritoneal surface extending 
directly into other nearby structures and/or causing a perforation of the bowel; N0=no lymph nodes contain 
tumour cells; N1=there are tumour cells in up to 3 regional lymph nodes; N2=there are tumour cells in 4 or 
more regional lymph nodes; M0=no metastasis to distant organs; M1=metastasis to distant organs.
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patients with stage II may benefit from adjuvant chemotherapy. Current guidelines 
list five high-risk characteristics in stage II colon cancer: T4, a poorly differentiated 
tumour, lymphovascular or perineural invasion, tumour perforation and inadequate 
sampling of lymph nodes defined as the sampling of <10 or 12 lymph nodes 
depending on the guideline.9-11 However, no prospective trials have demonstrated 
the predictive value of these features.12 In the Netherlands, 10-15% of all patients 
with ‘high risk’ stage II receive adjuvant chemotherapy.11, 13 In Stage IV colorectal 
cancer, 10-20% of the patients are eligible for curative treatment using a combination 
of local and systemic treatment options. The rest of the patients with stage IV 
colorectal cancer can be offered palliative (non-curative) treatment.14 
The overall 5-year recurrence free survival rate in colorectal cancer is estimated to 
be 95% in stage I, 80-85% in stage II and 60-70% in stage III disease.15 Similar, the 
5-year disease specific survival rate is higher in stage I-II (91%) compared to stage III 
(72%) and stage IV (13%).1 Although one may conclude that TNM staging holds 
considerable prognostic value, it should be noted that there are profound individual 
differences in clinical outcome within each stage. For example, one in five patients 
with stage II will develop recurrence of disease and these patients may thus be 
considered undertreated. Despite this recurrence rate, the small benefit of treating 
all stage II patients to prevent recurrence is too small to outweigh the hazards of 
chemotherapy for all patients which underlines the need for reliable criteria to 
identify the patients at risk.16, 17 The introduction of adjuvant chemotherapy in stage 
III colon cancer has reduced the recurrence rate from 50-60% to 30-40% suggesting 
adjuvant chemotherapy may be effective in 20% of all patients with stage III colon 
cancer.8 However, this also means 80% is over- or mistreated since 30-40% will still 
develop recurrent disease despite receiving adjuvant chemotherapy and roughly 
half of the patients with stage III colon cancer will never develop recurrence disease, 
irrespective of chemotherapy.
Therefore, additional factors are needed to complement the tool box of clinicians to 
come to a more tailor-made treatment for each individual patient. Currently, most 
effort in this field of research focuses on molecular biomarkers, characteristics 
enabling reliable disease identification. Well-maintained patient cohorts with both 
clinical data and biomaterial are key to conduct this type of research.
Due to a lack such patient cohorts, the MATCH study was initiated in 2007. The MATCH 
study (MicroArray and proteomics Technologies to analyse Colorectal cancer and 
Hepatic Metastases) was designed and set up to identify prognostic markers to predict 
colorectal cancer behaviour and response to treatment especially as far as liver 
metastasis is concerned using state of the art technology. The aim was to include a 
homogeneous population of approximately 1,000 patients with colorectal cancer 
201748 Robert Coebergh_binnenwerk.indd   11 12-12-17   15:41
CHAPTER 1
12
without metastatic disease and treated with curative surgical intent. In a collaborative 
project with the hospitals in Rotterdam-Rijnmond and neighbouring regions both 
detailed clinical data as well as high quality fresh frozen tissue samples of the resected 
primary tumours were collected. Eight hospitals (Maasstad Hospital, Rotterdam; Reinier 
de Graaf Hospital, Delft; Elisabeth-Tweesteden Hospital, Tilburg; Albert-Schweitzer 
Hospital, Dordrecht; IJsselland Hospital, Capelle a/d IJssel; Ikazia Hospital, Rotterdam; 
and Sint Franciscus Hospital, Rotterdam) ultimately included over 2,500 patients from 
the 1st of July 2007 onwards. This large number appeared to be necessary to include 
the estimated population of 1,000 patients without introducing a large variance in 
patient and tumour characteristics. All patient data and samples used in this thesis 
were collected as part of the MATCH study unless stated otherwise.
BIOLOGICAL SYSTEMS
The TNM staging system insufficiently reflects the clinical course of individual patients 
and does not represent the great variance in the biological behaviour of colorectal 
cancer. To fully understand the expansion of a malignant tumour, more insight is 
needed in the process of gene expression and the consecutive events within cancer 
cells. Briefly, the genetic and epigenetic processes can be split into four subsequent 
steps or layers of activity. 
The first layer is the genome, which consists of DNA (Deoxyribonucleic acid) molecules. 
The human genome comprises of 23 chromosome pairs with a total of 3 billion base 
pairs, and contains all information required to grow and develop, to function and to 
reproduce. On estimate, the human genome encodes 20,000-25,000 protein-coding 
genes (1-1.5% of the total DNA).18 Some of the regions that do not code protein encode 
noncoding RNA molecules (discussed below).19 Other parts of the DNA sequence play 
structural roles in chromosomes such as centromeres, which have an important role 
during DNA replication, and telomeres, which protect the end of the chromosome 
from fusion with neighbouring chromosomes and from deterioration.20, 21
The second layer is the epigenome, a system that comprises all chemical compounds 
that regulate the accessibility and gene expression without changing the DNA 
sequence.18 Epigenetic mechanisms are involved in the majority of biological 
processes in the human body including cell and tissue identity. During the 
transformation of multipotent cells (i.e. stem cells) to a specific type of cell, epigenetic 
changes silence genes involved in alternative lineages and genes necessary to stay 
pluripotent.22 In the large intestine, undifferentiated progenitor cells arising from 
stem cells located at the base of the crypt move upward while dividing multiple times. 
During this upward migratory process, cells differentiate into various cell types of 
the epithelial layer of the large intestine such as Paneth cells, goblet cells and 
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enterocytes.23 The effect of epigenetic marks can be long-lasting and irreversible 
which is essential in tasks such as memory or behaviour, but can also be reversible 
which is useful to regulate adaptations and development throughout life.24 Epigenetic 
phenomena can be categorized into two main categories, DNA methylation and 
histone modification. Methyl groups can attach to segments of DNA molecules, 
generally turning gene activity and subsequently protein production off. Histone 
proteins form spool-like structures to enable DNA to be wound up into chromosomes. 
A variety of chemical tags attached to these histone proteins can be discerned by 
proteins in cells. These chemical tags determine whether that region of DNA should 
be exploited or ignored in that cell, thus affecting its functionality.
The third layer is the transcriptome, the collection of all transcripts which are RNA 
(RiboNucleic Acid) molecules.18 The transcription of DNA into RNA molecules is the first 
step in gene expression, the process of carrying out an instruction encoded in the DNA. 
The transcriptome can be divided into messenger RNA (mRNA), which codes for 
proteins, and non-coding RNA, which include amongst others transfer RNAs, ribosomal 
RNAs, long non-coding RNAs and microRNAs. MicroRNAs are thought to function in 
mRNA silencing and post-transcriptional regulation of gene expression.25, 26 
The fourth and last layer is the proteome, the entire set of proteins expressed by 
the genome.27 Proteins are involved in virtually every process within cells, and have 
structural and mechanical functions. Proteins are produced through translation, a 
process during which the mRNA molecule binds to a ribosome, which then produces 
a chain of amino-acids based on the sequence of the mRNA molecule. When 
completed, this chain is folded to form the actual protein. During or after the 
synthesis, proteins can be modified in a process called posttranslational modification 
which often affects protein activity. 
ONCOGENESIS
Oncogenesis, the formation of a cancer, is the transformation of normal cells to 
cancer cells. This process is characterized by changes at cellular, genetic and 
epigenetic levels. These changes disturb the balance between cell proliferation 
and programmed cell death (apoptosis) thus leading to abnormal cell numbers. 
In 2000, the biological properties of malignant tumour cells underlying this 
imbalance were described as the hallmarks of cancer.28 In 2011, the same authors 
revisited, refined and extended these hallmarks, and gave an overview of the 
possible therapeutic approach per hallmark.29 This rapid expansion of the concept 
of cancer hallmarks illustrate the complexity of cancer and the pace at which 
progress is made (Figure 1). 
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Two important categories of genes involved in oncogenesis are oncogenes and 
tumour suppressor genes. Oncogenes are genes which stimulate the development 
of cancer while tumour suppressor genes would inhibit the development of cancer. 
The activation of an oncogene generally requires only one hit while loss of function 
of a tumour suppressor gene requires inactivation of both alleles of a gene known 
as the “two hit model”.30 These hits can occur on the level of the epigenome 
(hypermethylation) or genome (mutations). Mutations can be categorized in small- 
and large-scale genetic alternations to the nucleotide sequence of the genome. Small-
sized genetic aberrations include substitutions, insertions or deletions of one (Single 
Nucleotide Polymorphism [SNP]) or a few nucleotides (Figure 2). Large-scale 
aberrations include deletions, insertions, duplications, inversions and translocations 
of (part of) a chromosome arm (Figure 3). Mutations can cause a loss- or gain-of-
function, can produce a gene product which acts antagonistically to the wild-type 
allele, can be lethal or can restore or rescue the original phenotype. 
Furthermore, mutations can give rise to fusion genes, i.e. hybrid genes formed from 
parts of two previously separate genes, that may produce fusion transcripts and 
fusion proteins with altered functionality.31-33 
FIGURE 1. THE REVISITED HALLMARKS OF CANCER
(adapted from Weinberg et al.)28
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In colorectal cancer, the majority of the cancers develop through the classical 
‘adenoma-carcinoma sequence’ which was first described by Fearon and Vogelstein 
(Figure 4).34 These cancers derive from adenomatous polyps which arise from normal 
the colon epithelial layer due to cellular inactivating mutations of the APC tumour 
suppressor gene which leads to activation of the Wnt signalling pathway. In the 
classical model, this early event is followed by activating mutations of the KRAS 
oncogene, downregulation of SMAD4 tumour suppressor gene through either loss 
of chromosome 18q or inactivating mutations, and inactivating mutations of the TP53 
tumour suppressor gene.35-37 These cancers often display chromosomal instability, 
which is characterized by large-scale mutations giving rise to DNA copy number 
FIGURE 2. SMALL-SCALE MUTATIONS AND SUBSEQUENT CHANGES IN THE AMINO ACID SEQUENCE
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variations and/or aneuploidy, meaning cells containing an abnormal number of (part 
of) the affected chromosomes.38 Mechanisms behind this type of genomic instability 
involve defects in chromosomal segregation, centromere and telomere dysfunction, 
and deficiencies in DNA damage response.39-44
A minority of the colorectal cancers (10-15%) develop through alternative genetic 
and epigenetic alterations. Instead of chromosomal instability, these tumours display 
microsatellite instability (MSI), a result from inactivating mutations or promoter 
hypermethylation of DNA mismatch repair genes. 46, 47 Due to inactivation of these 
mismatch repair genes, tumours accumulate many small deletion or insertion 
mutations in microsatellites, elements of 1-6 nucleotides located throughout the 
genome. The repetitive nature of these sequences makes them vulnerable to these 
types of replication errors, which are normally repaired by the mismatch repair 
system. Tumours with MSI are mostly diploid in contrast to tumours with 
chromosomal instability, but accumulate 10-100 times more mutations.48 MSI is 
observed in 12% of all sporadic colorectal cancers and virtually in all patients with 
Lynch syndrome, one of the two types of hereditary colorectal cancer.49 
Tumours displaying MSI mostly contain epigenetic and genetic changes in the Wnt 
signalling pathway other than alterations in the APC gene.50 Activating BRAF oncogene 
mutations are often and almost exclusively restricted to sporadic microsatellite 
instable colorectal cancers, although KRAS mutations do occur in a minority of the 
cases.51 Importantly, mutations in the KRAS and BRAF gene are mutually exclusive.52 
Lastly, mutations in one or more genes such as TGFBR2, IGF2R and BAX provide a TP53-
independent mechanism of progression to carcinoma in these tumours (Figure 4).45
Colorectal cancers are also instable at an epigenomic level, which can be global 
hypomethylation or widespread CpG island hypermethylation at specific gene 
promoters called the CpG Island Methylator Phenotype (CIMP).53 (Hyper)methylation 
FIGURE 3. LARGE-SCALE MUTATIONS
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at these promoter regions leads to gene inactivation, which is thought to be the 
initiating event in these colorectal cancers. This phenomenon is present in almost 
all tumours with aberrant methylation of MLH1, the key mismatch repair gene in 
sporadic microsatellite instable colorectal cancers.54 
CONSENSUS MOLECULAR SUBTYPES
In 2015, an international consortium published “The consensus molecular subtypes 
of colorectal cancer”.55 The consortium used a total of 18 CRC gene expression-based 
data sets (n=4,151 patients) to show marked interconnectivity between six 
independent classification systems which resulted in four subtypes of colorectal 
cancer (Consensus Molecular Subtype [CMS] 1 to 4). Each subtype is characterized 
by distinctive biological features (Figure 5). Some of these features predominantly 
occur within one subtype such as MSI while other features such as KRAS mutations 
are less linked to a single subtype (Figure 5).
In an aggregated survival analysis which included patients with stage I-IV colorectal 
cancer who underwent divergent treatments, patients with a CMS4 tumour had a 
worse relapse-free and overall survival compared to patients with a CMS1-3 tumour 
(Figure 6). However, due to the above-mentioned heterogeneity the relevance of the 
CMS classification regarding clinical outcome and prediction of response to therapy 
in clinically relevant subgroups needs to be refined.
FIGURE 4. THE ADENOMA-CARCINOMA SEQUENCE
(adapted from Walther et al.)45
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BIOMARKERS IN CLINICAL PRACTICE
Currently, MSI is the only molecular biomarker used in stage I-III colorectal cancer 
to guide clinical decision making and inform the patient on the prognosis of the 
disease.11 Patients with a microsatellite instable tumour have a better prognosis 
compared to patients with a microsatellite stable tumour.56 Furthermore, patients 
with microsatellite instable stage II-III colon cancer have very little to no benefit from 
chemotherapy.57, 58 In contrast, recent studies have shown very promising results for 
immunotherapy in patients with treatment-refractory progressive metastatic 
microsatellite instable colorectal cancer.59 
FIGURE 6. CMS1 (YELLOW), CMS2 (BLUE), CMS3 (PINK) AND CMS4 (GREEN) WITH KAPLAN-MEIER SURVIVAL ANALYSIS 
IN THE AGGREGATED COHORT FOR OVERALL SURVIVAL (N = 2,129) (LEFT), RELAPSE-FREE SURVIVAL (N = 1,785) 
(RIGHT)
On the x axis is the time in months and on the y axis the portion of patients without an event (death [left] 
of relapse of disease [right]). (adapted from Guinney et al.)55
FIGURE 5. THE BIOLOGICAL FEATURES ASSOCIATED WITH THE DIFFERENT CMS GROUPS
CIMP=CpG island methylator phenotype; MSI=microsatellite instability; SCNA=somatic copy number alterations. 
(adapted from Guinney et al.)55
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OUTLINE OF THIS THESIS
As mentioned, 15-20% of patients with stage II colon cancer will develop recurrence 
of disease after curative surgery. Against the background of the information 
described above, the aim of this thesis was to identify biomarkers in colon cancer 
tissue at any molecular level that may help to identify these patients, thereby enabling 
a more personalized treatment.
The quality of tissue sampling and tissue storage is pivotal for successful translational 
research. In Chapter 2 we report the quality of a random set of fresh frozen samples 
from the MATCH study. The excellent preservation of RNA and DNA in fresh frozen 
tissue samples allows for high-throughput methods such as RNA sequencing to be 
used to reveal the presence and quantity of RNA in tumour samples. The 
interpretability of genomics data strongly depends on the bioinformatics pipeline 
used to process the data. In Chapter 3 we present a new normalization method 
‘GeTMM’ (Gene length corrected Trimmed Mean of M-values), which generates 
normalized RNA sequencing data suitable for both between-sample normalization 
as well as within-sample analyses. We compare GeTMM with existing normalization 
methods with respect to distributions, effect of RNA quality, subtype-classification, 
recall of differentially expressed genes and correlation to RT-qPCR data. In Chapter 
4 we investigate the interconnectivity of the tumour stage and tumour biology in 
(reflected by the Consensus Molecular Subtypes (CMS)) in colorectal cancer, and 
explore the added value of this knowledge in patients with stage II colon cancer. 
In Chapter 5 a systematic analysis of oncogenic fusions is presented, which resulted 
in the identification of several known and novel fusion genes. We introduced some 
of these fusion products in cell lines to assess the biological potential of these fusion 
genes to drive malignant development. In Chapter 6 we report a study on the 
prognostic value of the Spleen Tyrosine Kinase (SYK) gene, which has been posed as 
a marker for predicting both poor and favourable outcome in various epithelial 
malignancies including colorectal cancer. In Chapter 7 the validation of a metastasis-
specific microRNA signature and the underlying biology of these microRNAs is 
described. In Chapter 8 and 9 the design, proceedings, governance, opportunities, 
and pitfalls of three nationwide cohort studies designed to facilitate research by 
generating and sharing standardized high quality data is presented.
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ABSTRACT
The growing interest in the molecular subclassification of colorectal cancers is 
increasingly facilitated by large multicenter biobanking initiatives. The quality of 
tissue sampling is pivotal for successful translational research. This study shows the 
quality of fresh frozen tissue sampling within a multicenter cohort study for colorectal 
cancer (CRC) patients. Each of the seven participating hospitals randomly contributed 
ten tissue samples, which were collected following Standard Operating Procedures 
(SOP) using established techniques. To indicate if the amount of intact RNA is 
sufficient for molecular discovery research and prove SOP compliance, the RNA 
integrity number (RIN) was determined. Samples with a RIN < 6 were measured a 
second time and when consistently low a third time. The highest RIN was used for 
further analysis. 91% of the tissue samples had a RIN ≥ 6 (91%). The remaining six 
samples had a RIN between 5 and 6 (4.5%) or lower than 5 (4.5%). The median overall 
RIN was 7.3 (range 2.9–9.0). The median RIN of samples in the university hospital 
homing the biobank was 7.7 and the median RIN for the teaching hospitals was 7.3, 
ranging from 6.5 to 7.8. No differences were found in the outcome of different 
hospitals (p = 0.39). This study shows that the collection of high quality fresh frozen 
samples of colorectal cancers is feasible in a multicenter design with complete SOP 
adherence. Thus, using basic sampling techniques large patient cohorts can be 
organized for predictive and prognostic (bio)marker research for CRC.
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INTRODUCTION
Colorectal cancer (CRC) is the second most common malignancy in the Western World.1 
As in all cancer research, there is a strong trend towards molecular subclassification 
of CRC.2 The studies conducted to identify these molecular and clinically relevant 
markers demand large numbers of patients with accurate long-term clinical data 
combined with high quality tissue samples to be able to use state of the art techniques.3,4 
Subsequently, the standard enclosed formalin-fixed paraffin-embedded tissue can be 
used to develop assays for daily clinical practice. Therefore, large multicenter 
biobanking initiatives are needed to facilitate these research efforts.5,6 However, 10% 
of the fresh frozen tissue samples collected for research purposes are unsuitable for 
molecular analyses. This is due to multiple non-modifiable factors such as tissue type, 
intrinsic patient factors, warm ischemia time (extraction of the resection specimen 
after ligation of the large vessels) and modifiable factors such as cold ischemia time 
(tissue transport from the operating theatre to the pathology lab), the conservation 
(fixation/stabilization) method, subsequent transport and the storage of the tissue 
samples.7,8 The RNA Integrity Number (RIN), first described in 2006, is currently a 
common standard used to assess tissue quality.9 This method became well accepted 
to measure the SOP adherence of quality in tissue banking.10 
The current study assessed the tissue quality of the MATCH study, a multicenter 
cohort study in the region of Rotterdam, the Netherlands, enrolling patients with 
CRC and obtaining fresh frozen tissue samples in one university hospital with 
experience in tissue sampling and storage by dedicated personnel, and in six non-
university teaching hospitals that are not used to nor standardly equipped and 
staffed for routine fresh frozen tissue sampling. 
MATERIAL  AND METHODS
MATCH STUDY DESIGN
The MATCH study is an ongoing multicenter cohort study including adult patients 
with CRC undergoing curative surgery. The participating centers include one university 
hospital (Erasmus University Medical Center) and six non-university teaching hospitals 
(Elisabeth-Tweesteden hospital, IJsselland hospital, Ikazia hospital, Maasstad hospital, 
Reinier de Graaf Hospital, Franciscus Gasthuis). The MATCH study was approved by 
the Medical Ethical Board of the Erasmus University Medical Center, Rotterdam, the 
Netherlands (MEC-2007-088). All patients provide written informed consent for the 
collection of longterm clinical data and storage of tissue samples. The study is an 
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integrated approach using clinical patient care in non-university hospitals with 
university-based facilities for tissue and data storage. The rationale of this study was 
to identify subtypes of colorectal cancer, related prognostic markers and outcome 
of treatment. Liver metastases was defined as primary outcome defining a good or 
dismal outcome of disease progression as liver involvement has been demonstrated 
to be the main factor to determine long term outcome.
CLINICAL DATA
Medical specialists of departments of Surgery, Pathology, Gastroenterology, 
Radiology and Medical oncology were consulted. Clinical data included reports of 
colonoscopy, radiology and pathology, as well as surgical reports and postoperative 
complications. A standard case record was created in a web based multicenter access 
database. The follow-up of these patients was standardized in all hospitals following 
an intensive follow-up schedule according the national CRC guidelines.11
TISSUE SAMPLING
All tissue samples were handled following a Standard Operation Procedure (SOP) 
provided by the study team at the start of the study. In short, resection specimens 
were transported (at room temperature without any conservation fluids) from the 
operating theatre to the pathology department, immediately following removal of 
the specimen from the patient. At the pathology department the specimen was 
handled at room temperature and within two hours after resection samples were 
snap-frozen as described below. When the 2 h time limit was exceeded, no tissue 
samples were taken. 
Macroscopically, one to four tumor samples and one to two healthy colon tissue 
samples of 0.5–1 cm3 were taken by the pathologist. Tissue sampling for the MATCH 
study was not allowed to interfere with the standard pathology routine needed for 
clinical practice. Tumor and normal tissue were stored in labeled cryovials and snap 
frozen in liquid nitrogen or dry-ice.12 Samples were then stored at lowtemperature 
refrigerators (-80˚C) in the hospital of primary surgery and in batches transported 
to the central tissue bank (-196 ˚C liquid nitrogen barrels) at the university hospital. 
Of all new tissue specimens stored in the central bank, on a yearly base 2% is tested 
for quality, by determining the RNA integrity.10,13
TISSUE QUALITY ASSESSMENT
To assess the tissue quality of the samples collected in the MATCH study, we randomly 
selected 10 tissue samples per participating hospital, representing about 4% of the 
entire collection. Samples that were exposed to neoadjuvant chemotherapy and/or 
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radiotherapy were excluded as this may damage tissue resulting in failure of analysis.
RNA quality was determined by measuring of the RIN.9,14 For RNA isolation, 10–20 
tissue slides of 10 lm were cut. One slide was colored by hematoxylin and eosin 
(H&E) stain for morphological confirmation of the diagnosis. For RNA extraction, 
the slides were put in a Qiazol Lysis buffer and shaken for ten seconds to homogenize 
the tissue. RNA was then extracted using the miRNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to the method suggested by the manufacturer. The integrity 
of RNA was measured by the Bioanalyser (Agilent Technologies, Santa Clara, CA, 
USA) using the lab-on-a-chip, RNA 6000 nano assay. This is an automated system 
based on electrophoretic separation. The RIN is directly calculated by applying an 
algorithm on the ratio of 18S/ 28S ribosomal RNA bands. A tissue sample with a RIN 
of ≥ 6 is believed to be of good quality (Figure 1a).15 Samples with a RIN < 6 (Figure 
1b) were measured a second and if consistently low a third time. When the RIN was 
still low, the case was discussed with the technician to see if any deviation from 
protocol (e.g. during the freezing procedure or sample preparation) could explain 
the low RIN. When samples were measured multiple times, the highest RIN was 
used for further analysis.
FIGURE 1A. IMAGE INTACT RNA (RIN 9.0), OBTAINED FROM THE ELECTROPHEROGRAM AND VIRTUAL GEL
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STATISTICAL ANALYSIS
Statistical analyses were performed using SPSS (IBM Corp. Released 2012. IBM SPSS 
Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). Categorical data were 
described as frequencies with percentages and continuous data as median with the 
range. The Chi square test was used to compare categorical data, for continuous 
data the One-way ANOVA test was used. A p value less than 0.05 was considered to 
be statistically significant.
RESULTS
In total, 70 random samples were selected for analysis out of the 1700 samples 
collected in the study period 1st October 2007–1st January 2013. During the workup 
and data quality check, three samples were excluded leaving a total sample size of 
n = 67. Two tissue samples were exposed to neoadjuvant radiation therapy and one 
tissue sample was too small.
Out of the 67 samples, two samples were analyzed two times (3.0%) and seven samples 
three times (10.4%). The median overall RIN of all samples was 7.3 (range 2.9–9.0). The 
majority (n = 61) of the tissue samples had a RIN ≥ 6 (91%). The remaining six samples 
had a RIN between 5 and 6 (4.5%) or lower than 5 (4.5%) (Figures 2 and 3).
FIGURE 1B. IMAGE PARTIALLY DEGRADED RNA (RIN 3.3), OBTAINED FROM THE ELECTROPHEROGRAM AND 
VIRTUAL GEL
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Three of the seven samples that were measured three times had a RIN < 5 and were 
discussed with the technician. However, the low RIN could not be attributed to 
protocol deviations. The median RIN for a center specialized in tissue sampling 
(university hospital) was 7.7 and the median RIN for teaching hospitals without a 
wide experience in this field ranged from 6.5 to 7.8 (Table 1). The overall median RIN 
of the non-university teaching hospitals (median RIN = 7.3) did not differ significantly 
with the median RIN of the university hospital (p = 0.39) (Figure 4). When using the 
specialized university hospital as a reference, the median RIN of one non specialized 
teaching hospital (hospital 6) had a significantly lower median RIN than the university 
hospital (p = 0.02). However, a median RIN of 6.5 is still well above the cut-off of 6. 
Interestingly, the range of RIN for the non-university teaching hospitals tended to be 
larger than the range of RIN if the university hospital (Figure 3).
FIGURE 3. BOX PLOT WITH THE RIN PER HOSPITAL
FIGURE 2. THE RIN DISTRIBUTION IN 67 SAMPLES
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FIGURE 4. BOX PLOT WITH THE RIN FOR THE UNIVERSITY HOSPITAL AND NON-UNIVERSITY HOSPITALS
TABLE 1. MEDIAN RNA INTEGRITY NUMBER PER HOSPITAL
Hospital Number of samples Median RIN Range P-value
1: University hospital 10 7.7 6.8 - 9 0.391
2 9 7.3 5.9 - 8.1
3 10 7.2 4.3 – 8.2
4 10 7.8 5.8 – 8.7
5 10 7.4 3.3 – 8.7
6 9 6.5 6 – 7.8
7 9 7.5 2.9 -8.1
All Samples 67 7.3 2.9-9
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DISCUSSION
This study shows that the collection of high quality fresh frozen samples of CRC is 
feasible in a multicenter design including hospitals for which fresh frozen tissue 
sampling is not part of the daily routine. In our study, 91% had a RIN ≥ 6 and thus 
can be used for highly demanding gene array assays.
The RIN was developed and published in 2006 to meet the need for a reliable 
standard to estimate the integrity of RNA samples.9 A comparison study comparing 
a subjective evaluation of the electropherogram, the 28S–18S peaks ratio and the 
RIN showed a superior result for the manual and RIN method over the ratio method.15 
Nowadays, the RIN is widely used to quantify the RNA quality of samples and select 
samples for expression analyses. However, the cut-off used to select ‘high quality’ 
samples varies in literature, ranging from a RIN of 5–7. These cut-offs can be based 
on the recommendations in a manufacturer manual or on the experience of a lab.16-
19 At our hospital, we use a RIN of ≥ 6 as the cut-off which qualified 91% of the samples 
as high quality samples. When samples repeatedly have a RIN < 6, they may be 
excluded to prevent a transcript specific bias, or analytical or bioinformatics steps 
specifically dealing with the low quality samples should be included in the 
methodology.20,21 Furthermore, samples with a RIN < 6 can still be used for RT-qPCR 
applications in which only short amplicons are analyzed.
The quality of RNA expression in tissue samples is dependent on multiple factors 
such as tissue type, intrinsic patient factors, warm and cold ischemia time, the fixation 
method and the storage of the tissue samples. While tissue type and intrinsic patient 
factors cannot be modified, other factors (i.e. ischemia time, fixation method and 
the storage of samples) can be influenced. The RIN can be used to determine large 
influences during the pre-analytical phase. Smaller differences can be assessed based 
on RNA expression analyses.22 For fresh frozen samples, the most important factor 
appears to be the ischemia time and freeze thawing effects after freezing. A recent 
review specifically addressing the effect of cold ischemia on RNA stability concluded 
that in most studies only minimal changes in the RIN were observed (≤10%) during 
a cold ischemia times of 1–6 h.23 One outlier reported a significantly decreased RIN 
of 44% in samples with a cold ischemia time of 1.5 h compared to samples with a 
cold ischemia time of 10 min.18 However, the 28S:18S ratios did not significantly 
differ.18 Importantly, the definition of cold ischemia time differed between studies 
and often the cold ischemia time in the operating theatre was not taken into account. 
Furthermore, the effects of warm ischemia time are often ignored while they most 
likely interact with the effects of cold ischemia time. This may be explained by the 
fact that this factor is hard to reliably score and is considered to be a non-modifiable 
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factor since attempts to minimize warm ischemia time may affect patient care. Such 
nonmodifiable influences can only be documented to obtain a tool for determination 
of this influence.24 Although we did not specifically assessed the association between 
ischemia time and the RIN in our study, the maximum cold ischemia time was 2 h 
since this was included in the SOP. Thus, the high percentage of high quality samples 
in our study is in line with the current literature. For the few samples with consistently 
low RIN values, no protocol deviations were found suggesting the low RIN was caused 
by non-modifiable factors.
Our study shows that SOP compliance was positive in all the cooperating hospitals 
and high quality fresh frozen tissue sampling is possible in a multicenter setting 
including both university and non-university hospitals. These findings support the 
feasibility of emerging large-scale ‘fit-for-purpose’ biobanks to facilitate the 
increasingly complex field of fundamental and translational cancer research.5,6,25
In conclusion, our study shows that the collection of high quality fresh frozen samples 
of CRC is feasible in a multicenter design and using basic sampling techniques. Thus, 
large patient cohorts can be organized for predictive and prognostic (bio)marker 
research for CRC.
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ABSTRACT 
BACKGROUND
Current normalization methods for RNA-sequencing data allow either for intersample 
comparison to identify differentially expressed (DE) genes or for intrasample 
comparison for the discovery and validation of gene signatures. Most studies on 
optimization of normalization methods typically use simulated data to validate 
methodologies. We describe a new method, GeTMM, which allows for both inter- and 
intrasample analyses with the same normalized data set. We used actual (i.e. not 
simulated) RNA-seq data from 263 colon cancers to compare GeTMM with the most 
commonly used normalization methods (i.e. EdgeR, DESeq2 and TPM) with respect 
to distributions, effect of RNA quality, subtype-classification, recurrence score, recall 
of DE genes and correlation to RT-qPCR data. 
RESULTS
We observed a clear benefit for GeTMM and TPM with regard to intrasample 
comparison while GeTMM performed similar to EdgeR and DESeq2 in intersample 
comparisons. Regarding DE genes, recall was found comparable among the 
normalization methods, while GeTMM showed the lowest number of false-positive 
DE genes. Remarkably, we observed limited detrimental effects in samples with low 
RNA quality. 
CONCLUSIONS
We show that GeTMM outperforms established methods with regard to intrasample 
comparison while perfoming equivalent with regard to intersample normalization 
using the same normalized data. These combined properties enhance the general 
usefulness and comparability to public gene expression sources which provides an 
important advantage over existing normalization methods in the era of data sharing.
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BACKGROUND
In recent years, the analysis of the transcriptome has switched from using microarrays 
to the potentially more powerful and informative massive parallel sequencing of 
cDNA (RNA-seq).1 In RNA-seq, sequence reads are aligned to a reference genome, 
and the number of reads mapping to a feature – such as a gene – is a measure which 
is proportional to both the length and abundance of the said feature. Before 
performing downstream analyses, normalization has to be performed to correct for 
differences between sequencing runs (e.g. library size and relative abundances). 
Current normalization methods allow for either inter- or intrasample comparison. 
The two most commonly used normalization methods when interested in DE genes 
between samples (intersample comparison) are EdgeR2 and DESeq3, 4, which show 
consistent good performance compared to other methods.5-8 Notably, these methods 
do not correct the observed read counts for the gene length, which is theoretically 
irrelevant for intersample comparisons. However, this approach does not allow for 
intrasample comparison, because a longer gene will get more read counts compared 
to a shorter gene when expressed at equal levels. Thus, samples can seem highly 
correlated without correction when in fact the correlation is much lower after length 
correction (see Supplementary Figure 1), and in extremis can be correlated based 
on gene length instead of the expression levels. This problem extends to correlation 
based methods where for example a panel of genes of a sample is correlated to 
another sample, as is often done in hierarchical clustering (correlation is used as 
similarity metric). Furthermore, classifiers based on correlation of an established 
signature gene panel to a new sample such as the consensus molecular (CMS) 
subtypes in colorectal cancer will yield erroneous results without correcting gene 
expression levels for gene length. 
The most commonly used normalization method that includes gene length correction 
is TPM (Transcripts-Per kilobase-Million)9, as other methods like RPKM1/FPKM10 
(Reads/Fragments Per Kilobase per Million reads, respectively, proved to be 
inadequate and biased.5, 6, 11, 12
Ideally, a normalization method should generate a data set on which both between-
sample and within-sample analyses can be performed. We therefore introduce 
GeTMM (Gene length corrected, Trimmed Mean of M-values), a novel normalization 
method combining gene-length correction with the normalization procedure TMM, 
as implemented in EdgeR, to allow both inter- and intrasample comparison with the 
same normalized data set. We used true (i.e. not simulated) RNA-seq data of a large 
cohort of primary tumors of 263 colon cancer patients, and normalized these data 
using our new method GeTMM, alongside EdgeR, DESeq2 and TPM.6 We investigated 
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several properties of the normalized data sets with regard to distribution, effect of 
RNA quality, subtype-classification (i.e. the CMS classification)13, a clinical recurrence 
score14, recall of DE genes and correlation to RT-qPCR data generated from the same 
samples. The main objective of this study was to determine if GeTMM performs 
equivalent to the other normalization methods with regard to intersample analyses, 
and if and to what extent gene length correction influences intrasample analyses. 
METHODS 
The main objective of this study was to determine if GeTMM performs equivalent to 
the other normalization methods with regard to intersample analyses, and if and to 
what extent gene length correction influences intrasample analyses. 
DESCRIPTION OF COHORT
Fresh-frozen tumor tissue of 263 colon cancer patients of the MATCH study, a 
multicenter observational cohort study, who underwent surgery in one of seven 
hospitals in the Rotterdam region, the Netherlands, were used. Inclusion criteria and 
additional clinical characteristics have been described.15 
RNA ISOLATION, CDNA SYNTHESIS,  QPCR AND RNA-SEQ
Detailed description of the RNA-isolation has been described previously16, 17; briefly, 
RNA was isolated from 30 µm sections using RNA-Bee® according to the manufacturer’s 
instructions (Tel-Test inc., USA). Quality and quantity of RNA before and after genomic 
DNA (gDNA) removal and clean-up with the NucleoSpin RNA II tissue kit (Macherey-Nagel 
GmbH & Co. KG, Germany) were assessed with the Nanodrop ND-1000 (Thermo 
Scientific, Wilmington, USA) and the MultiNA Microchip Electrophoresis system 
(Shimadzu, Kyoto, Japan). RNA Integrity Numbers (RIN) were assessed using the MultiNA 
Microchip Electrophoresis system after gDNA removal and clean-up (Supplementary 
Figure 2 evaluates the relation between Agilent’s BioAnalyzer RIN value and the quality 
as measured by MultiNA). cDNA was generated from 1 μg total RNA with the RevertAid 
H Minus First Strand cDNA synthesis kit according to the manufacturer’s instructions 
(Fermentas, St Leon-Rot, Germany). RT-qPCR was performed with the Mx3000P QPCR 
machine (Agilent Technologies, the Netherlands) using ABgene Absolute Universal or 
Absolute SYBR Green with ROX PCR reaction mixtures (Thermo Scientific, USA) according 
to the manufacturer’s instructions. The intron-spanning assays to quantify levels of 33 
transcripts by the delta-delta Cq method were assessed as described before16, 17 and 
are summarized in Supplementary Table 1.
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For RNA-seq, 500 ng of total RNA after gDNA removal, clean-up and removing 
ribosomal RNA using Ribo Zero (Illumina, USA), was used as input for the Illumina 
TruSeq stranded RNA-seq protocol (paired-end). Libraries were pooled and 
sequenced on Illumina HiSeq2500 (2x101bp) or NextSeq (2x76bp) instruments. Pool 
sizes and the amount of samples per run were determined based on the percentage 
of tumor cells estimated from histological examination.15 We used the STAR 
algorithm18 (version 2.4.2a) to align the RNA-seq data on the GRCh38 reference 
genome (settings are listed in the Supplementary Methods). 
Gene annotation was derived from GENCODE Release 23 (https://www.gencodegenes.
org/). To obtain exon specific counts for CDK1 and MKI67, all unique HAVANA exons 
for each gene were extracted and used in FeatureCounts19 with the following settings 
“–t exon”, -O and –f. These settings, and the absence of –p (for paired-end counting), 
ensures that reads that overlap multiple exons are counted for each of these exons. 
This ensured all evidence for the presence of an exon was counted.
NORMALIZATION OF RNA-SEQ DATA
The raw read-counts of all samples were merged in a single read-count matrix. This 
matrix was used as input for the different normalization methods. The most 
commonly used RNA-seq normalization methods are implemented in EdgeR2 and 
DESeq2.3, 4 Both these methods do not employ any gene length normalization since 
their aim is to identify differentially expressed genes between samples and thus 
assume that the gene length is constant across samples. The TPM method adds to 
the previously used RPKM - for single-end sequencing protocols - or its paired-end 
counterpart FPKM. TPM uses a simple normalization scheme, where the raw read 
counts of each gene are divided by its length in kb (Reads per Kilobase, RPK), and 
the total sum of RPK is considered the library size of that sample. Next, the library 
size is divided by a million, and that is used as scaling factor to scale each genes’ RPK 
value. Thus, TPM does correct for gene length, but is lacking a sophisticated between-
sample correction; it does not account for a possible small number of highly 
expressed genes, thus comprising a large portion of the total library size of that 
sample. DESeq2 and EdgeR address this problem by estimating correction factors 
that are used to rescale the counts (see reference 2 and 3 for more details). In short, 
EdgeR employs the Trimmed Means of M values (TMM)2 in which highly expressed 
genes and those that have a large variation of expression are excluded, whereupon 
a weighted average of the subset of genes is used to calculate a normalization factor. 
DESeq2 also assumes most genes are not differentially expressed; here, for each 
gene the ratio of its read count in a sample over the geometric mean of that gene in 
all samples is calculated. The median of the ratios of all genes in a sample is used as 
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correction factor. Where EdgeR estimates a correction factor that is applied to the 
library size, the correction factor of DESeq2 is applied to the read counts of the 
individual genes.
Such normalized data are better comparable between samples, but still suffer from 
the inability to compare gene expression levels within a sample. To obtain a 
normalized data set that is equally suitable for between-samples and within-sample 
analyses, the following GeTMM method is proposed: first, the RPK is calculated for 
each gene in a sample: raw read counts / length gene (kb). In EdgeR, which uses 
TMM-normalization, normally the library size (total read count; RC) is corrected by 
the estimated normalization factor and scaled to per million reads, but in GeTMM 
the total RC is substituted with the total RPK (Figure 1).
Practically, this means calculating the RPK values and using these for input in EdgeR. 
The gene length is calculated using the annotation by gencode: the length of all exons 
with a unique exon_id annotated to the same gene_id is summed. DESeq2 only allows 
integers as input, thus the fractions generated by the gene length correction are 
rejected for input by DESeq2.
EdgeR and DESeq2 are available as R-packages (https://bioconductor.org/), and 
subsequent analyses were performed using R (v3.2.2). To obtain normalized data, the 
raw read count matrix (tab-delimited text file) was used as input. R commands to 
obtain normalized data are listed in the Supplementary Methods. After processing, 
read counts were log2-transformed (setting genes to NA when having 0 read counts).
The CMS classification was performed using the “CMSclassifier” package (https://
github.com/Sage-Bionetworks/CMSclassifier), using the single-sample prediction 
parameter. The Oncotype DX®14 recurrence score was performed as described (ref 
Clark-Lagone) for the RT-qPCR data, and using the RNA-seq normalized values as 
input for the algorithm.The signal-to-noise ratio was calculated as the (mean1 – 
mean2)/Sp, where Sp is the square root of the pooled variance Vp. This is calculated 
as Vp = [(n1 -1) V1 + (n2-1)V2]/(n1+n2-2), where V1 and V2 are the variance for each 
of the groups, and n1 and n2 the sample group sizes.
FIGURE 1. NORMALIZATION USING GETMM METHOD WITH N=NUMBER OF GENES AND I=GIVEN GENE I
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STATISTICS
Statistical tests were performed using R (v3.2.2) and are indicated in the main text, 
p-values were two-sided and p-values and FDRs were considered significant when 
below 0.05.
RESULTS 
We used primary tumor tissue of a cohort of 263 colon cancer patients to generate 
RNA-seq data. We aligned these data to the human reference genome (GRCh38) and 
generated read counts per gene. This read count matrix was used for several 
normalization procedures: EdgeR2, DESeq (version 2)3 and TPM, in addition to a newly 
proposed method of gene length correction in combination with the normalization 
used by EdgeR - GeTMM. To validate the results, the same RNA used for generating 
the sequence libraries was also used for RT-qPCR analysis of 33 genes (see 
Supplementary Table 1 for details). 
DISTRIBUTION OF RNA-SEQ DATA 
The library sizes (i.e. the number of mapped reads) of the samples ranged from 5.8 
to 37.8 million (mean 16.0 million and median 14.2 million). Density plots were 
generated to get an overview of the read count distributions (Figure 2). Panel 2A 
shows the raw read counts (not normalized), which clearly shows a bimodal 
distribution after the initial peak at 0, with peaks at 1.1~1.4 log2-read counts and a 
broader peak at 7~10 log2-read counts. Similar bimodal distributions were seen after 
normalization by DESeq2 and EdgeR (Figure 2B, 2C), which both do not correct for 
gene length. Splitting the EdgeR normalized data by genes < 5 kb and those ≥ 5 kb 
(Figure 2D) shows that the bimodality is largely attributable to the gene length; as 
expected, longer genes generally have higher read counts. Methods employing 
correction for gene length - TPM and GeTMM - both show a more Gaussian 
distribution (Figure 2E, 2F).
COMPARISON TO RT-QPCR GENERATED DATA: INTERSAMPLE ANALYSIS
To evaluate how the different normalization methods affect downstream analysis, 
we measured the expression levels of 33 genes (of which 3 reference genes - HMBS, 
HPRT1 and TBP) using RT-qPCR in the same RNA isolate as was used for sequencing. 
The RT-qPCR data were normalized using the reference genes and were considered 
as the gold standard to compare against. To assess the effect of the different 
normalization methods on intersample analysis, we correlated the normalized RNA-
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seq data of the 30 genes to the RT-qPCR levels over all samples (Figure 3, 
Supplementary Table 2 and Supplementary Figure 3 for a detailed example). 
Overall, correlation coefficients for GeTMM were very comparable to the correlation 
FIGURE 2. DENSITY PLOT BY NORMALIZATION METHOD
Each line corresponds to the distribution of expression levels in a sample. X-axis shows log2 of read counts. 
A-F respectively show the distribution without normalization, and normalization according to DESeq2, EdgeR, 
EdgeR by gene-size (black length < 5kb, red ≥ 5 kb), TPM and GeTMM.
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coefficients for DESeq2 and EdgeR, and higher than the correlation coefficients for 
TPM (Figure 3). For most genes, DESeq2 had the highest correlation coefficients in 
absolute numbers, although the average and median difference with GeTMM showed 
very little difference in individual coefficients (0.014 and 0.008, respectively). 
Furthermore, no significant difference was observed between DESeq2, EdgeR and 
GeTMM (Mann-Whitney test, see Supplementary Figure 4) while TPM resulted in 
significantly lower coefficients compared to the other methods (p=0.02, p=0.04 and 
p=0.03 for DESeq2, EdgeR and GeTMM, respectively). 
0.0 0.2 0.4 0.6 0.8 1.0
Correlation coefficient
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FIGURE 3. CORRELATION TO RT-QPCR DATA OF 30 GENES
Correlation coefficients (x-axis) of 30 genes comparing RNA-seq normalization methods to RT-qPCR generated 
data. Light orange cross: TPM, light blue triangle: GeTMM, dark orange circle: EdgeR and dark blue triangle: 
DESeq2.
201748 Robert Coebergh_binnenwerk.indd   47 12-12-17   15:41
CHAPTER 3
48
The aim of this part of the study was not to appraise the correlation coefficients 
obtained using the RT-qPCR data but to use the RT-qPCR data as benchmark so the 
RNA-seq normalization procedures could be compared with each other. Nonetheless, 
we further investigated the five genes that showed an R<0.6; MKI67, CDK1, ACTB, ESR1 
and ESR2. The poor correlation of the latter 2 genes may be caused by the very low 
expression of these genes according to the RNA-seq data (median read count was 
just 22 for both ESR1 and ESR2), indicating an insufficient sequencing depth for these 
genes. ACTB was the highest expressed gene of the 30 genes and had the lowest 
variance in 4 of 5 methods (0.25, 0.13, 0.16 and 0.16 for RT-qPCR, DESeq2, EdgeR 
and GeTMM, respectively), which may be the reason for the low correlation. For CDK1 
and MKI67, we re-analyzed all 263 samples to obtain the reads per exon. We observed 
a lower expression of exon 1 of CDK1, which may explain the poor correlation 
between the RT-qPCR and RNA-seq data as the RT-qPCR product spans exon 1 and 
2 (Figure 4A). A similar analysis for MKI67 did not show the same effect; here the 
FIGURE 4. BOXPLOTS OF READ COUNTS PER EXON
A shows the expression levels in read counts per 100 bp for each exon in CDK1 (NB no additional normalization 
was performed). The whiskers extend to 1.5 IQR (interquartile range) above the third, or below the first 
quartile, with the median indicated by a horizontal line in the box. The notch indicates the 95% confidence 
interval of the median. B shows the same data for the MKI67 gene.
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RT-qPCR assay spans exon 10 to 11, which both showed similar expression levels as 
the overall gene expression level (Figure 4B). So unless transcript XM_006717864, 
which was the only truncated transcript of MKI67 not covered by this RT-qPCR assay, 
is dominantly present in our sample cohort, we found no obvious explanation for 
this poor correlation.
COMPARISON TO RT-QPCR GENERATED DATA: INTRASAMPLE ANALYSIS
Previously20, RNA-seq normalization methods were compared to RT-qPCR data in 
the MicroArray Quality Control (MAQC) and Sequence Quality Control SEQC effort21, 
using an alternative setup; 996 genes were measured in a single sample by RT-qPCR 
and these were correlated to gene-expression levels as measured by RNA-seq of the 
same sample. To mimic the SEQC results, we repeated the analysis with the RT-qPCR 
data of the 30 genes, and calculated a Spearman’s rank correlation coefficient 
between RT-qPCR and the different RNA-seq normalization methods for each of the 
samples, yielding 263 correlation coefficients per method (Figure 5). 
FIGURE 5. VIOLIN PLOTS RANK CORRELATION BY METHOD
Spearman rank correlation coefficients of 263 samples by correlating each method with RT-qPCR generated 
data.
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GeTMM and TPM (the methods that include a gene length correction) both showed 
overall significant higher correlation to RT-qPCR data than DESeq2 and EdgeR (Mann-
Whitney p<0.0001). GeTMM showed a higher correlation coefficient in 262 of the 
263 cases. 
THE PERFORMANCE OF GETMM IS NOT AFFECTED BY POOR RNA QUALITY 
Next, we repeated the intersample correlation analysis with RT-qPCR data for the 76 
samples that had an RNA integrity (RIN) value <7 after the cleanup procedure (median 
RIN 5.3), and compared these to an equally sized group of 76 samples with the 
highest RIN values (RIN>9, median RIN 9.5). The median library size of the low RIN 
group was slightly lower at 5.58 million versus 6.52 million for the high RIN group 
(Mann-Whitney p=0.02, see Supplementary Figure 5A). However, a principle 
component analysis using all expressed genes showed no separation of the low/high 
RIN groups, regardless of normalization method (Supplementary Figure 5B-E). Next, 
we correlated the RT-qPCR data to the RNA-seq data for each normalization method 
for the low and high RIN group separately, and compared the correlation coefficients 
between the groups. Figure 6 A-D shows a Bland-Altman difference plot for the four 
methods with the mean bias and p-value (Student’s t-test under H0 that the difference 
is 0). Similar to the intersample comparison between RNA-seq and RT-qPCR in all 
samples, the result for GeTMM was similar to EdgeR and DESeq2, meaning the 
correlation coefficients were similar for the low and high RIN group. Normalization 
using TPM did result in significantly lower correlation coefficients in the low RIN group 
compared to the high RIN group (bias= -0.09477, p<0.0001), again indicating an 
advantage for GeTMM compared to TPM. 
GETMM BEST RESEMBLES RESULTS OF DIFFERENTIAL EXPRESSION ANALYSIS 
USING RT-QPCR
The correlation of the different normalization methods to RT-qPCR data already 
showed that GeTMM performed equivalent to EdgeR and DESeq2, but outperformed 
TPM. To further study the effect of the different normalization methods on an 
intersample analysis in a biological relevant context, the expression of the genes in 
left sided and right sided colon tumors was examined, since tumors in the left and 
right hemicolon are known to be biologically different. In short, right-sided tumors 
are frequently hypermethylated, hypermutated, microsatellite instable and BRAF-
mutated while left-sided tumors are frequently microsatellite stable and frequently 
carry an APC and KRAS-mutation.22 This characteristic roughly divided our cohort in 
half (48% left-sided en 52% right-sided). We evaluated all 30 genes in the RT-qPCR 
data set by a standard t-test and after multiple testing correction (Benjamini-
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Hochberg) 8 genes showed an FDR < 0.05: MYBL2, MYC, EPCAM, SYK, APOBEC3B, SPP1, 
CDK1 and IGF1. Next, to check if the RNA-seq normalization methods showed 
differences in the amount of removal/compression of relevant biological variation, 
we calculated the Signal-to-Noise ratio (SNR) for these 8 genes. Again, GeTMM 
performed similar to EdgeR and DESeq2 showing very comparable SNRs, but 
outperformed TPM (see Supplementary Table 3). Next, the statistical tests 
implemented by EdgeR and DESeq2 were run on the respective data sets, while for 
TPM and GeTMM data, Student’s t-tests were used on the 30 genes. Figure 7 shows 
the results of comparing FDR adjusted p-values by normalization method. Out of the 
22 genes that were not differentially expressed according to the RT-qPCR data, 
GeTMM had the lowest number of ‘false positives’ (5/22) compared to EdgeR (14/22), 
DESeq2 (7/22) and TPM (16/22). The recall was similar for all methods (4 out of 8 for 
EdgeR, and 3 out of 8 for the other methods). 
FIGURE 6. BLAND-ALTMAN PLOTS COMPARING SAMPLES WITH HIGH AND LOW RIN VALUES
Panel A-D: for each normalization method, a group of 76 samples with low RIN values (<7) was used to 
correlate expression data of 30 genes to RT-qPCR generated data. The same was performed for an equally 
sized high RIN sample group (>9) and the correlation coefficients were compared. X-axis shows the mean 
correlation, the y-axis the difference (high RIN – low RIN). The blue line indicates the bias (mean of all 
differences), the dashed light-blue lines show the 95% limits of agreement, the dashed black line at zero is 
the identity line (indicating no difference). The p-value is derived from a one-sample t-test.
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GENE LENGTH CORRECTION BENEFITS EDGER IN THE ONCOTYPE DX® RECURRENCE 
SCORE
An often used tool to estimate risk of recurrence in colon cancer is the Recurrence 
Score (RS) algorithm (Clark-Langone) of Oncotype DX®14, which uses a 7 cancer-gene 
panel. The RS was calculated for all samples, based on the RT-qPCR data as well as 
the RNA-seq normalized datasets (Figure 8). The distribution of the RT-qPCR 
generated scores are very similar to the scores generated using RNA-seq, except for 
the EdgeR derived RS. The overall lower scores will impact the RS evaluation, as the 
original RS is scaled such that negative scores will be set to zero. Using EdgeR, 41% 
of patients (n=109) would receive this score. Clearly GeTMM, which uses gene length 
correction on top of EdgeR normalization, improves the range and distribution of 
the RS scores.
GENE LENGTH CORRECTION IMPACTS CMS PREDICTION
Finally, the CMS classification was determined for each sample using data normalized 
by the different methods.13 In this classification five possible groups are predicted: 
CMS1-4 and mixed/indeterminate. The type of classification is based on correlation 
of gene-signatures specific for each subtype to an individual sample, making this an 
intrasample-type analysis. Perfect agreement in the predicted CMS groups was seen 
between DESeq2 and EdgeR (both without gene length correction), and between 
FIGURE 7. NUMBER OF DE GENES BETWEEN LEFT AND RIGHT SIDED TUMORS PER NORMALIZATION METHOD
RT-qPCR generated data were used as benchmark, showing 8 genes with FDR <0.05 (dark-grey) and 22 genes 
FDR>0.05 (black). For the RNA-seq normalization methods, black indicate true negatives (FDR>0.05, matches 
with RT-qPCR), white indicate false positives (FDR<0.05, not matching RT-qPCR), grey indicate true positives 
(FDR<0.05, matches RT-qPCR) and light-grey indicate false negatives (FDR>0.05, not matching RT-qPCR).
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TPM and GeTMM (both with gene length correction). However, gene length correction 
had a considerable impact on the prediction of the CMS groups: 40 samples (15.2%) 
were predicted in a different group when comparing EdgeR/DESeq2 and GeTMM/
TPM (Table 1).
FIGURE 8. VIOLIN PLOTS RECURRENCE SCORE. THE ONCOTYPE DX® RECURRENCE SCORE (RS) OF 263 SAMPLES BY 
METHOD
TABLE 1. PREDICTED CMS GROUP BY NORMALIZATION METHOD
GETMM
EdgeR CMS1 CMS2 CMS3 CMS4 Mixed/
indeterminate
Total
CMS1 46 0 0 0 7 53
CMS2 0 127 0 0 5 132
CMS3 0 0 23 0 0 23
CMS4 0 1 0 5 4 10
Mixed/indeterminate 3 14 6 0 22 45
Total 49 142 29 5 38 263
201748 Robert Coebergh_binnenwerk.indd   53 12-12-17   15:41
CHAPTER 3
54
DISCUSSION
The current study showed that GeTMM performed equivalent to the two most 
commonly used RNA-seq normalization methods DESeq2 and EdgeR (both use no 
gene length correction)6-8, in intersample analyses while outperforming these 
methods in intrasample comparisons. Therefore, GeTMM generates a normalized 
data set directly suited for multiple endpoints. The effects of the different methods 
on the distribution of the gene expression data, samples with different RNA quality, 
subtype-classification, recurrence score, recall of differentially expressed genes and 
correlation to RT-qPCR data were assessed in a large cohort of real (i.e. not simulated) 
data, obtained from 263 primary colon tumors. Importantly, the current study 
focused on the application of RNA-Seq data for differential expression analysis 
between and within samples, thus not covering other applications such as the 
detection of fusion events, variant analysis and gene isoforms.23 With regard to the 
latter, the normalization methods used in this study including GeTMM were not 
developed to distinguish possible isoforms, which requires estimating expression 
on a transcript level using more complex models and different statistics.10, 24, 25 Thus, 
the investigated normalization methods may not be fully appropriate for such 
transcript level analyses. 
The effect of gene length correction on downstream analysis is more important than 
it seems at first, when realizing that several frequently used standard analyses are 
vulnerable to gene length induced bias. Besides the theoretical example stated in 
the introduction, another example is e.g. in breast cancer, wherein the AIMS method26 
was developed to obtain a truly independent single sample classifier to robustly call 
molecular subtypes. Herein, subtype-specific genes are evaluated within each sample; 
e.g. when GRB7 (a 532 bp transcript) is higher expressed than BCL2 (a 239 bp 
transcript), it adds to the evidence for a HER2 subtype.26 Without correcting for gene 
length, this prediction method will not work as intended on RNA-seq data as GRB7 
read counts will be about 2-fold higher compared to the BCL2 read counts, when 
both genes are expressed at equal levels. Evaluating these intrasample-type analyses 
in the current study, GeTMM and TPM produced significantly better results compared 
to EdgeR and DESeq2 when correlating a set of genes measured by different methods 
within the same sample. A similar sort of analysis had been performed previously20 
using the data available from the MicroArray Quality Control (MAQC) effort, wherein 
more genes were measured by RT-qPCR, but only using two samples. In our study 
we used 263 samples, thus capturing the biological variation of gene expression 
levels much better. Regarding clinical applicability, this study showed that gene length 
correction influences the prediction of the subtypes (CMS) of colorectal cancer.13 
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Given the methodology of the CMS classifier, where the gene expression data of a 
single sample are correlated to a centroid of a set of genes that are specific to each 
of the 4 CMS groups, it makes more sense to use a normalization that includes a 
gene length correction, to avoid under- or overestimating the true expression levels 
of genes within a sample. Thus, assuming that the GeTMM classification reflects a 
more reliable prediction, 23 samples would change from a CMS group to mixed/
indeterminate using a method without gene length correction, and 1 sample would 
change from CMS2 to CMS4. In calculating the recurrence score (Oncotype DX®) 
EdgeR showed an overall much lower distribution and assigned almost half of the 
patients below a zero score. This was remedied by including a gene length correction 
(thus yielding GeTMM), resulting in scores very comparable and in the same range 
as the RT-qPCR generated scores. This illustrates the importance of using a 
normalization method like GeTMM, that results in a data set that is suited for both 
intersample as well as intrasample analyses. 
Several metrics were used to evaluate the normalization methods, summarized in 
Table 2. In general, TPM is not sufficient to correct for between-sample differences. 
This echoes previously reported results using RPKM and FPKM normalization5, 6, 11, 12, 
and it is reasonable to conclude that normalization by library size alone must be 
abandoned as viable method to detect DE genes between samples. DESeq2 and 
EdgeR differed only slightly with respect to distribution, correlation to RT-qPCR and 
sensitivity to RNA quality, and not at all with regard to the CMS classification. However, 
EdgeR seemed overly optimistic in identifying DE genes while DESeq2 is more 
conservative, a difference that was also observed by others.8 Given the strong 
similarities between the data after normalization with DESeq2 and EdgeR, the 
differences in the reported DE genes are more likely a result of differences in the 
statistical tests employed by both methods than by the normalization itself.
The analyses using subsets of samples with a low or high RIN value showed 
remarkably little difference in downstream results. It appears that samples with a 
low RIN value may yield sequencing data suitable for expression analyses. Still, this 
TABLE 2. SUMMARY OF RESULTS
NORMALIZATION 
METHOD
GENE LENGTH 
CORRECTION
DISTRIBUTION 
PER SAMPLE
INFLUENCE OF 
RIN
INTERSAMPLE 
CORRELATION
INTRASAMPLE 
CORRELATION
DESeq2 no bimodal no bias ++ +
EdgeR no bimodal no bias ++ +
TPM yes normal bias - ++
GeTMM yes normal no bias ++ ++
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conclusion may be very specific to the entire protocol that was used (RNA isolation, 
library prep etc.) and may therefore not be applicable to all studies and protocols. 
Still, a-priori disregarding samples with a low RIN value for sequencing could prove 
wasteful, though it is prudent to perform a robust QC on the generated sequencing 
data to spot failed samples.
Lastly, this study uses RT-qPCR as standard so the RNA-seq normalization methods 
could be compared with each other. RT-qPCR is known for its precise and reproducible 
measurements and may have a bigger dynamic range compared to the usual 
coverage of sequence data. The downside is that RT-qPCR measures just a small part 
of the gene, may miss or be affected by splice-variants, and can be affected by SNPs 
in the primer regions. In that respect, the RNA-seq generated data may be nearer 
the mark of the actual expression level of a gene. In the future, RNA-seq may replace 
RT-qPCR as the gold standard for expression data, provided a well-founded 
normalization method is used.
This study shows that GeTMM produces a versatile normalized RNA-seq data set, 
appropriate for both inter- and intrasample comparisons. This quality of GeTMM 
should further enhance the capacity of RNA-seq as a solid method to explore and 
compare gene expression profiles, and thus may become increasingly interesting in 
the current era of data sharing efforts.
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SUPPLEMENTARY METHODS
STAR ALGORITHM
The STAR algorithm (version 2.4.2a) was used to align the RNA-seq data on the 
GRCh38 reference genome. Settings were:
--outSAMstrandField intronMotif 
--outFilterIntronMotifs RemoveNoncanonicalUnannotated
--chimSegmentMin 12
--chimJunctionOverhangMin 12 
--alignSJDBoverhangMin 10
--alignMatesGapMax 200000
--alignIntronMax 200000
--outSAMtype BAM SortedByCoordinate
--outSAMunmapped Within
--alignEndsType Local
--chimOutType WithinBAM
--twopassMode Basic
--twopass1readsN -1
--quantMode GeneCounts
NORMALIZATION
The raw readcount matrix (tab-delimited text file) was used as input (x), in which the 
first column holds the geneID from Ensembl that are used as row names, the second 
column the gene length in kb and the remaining columns contain read counts of 
each sample.
# calculate RPK
rpk <- (x[,2:ncol(x)]/x[,1])
# remove length col in x
x <- x[,-1]
# for normalization purposes, no grouping of samples
group <- c(rep(“A”,ncol(x)))
EDGER
x.norm.edger <- DGEList(counts=x,group=group)
x.norm.edger <- calcNormFactors(x.norm.edger)
norm.counts.edger <- cpm(x.norm.edger)
201748 Robert Coebergh_binnenwerk.indd   60 12-12-17   15:41
61
 
RPK/EDGER
rpk.norm <- DGEList(counts=rpk,group=group)
rpk.norm <- calcNormFactors(rpk.norm)
norm.counts.rpk_edger <- cpm(rpk.norm)
TPM
tpm = rpk
for (i in 1:ncol(rpk) ) {
 tpm[,i] <- rpk[,i]/(sum(rpk[,i])/1e6)
} 
DESEQ2
# no group & no design implemented
colData = data.frame(group)
rownames(colData)=colnames(x)
dds<-DESeqDataSetFromMatrix(countData=x,colData=colData, design=~ 1)
dds <- estimateSizeFactors(dds)
sizefact <- sizeFactors(dds)
norm.counts.deseq <- counts(dds, normalized=TRUE)
After processing, read counts were log2-transformed (setting genes to NA when 
having 0 read counts).
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SUPPLEMENTARY F IGURES
READCOUNTS RPK
gene length (kb) sample1 sample2 sample1 sample2 
gene1 0.25 70 78 280.00 312.00
gene2 0.5 251 157 502.00 314.00
gene3 0.75 201 235 268.00 313.33
gene4 1 183 314 183.00 314.00
gene5 1.25 339 392 271.20 313.60
gene6 1.5 572 471 381.33 314.00
gene7 1.75 480 549 274.29 313.71
gene8 2 754 628 377.00 314.00
gene9 2.25 759 706 337.33 313.78
gene10 2.5 904 785 361.60 314.00
SUPPLEMENTARY FIGURE 1. IMPACT OF GENE LENGTH CORRECTION ON CORRELATION
Simulated expression data of 10 genes in 2 samples. Correlation based on read counts show different results 
after correcting for gene length. RPK indicates reads per kilobase.
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SUPPLEMENTARY FIGURE 4. COMPARISON CORRELATION COEFFICIENTS BY METHOD
Boxplots show correlation coefficient of 30 genes, comparing 4 methods to RT-qPCR generated data. P-values 
are derived from the Mann-Whitney test. 
SUPPLEMENTARY FIGURE 5. LIBRARY SIZE AND PCA PLOTS BY RIN
A shows the library size (log10) in samples with low RIN values (RIN<7) or high RIN (≥9). B-E show PCA plots, 
colored by samples with low RIN (red) or high RIN (blue), by normalization method.
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SUPPLEMENTARY TABLES
SUPPLEMENTARY TABLE 1. DETAILS ON THE RT-QPCR ASSAYS
Approved 
Gene 
Symbol
Approved Gene Name Method Assay ID Applied 
BioSystems
F sequence R sequence Probe context sequence reference NM_code exon 
boundery
product 
size (bp)
Specifics
TBP TATA box binding protein SYBR TTCGGAGAGTTCTGGGATTG ACGAAGTGCAATGGTCTTTAG NM_003194.4 3 -> 4 94 Reference gene
HPRT1 hypoxanthine phosphoribosyltransferase 1 
(Lesch-Nyhan syndrome)
SYBR TATTGTAATGACCAGTCAACAG GGTCCTTTTCACCAGCAAG NM_000194.2 3/4 -> 7 192 Reference gene
HMBS hydroxymethylbilane synthase SYBR CATGTCTGGTAACGGCAATG GTACGAGGCTTTCAATGTTG NM_000190.3 1 -> 4 139 Reference gene
CXCL5 chemokine (C-X-C motif) ligand 5 (CXCL5) SYBR  CTGTGTTGAGAGAGCTGCGT GTTTTCCTTGTTTCCACCGTC NM_002994.4 2 -> 3/4 218
MYBL2 v-myb myeloblastosis viral oncogene homolog 
(avian)-like 2
SYBR AGCAAGTGCAAGGTCAAATGG CTGTCCAAACTGCCTCACCA NM_002466.3 2 -> 3 72
ESR1 estrogen receptor 1 SYBR ATCCTACCAGACCCTTCAGTG GCCAGACGAGACCAATCATC NM_000125.3 4 -> 5 186 66 kD variant
VIM vimentin SYBR CAGATTCAGGAACAGCATGTC TCAGAGAGGTCAGCAAACTTG NM_003380.3 4 -> 4/5 158
ESR2 estrogen receptor 2 (ER beta) SYBR CATGCTCCTGGCAACTACTTC GCTCTTGGCAATCACCCAAAC NM_001291723.1 6 -> 7 221
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3B
SYBR CGCCAGACCTACTTGTGCTA GCCACAGAGAAGATTCTTAGCC NM_004900.4 5 -> 6 111
PTEN phosphatase and tensin homolog (mutated in 
multiple advanced cancers 1)
SYBR CGGGAAGACAAGTTCATGTAC CTCTATACTGCAAATGCTATCG NM_001304717.2 7 -> 8 222
CDC20 cell division cycle 20 homolog (S. cerevisiae) SYBR CTTCCCTGCCAGACCGTATC CCAATCCACAAGGTTCAGGTAATA NM_001255.2 5 -> 6 71
SYK spleen tyrosine kinase SYBR GCATCGACAAAGACAAGACAG GGATGGGAACCTGGAAGTTG NM_003177.6 4 -> 6 193
TGFB1 transforming growth factor, beta 1 SYBR GCCCTGGACACCAACTATTG CGTGTCCAGGCTCCAAATG NM_000660.5 2 -> 3 168
CDK1 cell division cycle 2, G1 to S and G2 to M, Homo 
sapiens cyclin-dependent kinase 1 (CDK1)
SYBR GCCGCCGCGGAATAAT CCTTCTCCAATTTTCTCTATTTTGGT NM_001786.4 1 -> 2 86 variant 1+2
IGF2 insulin-like growth factor 2 (somatomedin A) SYBR GCGGCTTCTACTTCAGCAG CAGGTGTCATATTGGAAGAAC NM_000612.5 2/3 -> 4 214
VEGFA vascular endothelial growth factor A SYBR TACCTCCACCATGCCAAG GGTACTCCTGGAAGATGTC NM_001025366.2 1 -> 3 148
IGF1 insulin-like growth factor 1 (somatomedin C) SYBR TGGTGGATGCTCTTCAGTTC GACAGAGCGAGCTGACTTG NM_001111283.2 2 -> 3 191
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 
1)
SYBR TTCCTGATGATGCTACTTCTC GCCCGGATTATGTTGTCTATG NM_001320611.1 3 -> 5 187
ACTB actin, beta Taqman assay AAGCCACCCCACTTCTCTCTAA ATGCTATCACCTCCCCTGTGT AGAATGGCCCAGTCCTCTCCCAAGTC NM_001101.3 6 -> 6 69
EPCAM tumor-associated calcium signal transducer 1 Taqman assay AGTTTGCGGACTGCACTTCA AATACTCGTGATAAATTTTGGATCCA AAGGAGATCACAACGCGT NM_002354.2 4/5 -> 5 72
PSCA prostate stem cell antigen Assay-on-demand Hs00194665_m1 not shared by supplier not shared by supplier GCAGCCAGGCACTGCCCTGCTGTGC NM_005672.4 1 -> 2 82 ONLY V1
MKI67 antigen identified by monoclonal antibody Ki-67 Assay-on-demand Hs00606991_m1 not shared by supplier not shared by supplier AAGATCTTTCAGGAATAGCTGAAAT NM_001145966.1 10->11 137
LEPR leptin receptor Assay-on-demand Hs00900242_m1 not shared by supplier not shared by supplier AATTAATAGTTTCACTCAAGATGAT NM_001003679.3 17->18 76
PTPRC protein tyrosine phosphatase, receptor type, C Assay-on-demand Hs00236304_m1 not shared by supplier not shared by supplier AGAGGCTGAATTCCAGAGACTTCCT NM_002838.4 26 -> 27 81
CDH2 cadherin 2, type 1, N-cadherin (neuronal) Assay-on-demand Hs00983062_m1 not shared by supplier not shared by supplier CACCGTGGTCAAACCAATCGACTTT NM_001792.4 9->10 78
TP53 tumor protein p53 Assay-on-demand Hs99999147_m1 not shared by supplier not shared by supplier CACTAAGCGAGCACTGCCCAACAAC NM_000546.5 8 -> 9 121
FN1 fibronectin 1 Assay-on-demand Hs00277509_m1 not shared by supplier not shared by supplier ACCACTCTGGAGAATGTCAGCCCAC NM_001306130.1 34->35 88
SPP1 secreted phosphoprotein 1 Assay-on-demand Hs00959010_m1 not shared by supplier not shared by supplier GCAGACCTGACATCCAGTACCCTGA NM_000582.2 5 -> 6 84
MYC v-myc avian myelocytomatosis viral oncogene 
homolog
Assay-on-demand Hs00905030_m1 not shared by supplier not shared by supplier AAACCAGCAGCCTCCCGCGACGATG NM_002467.4 1 -> 2 87
BGN biglycan Assay-on-demand Hs00959141_g1 not shared by supplier not shared by supplier GGCATCCCCAAAGACCTCCCTGAGA NM_001711.5 5 -> 6 65
FAP fibroblast activation protein, alpha Assay-on-demand Hs00990806_m1 not shared by supplier not shared by supplier TTTCCAGGCAATGTGGTACTCTGAC NM_004460.3 25 -> 26 67
INHBA inhibin, beta A Assay-on-demand Hs01081598_m1 not shared by supplier not shared by supplier TTGCCGAGTCAGGAACAGCCAGGAA NM_002192.2 2 -> 3 61
GADD45B growth arrest and DNA-damage-inducible, beta Assay-on-demand Hs04188837_g1 not shared by supplier not shared by supplier GTCTCCTGGTCACGAACCCTCACAC NM_015675.3 3 -> 4 66
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TGFB1 transforming growth factor, beta 1 SYBR GCCCTGGACACCAACTATTG CGTGTCCAGGCTCCAAATG NM_000660.5 2 -> 3 168
CDK1 cell division cycle 2, G1 to S and G2 to M, Homo 
sapiens cyclin-dependent kinase 1 (CDK1)
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SUPPLEMENTARY TABLE 2. CORRELATION COEFFICIENTS FOR EACH METHOD COMPARED TO RT-QPCR
ENSG NAME LENGTH (KB) DESEQ2 EDGER RPK/EDGER TPM
ENSG00000115414 FN1 15.601 0.963 0.962 0.963 0.926
ENSG00000118785 SPP1 4.578 0.961 0.957 0.957 0.941
ENSG00000170558 CDH2 5.709 0.915 0.908 0.909 0.865
ENSG00000141510 TP53 9.345 0.914 0.908 0.911 0.795
ENSG00000078098 FAP 3.252 0.908 0.899 0.9 0.88
ENSG00000182492 BGN 2.394 0.877 0.878 0.88 0.811
ENSG00000163735 CXCL5 2.534 0.86 0.858 0.858 0.835
ENSG00000026025 VIM 3.188 0.857 0.845 0.849 0.68
ENSG00000122641 INHBA 7.691 0.853 0.846 0.846 0.737
ENSG00000179750 APOBEC3B 2.823 0.832 0.812 0.815 0.715
ENSG00000167653 PSCA 1.566 0.825 0.824 0.824 0.8
ENSG00000116678 LEPR 14.642 0.82 0.803 0.807 0.737
ENSG00000112715 VEGFA 9.98 0.805 0.777 0.773 0.528
ENSG00000101057 MYBL2 3.445 0.798 0.773 0.77 0.619
ENSG00000081237 PTPRC 7.225 0.793 0.774 0.772 0.626
ENSG00000165025 SYK 5.16 0.793 0.74 0.743 0.383
ENSG00000167244 IGF2 14.849 0.791 0.795 0.794 0.765
ENSG00000017427 IGF1 15.78 0.785 0.784 0.784 0.681
ENSG00000117399 CDC20 2.047 0.771 0.743 0.741 0.621
ENSG00000119888 EPCAM 2.415 0.734 0.701 0.703 0.611
ENSG00000182481 KPNA2 2.766 0.677 0.666 0.673 0.501
ENSG00000099860 GADD45B 2.03 0.661 0.646 0.642 0.524
ENSG00000136997 MYC 8.663 0.66 0.624 0.629 0.442
ENSG00000105329 TGFB1 2.762 0.657 0.644 0.643 0.422
ENSG00000171862 PTEN 10.292 0.653 0.614 0.619 0.43
ENSG00000148773 MKI67 15.667 0.492 0.511 0.516 0.489
ENSG00000170312 CDK1 5.581 0.456 0.419 0.428 0.438
ENSG00000075624 ACTB 1.911 0.347 0.234 0.248 0.145
ENSG00000140009 ESR2 11.903 0.336 0.344 0.347 0.274
ENSG00000091831 ESR1 15.485 0.334 0.345 0.349 0.202
SUPPLEMENTARY TABLE 3. SIGNAL-TO-NOISE RATIOS
GENE DESEQ2 EDGER RPK/EDGER TPM
MYBL2 0.586 0.562 0.560 0.305
MYC 0.541 0.512 0.505 0.218
EPCAM 0.330 0.283 0.279 -0.042
SYK 0.120 0.094 0.090 -0.170
APOBEC3B 0.119 0.106 0.103 -0.048
SPP1 -0.447 -0.453 -0.454 -0.510
CDK1 -0.122 -0.137 -0.141 -0.340
IGF1 -0.017 -0.027 -0.028 -0.146
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ABSTRACT
INTRODUCTION
There are profound individual differences in clinical outcome within tumor stages 
of colorectal cancer. Tumor biology, in conjunction with the traditional TNM staging, 
is a promising way for predicting patient outcomes and treatment efficacy. This study 
was conducted to investigate the interconnectivity between tumor stage and tumor 
biology (reflected by the Consensus Molecular Subtypes (CMS)) in colorectal cancer, 
and explore the added value of this knowledge in patients with stage II colon cancer.
METHODS
The analyses were performed in a large series of colorectal cancer patients of which 
gene expression data was available that could be used to determine the CMS 
classification. The interconnectivity was assessed by investigating the association 
between CMS and TNM, and investigating differential gene expression between 
various TNM stages within and across disease subtypes. Furthermore, the prognostic 
value of CMS in stage II colon cancer patients in light of the issue of stage migration 
was evaluated.
RESULTS
CMS4 was more prevalent in advanced stages of disease, and in stage II colon cancer 
patients with inadequate lymph node assessment. The majority of genes that were 
differentially expressed between tumor stages were no longer differentially expressed 
when stratifying patients according to CMS subtype. CMS held prognostic value in 
stage II colon cancer patients with inadequate lymph node assessment.
CONCLUSION
The results of this study suggest considerable interconnectivity between tumor 
biology and tumor stage in colorectal cancer. This implies that TNM stage in addition 
to disease progression is a reflection of a distinct biological disease process. An 
important advantage of CMS compared to TNM is that it also provides insight in 
tumor biology, which might both predict the prognosis and specific treatment 
options. In particular, we show that CMS could help to guide treatment decisions in 
stage II colon cancers with inadequate lymph node assessment. 
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INTRODUCTION
As in most solid tumors, clinical decision making in colorectal cancer (CRC) is mainly 
driven by clinical and traditional pathological features. Although these features hold 
considerable prognostic and predictive value, one should acknowledge that there 
are profound individual differences in clinical outcome within for instance a single 
tumor stage. Currently, most efforts are directed towards the identification of 
prognostic and predictive biomarkers that complement the traditional features or 
identify a subgroup within a seemingly homogeneous subgroup.1, 2 However, the 
traditional features may very well be interconnected with biomarkers that resemble 
tumor biology, which can hamper such biomarker studies. 
The consensus molecular subtypes (CMS) classification is an upcoming stratification 
tool for CRC defining four groups (CMS 1-4) with distinct clinical features.3 Specifically, 
patients with a CMS4 tumor (‘the mesenchymal subtype’) were associated with a 
worse relapse-free and overall survival compared to patients with a CMS1-3 in an 
aggregated cohort of patients with stage I-IV colorectal cancer.3 In addition, CMS 
subtypes are associated with different responses to currently employed drugs.4-6 
Importantly, the distinct subtypes present with vastly different biological and 
molecular features. These range from frequencies of genetic driver events, the 
presence of microsatellite instability but also stromal composition.3 Furthermore, 
we previously reported that the various colorectal cancer subtypes relate to distinct 
precursor lessions.7 Hence, the CMS taxonomy offers an ideal framework to elucidate 
whether TNM solely resembles disease progression or biologically different entities 
that preferentially present with a specific stage of disease.
This study was conducted to investigate the interconnectivity between tumor stage 
and tumor biology in colorectal cancer, and to investigate the added value of this 
knowledge in patients with stage II colon cancer, a subgroup in which accurate 
prognostication and selection for adjuvant systemic treatment is still an unmet need.
METHODS
PATIENT SELECTION
Patients were selected from two sources. The first source were public data sets for 
which staging information and the CMS classification was available.3 The second 
source was the MATCH study, an independent prospective multicenter observational 
cohort study that was initiated in 2007, in which patients undergoing curative surgery 
for CRC were enrolled. Informed consent was given for the collection of clinical data 
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and the storage and use of biobank samples for research purposes (Institutional 
Review Board number MEC 2007-088). 
AFFYMETRIX ARRAY
A detailed description of sample collection and processing for the MATCH cohort 
was described previously.8 In short, RNA was isolated from 30-mm sections taken 
from the frozen tumor tissue obtained at primary surgery. Only samples with an RNA 
integrity (RIN) value of at least 7.0 were included in the final analysis. Fragmentation 
of RNA, labeling, hybridization to Human Genome U133 Plus 2.0, microarrays 
scanning and the Affymetrix microarray analysis were performed following the 
manufacturer’s protocol (Affymetrix).
CMS CLASSIFICATION
The consensus groups were identified using a consensus clustering approach. This 
approach included the construction of a network followed by network clustering 
using a Markov cluster algorithm9, and cluster evaluation by repeating the first two 
steps 1,000 times. Then, the optimal number of clusters was determined using the 
weighted Silhouette width (R package ‘WeightedCluster’). This approach generated 
four consensus molecular subtypes. A random forest algorithm10 was used to define 
a ‘group classifier’ to classify sets of samples. Furthermore, a ‘single-sample-predictor 
(SSP) classifier’ was developed as an R package to classify future samples in an 
individual fashion. 
The labels from the group classifier were used for the analyses in the aggregated 
data set.3 For the survival analysis in the aggregated cohort of stage II colon cancer 
patients, the raw expression data were normalized in one batch using Robust Multi-
array Average (RMA) and labeled using the SSP classifier.3, 11
BIOINFORMATIC ANALYSIS AND GENE SET ENRICHMENT ANALYSIS (GSEA)
The R2: Genomic Analysis and Visualization Platform (Academic Medical Center, 
Amsterdam, the Netherlands; http://r2.amc.nl) was used to identify differentially 
expressed genes between the different tumor stages and different CMS groups in 
the GSE39582 and TCGA data set.12 For overall differentially expressed genes the 
ANOVA test (false discovery rate (FDR) corrected p<0.05) was used, for individual 
groups the limma-test (FDR corrected p<0.05). For each analysis, a random set of 
200 tumors per group was sampled to correct for the effect of group size on the 
number of differentially expressed genes. Visualization of the genes that display 
significant differences between tumor stages in the whole group of colon cancers 
was done using a t-distributed stochastic neighbor embedding (t-SNE) algorithm.13 
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The basic idea of the t-SNE algorithm  is to minimize the difference between specially 
defined conditional probability distributions that represent similarities, which is 
calculated for the data points in the high and low dimensional representations. The 
central assumption is that the conditional probabilities will be equal if the low 
dimensional mapped points in Y space correctly model the similarity structure of its 
higher dimensional counterparts in X. 
STATISTICAL ANALYSIS
The Chi square test and Kruskal-Wallis test were used to assess differences in patient 
and tumor characteristics among the cohorts. The Kaplan-Meier method was used 
to estimate survival. Survival curves were compared using the log-rank test. Disease-
free survival (DFS) times of >60 months were censored at 60 months. Lymph node 
assessment was considered inadequate when <10 lymph nodes were assessed or 
the number of assessed lymph nodes was unknown. Statistical analyses were 
performed using the SPSS statistical package version 21.
RESULTS
CONSENSUS MOLECULAR SUBTYPES ARE INTERCONNECTED WITH THE TNM 
CLASSIFICATION
To assess the interconnectivity between CMS and tumor stage, we investigated the 
association between CMS and tumor stage in a large aggregated cohort of colorectal 
cancer samples for which detailed staging information was available and which we 
classified previously in molecular subtypes (n=1,713).14 Details on the cohort are 
listed in Supplementary Table 1. We observed that the prevalence of the poor-
prognosis mesenchymal subtype (CMS4) increased with the extent of the disease 
(stage I 20.7%, stage II 23.6%, stage III 32.0% and stage IV 40.1%, p<0.001) (Figure 
1A). As microsattelite instability (MSI) is considered to be a very distinct and well-
defined phenotype that is mostly confined to CMS1 and is well known to infrequently 
present with metastatic disease, we also investigated the distribution of CMS in 
microsatellite stable (MSS) tumors.15 We detected an even more striking trend 
regarding the prevalence of CMS4 cancers in each tumor stage (stage I 12.4%, stage 
II 27.4%, stage III 31.7% and stage IV 39.5%, p=0.001) (Figure 1B). The increased 
proportion of mesenchymal tumors was not dependent on altered frequencies of 
the epithelial type subtypes as we detected similar distributions when CMS2, 
representing the canonical colon cancer subtype with a pronounced epithelial-like 
expression signature and high levels of Wnt target genes, and CMS3 also characterized 
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by high expression of intestinal epithelial specific gene expression but unique 
because of a marked metabolic deregulation, were combined (Figure 1C). Importantly, 
the association between CMS4 and advanced stages of disease was consistently 
observed in the individual cohorts (Supplementary Figure 1 and Supplementary 
Table 2). Together these data indicate that distinct TNM stages represent with 
different distributions of molecular subtypes. Most strikingly, the proportion of 
mesenchymal colon cancers increases with more advanced cancer stage. 
TUMOR STAGE RESEMBLES TUMOR BIOLOGY RATHER THAN DISEASE 
PROGRESSION
In order to test the hypothesis that tumor stage does not only presents disease 
progression but also reflects molecular features, we investigated the changes in gene 
expression between distinct TNM stages and related these to the gene expression 
differences found between molecular subtypes. Initially, we performed a differential 
expression analysis (ANOVA) for individual genes on the MSS tumors. Details on the 
distribution of TNM and CMS is shown in Supplementary Table 3. We assessed the 
number of differentially expressed genes between tumor stages in the total cohort 
FIGURE 1. DISTRIBUTION OF CMS PER TUMOR 
STAGE
Panel A and B show the distribution of the 
CMS groups in the overall cohort (A) and the 
subgroup of patients with an MSS tumor (B), 
respectively. Panel C shows the distribution of 
the epithelial and mesenchymal tumors in the 
subgroup of patients with an MSS tumor (C). 
%
%
%
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consisting of all subtypes, and in the CMS groups separately, by ANOVA. As the total 
number of patients in CMS3, and especially CMS1 because we only analysed MSS 
cancers, was too small we excluded these subgroups for analysis. 
The analysis revealed considerable gene expression differences in the total group 
between TNM stages (Figure 2A). However, when stratifying by CMS, the number of 
differentially expressed genes was significantly less in CMS2 and CMS4 compared to 
the overall analysis (p=0.002 and p<0.001, respectively) (Figure 2A). The far majority 
of the gene expression differences (98%) were observed when comparing the non-
metastasized (stage I-II) with metastasized (stage III-IV) tumors while only marginal 
gene expression differences were observed when comparing stage I vs II and stage 
III vs IV. Of note, especially in CMS4 cancers no differentially expressed genes were 
detected between early stage and advanced disease. This indicates that the 
fundamental biology of these cancers does not change when these cancers progress 
and are primed for metastatic spread (Figure 2A). Visualization of the genes that 
display significant differences between tumor stages in the whole group of colon 
cancers (ANOVA p< 0.05; n=2191) using the t-SNE algorithm showed clear separation 
for the mesenchymal (CMS4) and the epithelial subtypes (CMS2/3) (Figure 2B). To 
more specifically investigate the association between CMS4 and more advanced 
tumor stages, we built a gene signature to segregate stage I-II vs stage III-IV cancers, 
and a gene signature to segregate epithelial (CMS2-3) vs mesenchymal (CMS4) 
subtypes using the top 100 differentially expressed genes. Both signatures were 
used to calculate a TNM III-IV and CMS4 signature score for each sample. Remarkably, 
the two scores were highly correlated (rs=0.85, p<0.001) (Figure 2C), confirming 
marked interconnectivity between more advanced tumor stages and CMS4. These 
analyses demonstrate that the differences in gene expression between TNM stages 
of disease are in essence only a reflection of the relative abundance of the various 
subtypes, and do not reflect changes in tumor biology associating with disease 
progression.
CMS IS ASSOCIATED WITH STAGE MIGRATION IN STAGE I I  COLON CANCER
In order to employ these new insights to a clinically relevant problem we investigated 
the issue of stage migration in early stage colon cancer. In some cases patients that 
in fact have stage III disease are staged as stage II because a positive lymph node 
is missed during pathological assessment, for example due to a low number of 
assessed lymph nodes. This is of direct importance as stage III colon cancer patients 
are treated with adjuvant chemotherapy and sage II are not in most cases. However, 
stage II patients with high risk features, including inadequate number of lymfnodes 
assessed are offered adjuvant chemotherapy as well in some cases. Based on the 
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association between CMS and tumor stage, one may hypothesize that CMS4 may 
be informative in predicting stage III disease when a low number of lymph nodes is 
available for analysis. 
To test this hypothesis, we first investigated the impact of the number of assessed 
lymph nodes on the chance of finding one or more positive lymph nodes in a cohort 
of colon cancers that underwent surgery from 1994-2001 when the number of lymph 
nodes was not yet widely implemented in pathological assesement protocols. This 
cohort contained 410 patients with stage II-III colon cancer for which basic 
FIGURE 2. GENE EXPRESSION ANALYSIS
Panel A depicts the cumulative number of differentially expressed genes (y-axis) plotted against the p value 
used as cut-off to define differential expression (x-axis). The analysis showed considerable gene expression 
differences in the total group. When stratifying CMS, the number of differentially expressed genes was 
significantly less in CMS2 and CMS4 compared to the overall analysis (p=0.002 and p<0.001, respectively). 
Panel B is a visualization of the genes that display significant differences between tumor stages in the whole 
group using a t-SNE algorithm with clear separation of the mesenchymal (CMS4) and the epithelial subtypes 
(CMS2/3) (x- and y-axis are the conditional probabilities based on the higher and low dimensional 
representations, respectively). Panel C displays the correlation between the tumor stage III-IV (x-axis) and 
CMS4 (y-axis) signature score (rs=0.85, p<0.001).
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characteristics are listed in Supplementary Table 4. This analysis showed that the 
percentage of stage III colon cancers increased with an increase of the number of 
assessed lymph nodes and plateaued at 10 lymph nodes (Figure 3A). We then 
investigated the association between CMS and the number of assessed lymph nodes, 
and found that CMS4 was more prevalent in patients with inadequate lymph node 
assessment compared to patients with adequate lymph node assessment (17.6% vs 
7.3%, p=0.018 respectively) (Figure 3B). These results indicate that CMS may be 
associated with stage migration, is uncommon in properly staged stage II colon 
cancers, and may help to identify patients who are at risk to be understaged. More 
specifically, mesenchymal cancers are at higher risk for inadequate staging. 
FIGURE 3. CMS AND STAGE II COLON CANCER
Panel A shows that the chance of finding a positive lymph node (y-axis) increases with an increasing number 
of assessed lymph nodes (x-axis), which plateaus after 10 lymph nodes. Panel B shows the distribution of 
CMS in stage II colon cancer (y-axis distribution in percentages) stratified for lymph node assessment with 
CMS4 being more prevalent in patients in whom <10 lymph nodes were assessed. Panel C and D display the 
disease-free survival (x-axis in months) of the total set of patients with stage II colon cancer (C), and the 
subset of patients with stage II colon cancer and <10 assessed LN (D) (y-axis survival in percentages).
201748 Robert Coebergh_binnenwerk.indd   79 12-12-17   15:41
CHAPTER 4
80
TA
BL
E 
1.
 B
AS
EL
IN
E 
CH
AR
AC
TE
RI
ST
IC
S 
OF
 P
AT
IE
NT
S 
W
IT
H 
UN
TR
EA
TE
D 
ST
AG
E 
II 
CO
LO
N 
CA
NC
ER
TO
TA
L
MA
TC
H 
CO
HO
RT
GS
E1
43
33
GS
E3
31
13
GS
E3
95
82
P 
VA
LU
E
n=
45
9
n=
11
2
n=
63
n=
90
n=
19
4
G
en
de
r
Fe
m
al
e
21
6
47
.1
%
57
50
.9
%
31
49
.2
%
48
53
.3
%
80
41
.2
%
0.
27
M
al
e
24
3
52
.9
%
55
49
.1
%
32
50
.8
%
42
46
.7
%
11
4
58
.8
%
A
ge m
ed
ia
n 
(in
te
rq
ua
rt
ile
 r
an
ge
)
71
(6
3-
78
)
70
(6
3-
76
)
71
 (6
3-
78
)
73
(6
0.
8-
79
.3
)
71
(7
1-
78
)
0.
64
T~ 3
33
9
73
.9
%
10
7
95
.5
%
0
0.
0%
81
90
.0
%
15
1
77
.8
%
0.
00
1
4
50
10
.9
%
5
4.
5%
0
0.
0%
9
10
.0
%
36
18
.6
%
m
is
si
ng
7
1.
5%
0
0.
0%
63
10
0.
0%
0
0.
0%
7
3.
6%
LN
 a
ss
es
se
d
m
ed
ia
n 
(r
an
ge
)
14
(1
-4
6)
14
(5
-2
8)
-
12
(1
-4
6)
-
0.
08
LN
 a
ss
es
se
d*
< 
10
 
45
9.
8%
14
12
.5
%
0
0.
0%
31
34
.4
%
0
0.
0%
<0
.0
01
≥ 
10
 
14
7
32
.0
%
98
87
.5
%
0
0.
0%
49
54
.4
%
0
0.
0%
m
is
si
ng
10
2.
2%
0
0.
0%
63
10
0.
0%
10
11
.1
%
19
4
10
0.
0%
Tu
m
or
 lo
ca
ti
on
Le
ft
20
5
44
.7
%
49
43
.8
%
30
47
.6
%
42
46
.7
%
84
43
.3
%
0.
91
Ri
gh
t
25
4
55
.3
%
63
56
.3
%
33
52
.4
%
48
53
.3
%
11
0
56
.7
%
M
SI
~
M
SS
27
6
60
.1
%
79
70
.5
%
0
0.
0%
64
71
.1
%
13
3
68
.6
%
0.
22
M
SI
85
18
.5
%
28
25
.0
%
0
0.
0%
26
28
.9
%
31
16
.0
%
M
is
si
ng
98
21
.4
%
5
4.
5%
63
10
0.
0%
0
0.
0%
30
15
.5
%
CM
S
1
99
21
.6
%
29
25
.9
%
15
23
.8
%
20
22
.2
%
35
18
.0
%
0.
05
3
2
17
8
38
.8
%
52
46
.4
%
16
25
.4
%
31
34
.4
%
79
40
.7
%
3
52
11
.3
%
11
9.
8%
7
11
.1
%
9
10
.0
%
25
12
.9
%
4
62
13
.5
%
5
4.
5%
11
17
.5
%
16
17
.8
%
30
15
.5
%
M
ix
ed
 o
r 
in
de
rm
in
at
e
68
14
.8
%
15
13
.4
%
14
22
.2
%
14
15
.6
%
25
12
.9
%
~ 
Co
m
pa
ri
so
n 
be
tw
ee
n 
th
e 
M
AT
CH
, G
SE
33
11
3 
an
d 
G
SE
39
58
2 
co
ho
rt
. *
 C
om
pa
ri
so
n 
be
tw
ee
n 
th
e 
M
AT
CH
 a
nd
 G
SE
33
11
3 
co
ho
rt
201748 Robert Coebergh_binnenwerk.indd   80 12-12-17   15:41
81
 
CMS HOLDS PROGNOSTIC VALUE IN STAGE I I  COLON CANCER WITH 
INADEQUATE LYMPH NODE ASSESSMENT
As prognostication is still an unmet need in stage II colon cancer, we investigated the 
prognostic value of CMS in stage II colon cancer in general, and specifically in patients 
in whom stage migration may be relevant. To this end, we selected patients with 
stage II colon cancer who were treated with surgery alone from the four cohorts for 
which information on age, location of the tumor (colon or rectum), tumor stage, 
adjuvant therapy and disease-free survival were available (MATCH, GSE1433316, 
GSE331137 and GSE3958212 cohort).
The aggregated cohort of stage II colon cancer consisted of 459 patients and included; 
[i] 112 patients from the MATCH cohort, [ii] 63 patients from the GSE14333 cohort, 
[iii] the entire GSE33113 cohort (n=90), and [iv] 194 patients of the GSE39582 cohort 
(patient selection is shown in Supplementary Figures 2-4 and baseline characteristics 
are listed in Table 1). Overall, patients with a CMS4 tumor had a worse 5-year DFS 
compared to the other subtypes (CMS4 73.0% vs CMS1 87.2% p=0.032, CMS2 80.7% 
p=0.19, CMS3 85.4% p=0.09) (Figure 3C). We then analyzed the DFS of patients per 
subtype stratified for lymph node assessment in the two cohorts for which the 
number of lymph nodes was known (MATCH and GSE33113 cohort). In particular, in 
the subset of patients with inadequate lymph node assessment, CMS4 had a worse 
5-year DFS rate (37.5%) compared to CMS1 (100%), CMS2 (90.9%) and CMS3 (80.0%) 
(p=0.006, p=0.002 and p=0.10, respectively) (Figure 3D). This suggests that CMS might 
be a classification strategy to assist TNM based classification when reliable 
determination of the tumor stage is not feasible. 
DISCUSSION
CMS is a widely implemented and robust classification system for colorectal cancer 
which identifies four subtypes with distinguishing biological features and 
corresponding prognosis.3 We therefore took advantage of this taxonomy to elucidate 
whether tumor stage resembles intrinsic features of tumor biology that are installed 
early during tumor development or disease progression. This study was conducted 
to investigate the interconnectivity between tumor stage and tumor biology in 
colorectal cancer, and investigate the added value of this knowledge in patients with 
stage II colon cancer.
The first observation that suggested interconnectivity between tumor biology and 
tumor stage was the increase of CMS4 patients with advancing stages of disease, 
which was observed consistently in the total group, the MSS patients and all individual 
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cohorts. These results may suggest that the poor prognosis (i.e. poor DFS en overall 
survival) for increased stages of disease is (in part) explained by the aggressive tumor 
biology of CMS4, given the poor prognosis of CMS4 compared to the other subtypes.3 
Within stage II, CMS4 was more prevalent in patients with inadequate lymph node 
assessment compared to patients with adequate lymph node assessment. These 
results illustrate the issue of stage migration in these patients, and suggest that the 
CMS classification may be useful to reduce the risk of understaging and 
undertreatment in patients with inadequate lymph node staging. Currently, 
inadequate lymph node assessment is considered to be a high risk factor in stage II 
colon cancer, and is subsequently used as an argument to offer adjuvant 
chemotherapy to these patients.17-19 Interestingly, none of the five factors that are 
used to define high risk stage II colon cancer have been demonstrated to have the 
predictive value in prospective trials.14 The survival analysis in patients with stage II 
colon cancer showed that CMS was of added value in patients with an uncertain 
lymph node status (<10 or unknown number of lymph nodes).18-20 This suggests that 
CMS may help to identify patients at high risk of recurrence within the subset of 
patients with inadequate lymph assessment. However, these results should be 
validated in larger series given the relatively small number of patients. Given the 
distinct biological features of the four CMS groups, this classification may not only 
be helpful to identify high risk patients, but may also be used to select patients for 
specific treatments in contrast to the currently used high risk factors.14 Patients with 
an MSI tumor (mostly CMS1) are known to have very little to no benefit from 
chemotherapy.21, 22 However, these patients may very well benefit from 
immunotherapy as was shown in patients with heavily pre-treated metastasized 
colorectal cancer.23 Patients with a CMS2 tumor were shown to be responsive to 
Oxaliplatin-containing chemotherapy while mesenchymal tumors (CMS4) seemed 
refractory to 5FU-based chemotherapy, suggesting CMS may also be used to select 
patients for specific chemotherapy regimens.4, 5 Future prospective studies should 
be conducted to confirm these hints on CMS-specific drug sensitivity, as these 
findings originate from retrospective and therefore potentially biased studies. 
A second observation in support of the interconnectivity between tumor stage and 
tumor biology was the marked decrease in differentially expressed genes between 
tumor stages when stratifying for CMS. This shows that almost all biological 
differences between tumor stages seem to be explained by CMS, which in turn 
strongly supports the hypothesis that different tumor stages are largely driven by 
intrinsic features of tumor biology that are installed early during tumor development 
rather than disease progression. Naxerova et al. showed that lymph node metastases 
(stage III) and distant metastases (stage IV) arose from different independent 
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subclones in the primary tumor in the majority of their cohort.24 These findings 
further underline that different biological entities are likely to have different 
metastatic potential and corresponding prognosis. Still, our gene expression analysis 
suggested that the biological differences between non-metatasized (stage I-II) and 
metastasized (stage III-IV) disease largely exceeds the biological differences within 
these two groups (i.e. stage I vs II and stage III vs IV). In line with these observations, 
we previously uncovered that most of the published gene signatures that are 
generated by comparing patients with and without metastases mostly identify the 
same patients, namely those with a poor prognosis.7 The majority of the patients 
who were marked as having a poor prognosis by the investigated prognostic gene 
signatures including the Oncotype Dx25 were colon cancer subtype 3 (CCS3), the 
mesenchymal subtype corresponding with CMS4. Furthermore, none of these 
signatures held prognostic value after correcting for colon cancer subtype. Thus, 
CMS appears to identify the same high risk patients as these signatures, and has the 
advantage that it distinguishes four subtypes with extensive biological differences 
which helps in the understanding and specific targeting of these subgroups.
In line with the results from basic and translational studies that support the 
interconnectivity between tumor stage and tumor biology7, 24, several clinical studies 
also provide support for the interconnectivity between tumor stage and tumor 
biology.26-29 These studies, in which the clinical outcome in colorectal cancer patients 
with synchronous versus metachronous liver metastases was compared, showed 
that patients with synchronous and metachronous liver metastases had a similar 
overall survival after development of liver metastases. These findings were reported 
both in patients who underwent a radical metastasectomy and patients with 
irresectable disease who received palliative systemic therapy.26-29 This suggests that 
tumor biology installed at an early moment in tumor development rather than the 
progression over time is the main determinant for prognosis in these patients. 
This study provides substantial evidence to support the theory that tumor stage and 
the corresponding prognosis are largely driven by tumor biology. Therefore, CMS 
has the potential to be a major contributor to clinical decision making. Future efforts 
should focus on further substantiating these findings and the development of a 
clinically applicable CMS test. 
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SUPPLEMENTARY F IGURES
SUPPLEMENTARY FIGURE 1. DISTRIBUTION OF CMS PER TUMOR STAGE IN THE INDIVIDUAL COHORTS
The association between CMS4 and advanced stages of disease was consistently observed in the individual 
cohorts. Absolute numbers are listed in Supplemental Table 2.
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SUPPLEMENTARY FIGURE 2. PATIENT SELECTION IN THE MATCH STUDY
A total of 112 out of 271 patients with stage II colon cancer who were included in the first five years of the 
MATCH study were excluded because of receiving adjuvant chemotherapy (n=15), age <55 or >85 years 
(n=31), insufficient follow up (n=71), other survival determining malignancies (n = 6), a second primary 
colorectal tumor (n=2) and samples did not pass the quality checks in the lab(n=34)).
201748 Robert Coebergh_binnenwerk.indd   89 12-12-17   15:41
CHAPTER 4
90
SUPPLEMENTARY FIGURE 3. PATIENT SELECTION IN THE GSE14333 COHORT
A total of 227 patients were excluded because of rectal cancer or unknown type (n=40), stage III-IV disease 
(n=168) and adjuvant chemotherapy (n=19).
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SUPPLEMENTARY FIGURE 4. PATIENT SELECTION IN THE GSE39582 COHORT
A total of 372 patients were excluded due to stage 0, I, III or IV (n=302), inconsistency between T and TNM 
stage (n=4), adjuvant or unknown chemotherapy data (n=57), and incomplete DFS data (n=9).
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SUPPLEMENTARY TABLE 3.
Distribution of CMS per tumor stage for the MSS tumors of 
the Marisa and TCGA cohort (n=88 mixed/indeterminate).
Stage I Stage II Stage III Stage IV Total
CMS 1 3 9 16 6 34
  3.1% 2.9% 5.7% 5.3% 4.3%
CMS 2 62 163 141 52 418
  63.9% 53.1% 50.2% 45.6% 52.3%
CMS 3 20 51 35 11 117
  20.6% 16.6% 12.5% 9.6% 14.6%
CMS 4 12 84 89 45 230
  12.4%% 27.4% 31.7% 39.5% 28.8%
Total 97 307 281 114 799
100.0% 100.0% 100.0% 100.0% 100.0%
SUPPLEMENTARY TABLE 4.
Characteristics extended GSE33113 cohort.
Total
n=410
Gender
Female 205 50%
Male 205 50%
Age
median (interquartile range) 68 (59-77)
TNM
2 246 60%
3 164 40%
Ln Assessed
median (range) 11 (0-100)
Ln Assessed
< 10 159 39%
≥ 10 225 55%
missing 26 6%
Tumor location
Left 250 61%
Right 155 38%
Both 5 1%
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ABSTRACT
Genomic rearrangements that give rise to oncogenic gene fusions can offer actionable 
targets for cancer therapy. Here we present a systematic analysis of oncogenic gene 
fusions among a clinically well-characterized, prospectively collected set of 278 
primary colon cancers spanning diverse tumor stages and clinical outcomes. Gene 
fusions and somatic genetic variations were identified in fresh frozen clinical 
specimens by Illumina RNA-sequencing, the STAR fusion gene detection pipeline, 
and GATK RNA-seq variant calling. We considered gene fusions to be pathogenically 
relevant when recurrent, producing divergent gene expression (outlier analysis), or 
as functionally important (e.g., kinase fusions). Overall, 2.5% of all specimens were 
defined as harboring a relevant gene fusion (kinase fusions 1.8%). Novel 
configurations of BRAF, NTRK3, and RET gene fusions resulting from chromosomal 
translocations were identified. An R-spondin fusion was found in only one tumor 
(0.35%), much less than an earlier reported frequency of 10% in colorectal cancers. 
We also found a novel fusion involving USP9X-ERAS formed by chromothripsis and 
leading to high expression of ERAS, a constitutively active RAS protein normally 
expressed only in embryonic stem cells. This USP9X-ERAS fusion appeared highly 
oncogenic on the basis of its ability to activate AKT signaling. Oncogenic fusions were 
identified only in lymph node–negative tumors that lacked BRAF or KRAS mutations. 
In summary, we identified several novel oncogenic gene fusions in colorectal cancer 
that may drive malignant development and offer new targets for personalized 
therapy. 
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INTRODUCTION
Colorectal cancer is the third most common malignant disease in men and second 
in women with an estimated yearly incidence of 1.35 million new cases associated 
with 694,000 annual deaths.1,2 Within colorectal cancer, colon cancer and rectal 
cancer are considered two separate disease entities that are treated differently.3 This 
article focuses on primary nonmetastatic colon cancer (stage I to III) to avoid the 
identification of genetic aberrations that are a result of neoadjuvant treatment (e.g., 
in case of rectal cancer). The classical driver mutations of colon cancer have been 
studied extensively and consist of constitutive activation of the WNT pathway by 
mutations in the tumor suppressor APC, inactivation of TP53 and activation of RAS/
MAPK pathways through mutation of RAS family members.4 These key primary drivers 
are sufficient for the transformation of primary colon stem cells into genomically 
instable adenocarcinomas.5,6 Besides these classical driver genes, large-scale genomic 
screening has revealed hypermutated and nonhypermutated colorectal cancer, which 
contain a different repertoire of mutated genes.7 Nonhypermutated colorectal 
cancers mostly carry mutations in the classical driver genes APC, TP53, KRAS, PIK3CA, 
and SMAD4 and form the majority of colorectal tumors. Hypermutated colorectal 
cancers often harbor genetic changes in DNA mismatch repair genes along with 
mutations in BRAF, APC, TGFBR2, and ACVR2A.7
Genomic instability is a frequent hallmark of colorectal cancer, particularly of 
nonhypermutated tumors. Profiling of genomic copy number aberrations has 
revealed numerous recurrent changes, located at known fragile sites (FHIT, WWOX) 
or targeting tumor suppressors (APC, PTEN, SMAD4).7 Genomic instability can lead to 
the formation of fusion genes.8-10 Fusion genes have attracted significant attention 
because they were identified as potential cancer-specific targets for treatment. 
Several fusion genes (e.g., BCR-ABL, EML4-ALK) are clinically used to select patients 
for treatment.9 One of the most prevalent fusion genes described in colorectal cancer 
involve the R-spondin family members RSPO2 and RSPO3.11 R-spondin fusions can 
activate WNT signaling and are mutually exclusive with mutations in APC. Recent 
work showed that inhibition of RSPO3 fusions impairs tumor growth.12 Other 
recurrent fusions in colorectal cancer contain the TCF7L1 and TCF7L2 genes, encoding 
TCF3 and TCF4 transcription factors, although their relevance for colorectal cancer 
development is currently unknown.7,13,14 Finally, a variety of kinase fusions have been 
observed in colorectal cancer, such as those involving BRAF or receptor tyrosine 
kinases.10,11,15,16 Despite the growing support for a role of gene fusions in colorectal 
cancer development and their potential therapeutic value, small sample sizes, 
differences in experimental approaches, and the low frequency of fusions have 
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resulted in conflicting results regarding their prevalence and relevance. We report a 
comprehensive and unbiased screening for gene fusions in a unique, clinically well-
defined, and prospectively collected cohort of 278 primary stage I to III colon cancers. 
We found that 2.5% of colon cancers in our dataset contained an oncogenic gene 
fusion and we identified novel fusions, including an USP9X-ERAS fusion with strong 
oncogenic activity in vitro.
MATERIALS AND METHODS
SAMPLE COLLECTION
Patients were selected from the MATCH study, a prospective multicenter cohort study 
from 2007 onwards including adult patients undergoing curative surgery in one of 
seven hospitals in the Rotterdam region, the Netherlands (institutional review board 
number MEC-2007-088). All patients gave written informed consent for the storage 
and use of tissue samples for research purposes, and the collection of clinical data. 
The study has been conducted in accordance with the guidelines of the Declaration 
of Helsinki.
Only samples with at least 40% invasive tumor cells were included in the final analysis, 
with the number of samples per RNA sequencing run depending upon this percentage.
DNA and RNA was isolated from 30-mm sections taken from the frozen tumor tissue 
obtained at primary surgery. Only samples with an RNA integrity value of at least 7.0 
were included in the final analysis. 
RNA-SEQUENCING
Total RNA (500 ng) from tumor samples was used as input for the Illumina TruSeq 
stranded RNA-seq protocol. Libraries were pooled and sequenced on Illumina 
HiSeq2500 or NextSeq instruments. We used the STAR fusion gene detection pipeline 
(version STAR-2.4.1) for analysis of RNA-seq data.17
A list of filtered junctions was annotated by adding fusion gene counts, donor gene 
counts, acceptor gene counts, overlap with protein domains and calculation of 
expression z-scores for the donor and acceptor genes relative to samples without 
the fusion. GATK RNA-seq variant calling best practices were used for somatic variant 
calling in RNA-seq data.
MATE-PAIR SEQUENCING AND ANALYSIS
Mate-pair library preparation was done using the Illumina Nextera Mate Pair library 
kit. Libraries were sequenced on NextSeq using 2*75 bp configuration. Discordant 
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read pairs were detected from BAM files using a custom analysis pipeline as described 
previously.18 FREEC was used to detect copy number variations.19
WHOLE EXOME SEQUENCING
DNA was sequenced by GATC Biotech using Illumina’s HiSeq protocol (paired-end 
100 bp, captured regions according to SureSelect v5).
Raw sequence data for both normal and tumor DNA were mapped to the human 
reference genome GRCh37 using BWA (v 0.7.5a-r405).20 BAM files were used for 
variant calling using GATK (v3.3.0) and Mutect (v1.1.6), followed by custom filtering 
steps.21,22
FUSION GENE EXPRESSION AND WESTERN BLOTTING
HEK293T cells or NIH-3T3-A14 cells were transfected with 2 mg of pBABE constructs 
containing fusion genes by the calcium phosphate method. NIH-3T3-A14 cells were 
obtained from Burgering and colleagues in 2014.23 HEK293T cells were obtained from 
ATCC in the late 1980s. Both cell lines have only been tested and authenticated on 
the basis of their morphologic appearance. The cell lines were cultured for up to ten 
passages after thawing before use in experiments. Mycoplasma testing was done 
every three months using MycoAlert (Lonza). Cells were cotransfected with constructs 
encoding either MYC-tagged ERK1 or GFP-tagged AKT. Western blotting was done 
with rabbit polyclonal antibodies directed against phospho-AKT (Ser473; D9E, Cell 
Signaling Technology), phospho-p44/42 MAPK (ERK1/2, Thr202/Tyr204, Cell Signaling 
Technology), c-MYC (910E, Santa Cruz Biotechnology), and mouse monoclonal anti-
a-Tubulin (CP06, Calbiochem). Detection was done with fluorescently labeled 
secondary antibodies (goat-anti-rabbit IgG (H+L) 800 CW and donkey-anti-mouse 
(680 RD) from LI-COR Biosciences).
DATA ACCESS
The sequencing data described in this study can be accessed through the European 
Genome Phenome Archive under accession number EGAS00001002197.
A detailed description of materials and methods can be found in the Supplementary 
Materials and Methods.
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RESULTS
TRANSCRIPTOME SEQUENCING OF 278 PRIMARY COLON TUMORS
To identify rearranged transcripts we explored the transcriptomic profile of colon 
cancers, making use of a large prospectively collected cohort of primary tumor 
samples from patients with stage I to III colon cancer (Rotterdam MATCH study). 
Primary tumor samples were selected from our database, based on clinical and 
technical criteria (Supplementary Figure 1). The study cohort included stage I (n = 
66), stage II (n = 115) and stage III (n = 97) pathologically confirmed adenocarcinomas 
(Table 1). Detailed clinical description including follow-up time, adjuvant therapy, 
disease outcome, tumor stage, lymph node status, histologic data, and patient details 
was collected (Supplementary Table 1).
Tumor samples with at least 40% invasive tumor cells (based on histologic examination) 
were sectioned and tissue slices were consecutively used for RNA and DNA isolation. 
Total RNA was extracted from tissue slices and used for the preparation of RNA-seq 
libraries subsequent to removal of abundant noncoding mRNAs (ribominus). Libraries 
were sequenced at a mean depth of 27M paired reads per library in either 2100*bp 
or 2*75 bp configuration (Supplementary Table 1). Next, the data were mapped to 
the human reference genome (GRCh37) to identify discordantly mapping reads 
indicating potential somatic fusion genes using STAR software and a custom annotation 
pipeline.17 The pipeline parameters were set to achieve maximal sensitivity, leading to 
the prediction of 3 million raw potential fusion gene calls. These calls were subsequently 
filtered through a series of rational filtering steps (Figure 1), including read coverage, 
removal of paralogous gene sets, filtering against control data, prediction of in-frame 
fusion and recurrence among tumor samples.16 Using these specific filtering criteria, 
we obtained a dataset of 75 fusion genes, which were subjected to experimental 
verification by RT-PCR (Supplementary Figure 2; Supplementary Table 2). A total of 
22 out of 75 tested fusion genes were validated in the correct tumor specimen and 
were absent in the corresponding control tissue. We observed two cases where a TFG-
GPR128 fusion was present in both tumor and corresponding normal colon tissue. This 
fusion has previously been described in renal cell cancer and was later shown to be 
caused by a germline structural genomic variation.24,25 For a DLG1-BRAF fusion, we also 
observed a weak RT-PCR product in the corresponding control tissue, which is likely a 
result of contamination of the control tissue with tumor cells. For 35 predicted fusion 
genes, we did not observe an RT-PCR product, indicating that these are either false 
positive calls or that the fusion gene RT-PCR detection assay was suboptimal. The 
remainder of fusion genes was not specific for the tumor sample. To assess whether 
our filtering strategy indeed enriched for true positive fusion genes, we also subjected 
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TABLE 1. PATIENT AND TUMOR CHARACTERISTICS
CHARACTERISTICS ALL PATIENTS LYMPH NODE 
NEGATIVE 
TUMORS
LYMPH NODE 
POSITIVE TUMORS
NO FUSION GENE FUSION GENE
  N=278 (%) N=181 (%) N=97 (%) N=271 (%) N=7 (%)
Gender
Female 132 47.5% 92 50.8% 40 41.2% 127 46.9% 5 71.4%
Male 146 52.5% 89 49.2% 57 58.8% 144 53.1% 2 28.6%
Age
Median (IQR) 68.2 (62.4 - 75.2) 70.2 (63.2 - 76.9) 70.0 (61.4 - 70.8) 68.1 (62.4-75.2) 71.1 (67.4-76.1)
Tumor stage
Stage I 66 23.7% 66 36.5% - - 65 24.0% 1 14.3%
Stage II 115 41.4% 115 63.5% - - 109 40.2% 6 85.7%
Stage III 97 40.2% - - 97 100% 97 35.8% 0 0%
T status
T2 79 28.4% 66 36.5% 13 13.4% 78 28.8% 1 14.3%
T3 194 69.8% 110 60.8% 84 86.6% 190 70.1% 4 57.1%
T4 5 1.8% 5 2.8% - - 3 1.1% 2 28.6%
Nodal status
N0a 148 53.2% 148 81.8% - - 143 52.8% 5 71.4%
N0b 33 11.9% 33 18.2% - - 31 11.4% 0 0%
N1 64 23.0% - - 63 64.9% 64 23.6% 0 0%
N2 33 11.9% - - 34 35.1% 33 12.2% 2 28.6%
N0 181 65.1% 181 100% - - 174 64.2% 7 100%
N+ 97 34.9% - - 97 100% 97 35.8% 0 0%
Tumor grade
Good 23 8.3% 16 8.8% 7 7.2% 23 8.5% 0 0%
Moderate 220 79.1% 152 84.0% 68 70.1% 213 78.6% 7 100%
Poor 24 8.6% 10 5.5% 14 14.4% 24 8.9% 0 0%
Unknown 11 4.0% 3 1.7% 8 8.2% 11 4.1% 0 0%
Adjuvant therapy
No 182 65.5% 182 100% 1 1.0% 175 64.6% 7 100%
Yes 96 34.5% - - 95 99.0% 96 35.4% 0 0%
MSI-status
MSS 217 78.1% 134 74.0% 83 85.6% 215 79.3% 2 28.6%
MSI 61 21.9% 45 24.9% 14 14.4% 56 20.7% 5 71.4%
Location
Left 133 47.8% 84 46.4% 49 50.5% 130 48.0% 3 42.9%
Right 145 52.2% 97 53.6% 48 49.5% 141 52.0% 4 57.1%
Abbreviation: MSI, microsatellite instability. a Total lymph node yield ≥ 10. b Total lymph node yield < 10.
201748 Robert Coebergh_binnenwerk.indd   103 12-12-17   15:41
CHAPTER 5
104
a series of 70 predicted fusions that did not pass our filtering steps to experimental 
verification by RT-PCR. Out of these 70 predicted fusions none could be confirmed 
(data not shown).
BRAF FUSIONS ARE RECURRENT AND PRESENT AT LOW FREQUENCY IN COLON CANCER
We next searched among the validated fusion transcripts for those, which were 
recurrent and in-frame. We identified three unique fusions (1.1% of 278 samples) 
involving the BRAF oncogene (AGAP3-BRAF, TRIM24-BRAF, DLG1-BRAF, Figure 2A; 
Supplementary Figure 3). BRAF fusions have been described in a variety of cancer 
types.10,16 The structure of the TRIM24-BRAF fusion was identical to those reported 
previously, with exon 3 of TRIM24 connected to exon 10 of BRAF.15 The AGAP3-BRAF 
fusion contained a junction between exon 8 of AGAP3 and exon 9 of BRAF, which is 
different from the exon 9-exon 9 configuration previously described.15 The DLG1-BRAF 
fusion, containing a junction between exon 5 of DLG1 and exon 9 of BRAF, is novel 
and extends the broad spectrum of known BRAF fusions in cancer.
FIGURE 1. OVERVIEW OF FUSION GENE DETECTION AND FILTERING APPROACH
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We sequenced the genomes of the tumor samples with BRAF fusion genes using 
large-insert mate-pair sequencing (insert size 2.5 kb) to detect somatic structural 
variations that could account for BRAF fusion formation. In two cases (AGAP3-BRAF 
and TRIM24-BRAF) the fusion was caused by an inversion event, while the novel DLG1-
BRAF fusion resulted from a reciprocal translocation between chromosomes 3 and 
7 (Figure 2A).
All three fusion genes contained the entire C-terminal kinase domain of BRAF by 
fusion of exon 9 or 10 to their respective donor genes. We hypothesized that 
disconnection of the BRAF kinase domain from its N-terminal autoinhibitory domain 
leads to constitutive activation.26 To assess whether our BRAF fusions can activate 
signaling pathways, we cloned the DLG1-BRAF and AGAP3-BRAF fusion genes and 
expressed them in HEK293 cells. Subsequent analysis for activation of ERK/MAPK 
signaling was performed by coexpression of ERK1. Protein analysis revealed a strong 
effect of BRAF fusion proteins on ERK1 phosphorylation, underscoring their role as 
oncogenes in colon cancer (Figure 2B). Although the effect of BRAF fusions on ERK1 
phosphorylation appeared stronger than for the native BRAF protein, the effect was 
less strong than for BRAF carrying the activating V600E mutation.
IDENTIFICATION OF NTRK3  AND RET  KINASE FUSION GENES
To further evaluate the relevance of the remaining fusion genes that were verified by 
RT-PCR, we reasoned that fusions that lead to upregulation of the acceptor gene may 
be of particular importance.27 Therefore, we analyzed the expression of our entire set 
of fusions and compared the expression of the donor and acceptor genes to all other 
tumor samples without such a fusion (outlier analysis, Supplementary Table 2).
An EML4-NTRK3 fusion was among the top hits that resulted from this analysis with 
an expression Z score of 17.96 for the NTRK3 gene. This fusion was formed through 
a reciprocal translocation that joined the 50 part of EML4 (ending with exon 2) with 
the 30 exons of NTRK3 (starting with exon 14) in a lymph node negative 
adenocarcinoma (Figure 2A; Supplementary Figure 4A). An additional NTRK3 fusion 
(ETV6-NTRK3) has been reported previously in colon cancer and an EML4-NTRK3 fusion 
has been observed in glioma.11,28 By examining the expression of the individual exons 
across ETV6-NTRK3, we noticed that the fusion also leads to an increased expression 
of the exons encoding the tyrosine kinase domain, which is retained in the fusion 
transcript (Supplementary Figure 4B). On the basis of these results, we analyzed 
the exonic expression in 732 RNA-sequencing datasets of colorectal cancer samples 
from The Cancer Genome Atlas (TCGA) and observed a similar increase in expression 
of the kinase encoding exons in two datasets derived from colon adenocarcinomas, 
suggesting the presence of NTRK3 fusion genes (Supplementary Figure 4C).7
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Neurotrophin tyrosine kinase (NTRK) 1 and 3 are receptor kinases that are frequently 
activated by gene fusion in a variety of cancers.10 The tyrosine kinase domain is 
always maintained in the chimeric proteins and fused to an oligomerization domain 
provided by the N-terminal fusion partner. To assess the molecular effects of the 
EML4-NTRK3 fusion gene reported here, we expressed it in HEK293 cells together 
with ERK1 and found that the EML4-NTRK3 fusion activates MAPK/ERK signaling by 
phosphorylation of ERK1 (Figure 2B). A truncated version of the fusion gene was not 
active, suggesting that the EML4 coiled-coil domain (CCD) is supposed to promote 
receptor activation by dimerization, similar as for EML4-ALK fusions found in lung 
cancer.29 We also tested the same fusion construct in the context of A14 cells 
cotransfected with AKT. Following serum starvation, we observed phosphorylation 
of AKT exceeding the levels of AKT phosphorylation by KRAS V12A under the same 
conditions (Figure 2C). Altogether, we conclude that the EML4-NTRK3 fusion affects 
oncogenic signaling pathways and that NTRK3 fusion genes are recurrent but low-
frequent in colorectal cancer.
Another top candidate with a high expression Z-score involved an in-frame fusion 
with exon 1–9 of the integral endoplasmic reticulum membrane protein Ribosome-
binding protein 1 (RRBP1) fused to exons 12–20 of the RET gene, harboring the 
complete N-terminal kinase domain (Supplementary Figure 5A; Supplementary 
Figure 5B). The N-terminal part of RRBP1 contains the ribosome receptor lysine/
proline domain as well as a coiled coil domain (CCD). Previously reported fusions of 
RET to CCDs of 50 partners have been shown to initiate ligand-independent activation 
of the kinase domain, suggesting a similar mechanism in this fusion.30,31 The RET gene 
is a known target for gene fusions in hereditary and sporadic papillary thyroid cancers 
and lung adenocarcinoma, and RET fusions have recently also been described in 
advanced colorectal cancer.32-34
In addition, we observed a fusion involving the kinase gene PSKH2, which is highly 
expressed in the sample with the fusion, but not at all in other tumor samples 
(Supplementary Table 2). However, this fusion was not pursued further because 
we observed several different splice variants with only partial open reading frames.
ERAS  ACTIVATION THROUGH GENE FUSION IN COLON CANCER
One particularly interesting novel fusion gene that resulted from our outlier 
expression analysis contained the ERAS gene (Figure 3A and B). ERAS is a single-exon 
RAS-family member that is expressed only in embryonic stem cells.35 The ERAS 
protein is constitutively active and leads to enhanced PI3K signaling and cellular 
transformation. Elevated ERAS expression has been described in some gastric cancer 
samples and a role in tumorigenesis has been implied.36 We observed that ERAS was 
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highly expressed in one tumor sample in our dataset and no detectable expression 
was observed in the other tumor samples (Figure 3B). The high expression was 
driven by the fusion of ERAS with USP9X, a highly expressed housekeeping gene 
(Figure 3A; Supplementary Figure 6A). As opposed to canonical fusion genes, 
which often involve formation of a novel chimeric protein sequence, the USP9X-ERAS 
fusion was formed by fusion of 5’UTR sequences, which leads to an exchange of the 
ERAS promoter with the USP9X promoter and not the formation of a novel chimeric 
protein sequence.
To gain insight in the formation of the USP9X-ERAS fusion, we analyzed structural 
variations using mate-pair sequencing. This revealed that the fusion gene was caused 
FIGURE 2. STRUCTURE AND CHARACTERIZATION OF FUSION GENES.
(A) Exon and protein structure of the TRIM24-BRAF, AGAP3-BRAF, DLG1-BRAF, and EML4-NTRK3 fusions. On 
top of the exonic structures, we plotted arcs indicating breakpoint junction sequence reads detected by 
mate-pair sequencing of tumor genomicDNA. Coloring of the arcs indicates orientation of the breakpoint 
junction as indicated by the respective mate-pair reads: red, head-to-head inverted; yellow, tail-to-tail inverted; 
blue, tail-to-head; green, head-to-tail. Below the exonic structures, chimeric RNA-seq reads are plotted (black 
arcs) indicating which exon–exon connections were observed from the sequence data. KD, kinase domain; 
L27, L27 protein interaction module; PH, pleckstrin homology; RING, zinc finger domain ring type; BBOX1, 
B-box-type zinc finger domain; PTK, protein tyrosine kinase domain; CC, coiled-coil domain. (B) Western blot 
results depicting the effects of fusion genes overexpression in HEK293 cells on ERK1 phosphorylation. (C) 
Western blot results displaying the effects of fusion gene overexpression on AKT phosphorylation in NIH-
3T3-A14 cells. 
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at the genomic level by a highly local chromothripsis event on chromosome X 
spanning solely the region covered by USP9X and ERAS (Figure 3C). The chromothripsis 
involved at least 18 genomic breakpoint junctions and led to multiple copy number 
changes. We cloned the USP9X-ERAS fusion gene and expressed it in NIH-3T3 A14 
cells. Analysis of phosphorylated AKT showed that the USPX9-ERAS fusion can activate 
AKT signaling (Figure 2C). To get further support for a potential role of ERAS 
expression in cancer development, we assessed 521 RNA-seq datasets from colon 
cancer from the TCGA consortium (Supplementary Table 3). This revealed several 
colon cancer datasets showing detectable mRNA expression levels of ERAS 
(Supplementary Figure 6B), albeit not as high as the sample with the USP9X-ERAS 
fusion described here. We also assessed stomach cancer RNA-seq datasets from 
TCGA and observed one sample with high expression of ERAS (Supplementary Figure 
6C). Altogether, our data suggest that induction of ERAS expression could be an 
alternative mode of promoting oncogenesis through the AKT pathway in colon 
cancer.
FIGURE 3. GENOMIC ORIGIN, STRUCTURE, AND EXPRESSION OF A NOVEL USP9X-ERAS FUSION GENE
(A) Schematic drawing indicating the transcript structure of the USP9X-ERAS fusion. The fusion was caused 
by a breakpoint junction in the 5’UTR of USP9X and ERAS, resulting in control of ERAS by the USP9X promoter. 
(B) ERAS expression levels across the entire cohort of 278 colon tumors included in this study. (C) RNA-seq 
and mate-pair sequencing data across chromosomal regions involving the ERAS and USP9X genes. Individual 
chimeric RNA-seq reads are depicted as black arcs. Genomic breakpoint junctions (not individual sequence 
reads) are shown as colored arcs (red, head-to-head inverted; yellow, tail-to-tail inverted; blue, tail-to-head; 
green, head-to-tail). The genomic copy number profile is displayed using black dots, which each represent 
the copy number of a genomic interval as determined based on analysis of mate-pair data using FREEC.
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LOW FREQUENCY OF KNOWN R-SPONDIN FUSIONS
Previous work reported a number of different fusion genes in colon cancer most 
prominently those that involve genes that interact with the WNT signaling 
pathway.11,13 Fusions involving the R-spondin genes RSPO2 and RSPO3 have been 
reported in up to 10% of microsatellite stable (MSS) colorectal cancers in one study 
and appear mutually exclusive with mutations in APC.11 To achieve maximal 
sensitivity for picking up gene fusions, we evaluated our raw fusion gene calls for 
the presence of both types of RSPO fusion genes, but could only detect one EIF3E-
RSPO2 fusion in an MSS sample (Supplementary Figure 7A). To verify the sensitivity 
of our pipeline for picking up RSPO2 and RSPO3 fusion genes, we reanalyzed the raw 
RNA-seq FASTQ files as published recently using our STAR-based pipeline.11 Our 
bioinformatics pipeline could detect all seven published fusions. In addition, we 
measured normalized read depth across the RSPO2 and RSPO3 genes, revealing a 
strong upregulation of expression for samples with the corresponding R-spondin 
fusion in the published tumor samples (Supplementary Figure 7B). We only 
observed elevated RSPO2 expression for the one tumor sample in our cohort that 
showed the presence of an EIF3E-RSPO2 fusion (Supplementary Figure 7C), further 
supporting the low frequency of RSPO fusion genes in our dataset. We conclude that 
R-spondin fusions may not be as frequently present as previously indicated or that 
sampling bias, selection bias or treatment regime may explain the observed 
discrepancies.
ONCOGENIC  FUSIONS ARE MUTUALLY EXCLUSIVE  WITH ACTIVATING MUTATIONS 
IN  KRAS ,  BRAF ,  AND NRAS  AND RESTR ICTED TO  STAGE  I  AND I I  TUMORS
We used the GATK-RNAseq mutation calling pipeline to detect indels and single-
nucleotide changes in the RNA-seq data from all 278 tumor samples (stage I–III). The 
analysis was focused on cancer genes that are of major relevance for colon cancer 
development, including BRAF, KRAS, HRAS, NRAS, SMAD4, TP53, APC, and PTEN. Passed 
variant calls in BRAF, KRAS, HRAS, and NRAS were overlapped with known hotspot 
mutations from the COSMIC database.37 For mutations in tumor suppressor genes, 
we filtered the variants against existing databases of germline variants to enrich for 
somatic variants. To estimate the reliability of the RNA-based variant calls, we 
compared them against paired tumor–normal exome sequencing data that were 
generated for a subset of 44 samples. For BRAF, KRAS, HRAS, and NRAS, all variants 
identified in the RNA-seq data were also found in the exome data and false negatives 
were not observed. On the basis of the RNA-seq variant calls, we identified 27 BRAF 
V600E mutations in the entire cohort of 278 tumors, which is in line with the estimated 
frequency (10%) of this mutation type in colorectal cancer.7 Our analysis of fusion 
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genes showed that activation of BRAF may additionally be caused by fusion gene 
formation in an additional 1.1% of colon cancers (Figure 4).
Besides mutations in BRAF, we also found 103 tumors with a hotspot mutation in 
KRAS (n = 99.36%) and NRAS (n = 4, 1.4%). In line with previous observations in other 
cancer types, we observed that the presence of MAPK/ERK and PI3K/AKT activating 
hotspot mutations in BRAF, KRAS, and NRAS are mutually exclusive with the presence 
of oncogenic fusion genes in colon cancer (P = 0.018).15,16 Finally, we noted that all 
oncogenic fusions (including EIF3E-RSPO2) were found in samples with lymph node–
negative stage I and II tumors (P = 0.047) and none of the samples showed a relapse 
in subsequent years (median follow up 50.9 months). However, the latter results 
should be interpreted with caution due to the small numbers. 
DISCUSSION
Our comprehensive analysis of RNA sequencing data from 278 well-characterized 
stage I to III colon cancers yielded a number of known and novel fusion genes, which 
may have clinical implications. In the era of personalized medicine, tumors are 
increasingly molecularly profiled, leading to better identification of patients for 
specific treatments.38 For colorectal cancer, small gene panels including BRAF, KRAS, 
and NRAS are most often used since mutations in these genes are of clinical 
relevance.39 Our analyses show that beyond these single gene tests, fusion genes 
may also be important.
Three of the fusion genes identified in our cohort involve the BRAF oncogene, which 
has previously been found in 4 (0.2%) colon cancer samples out of 2,154 colorectal 
cancer samples.15 Here we show that BRAF fusions occur in 1.1% of stage I–III colon 
cancers. Two of the BRAF fusions (AGAP3-BRAF and TRIM24-BRAF) consist of know 
fusion configurations, while the DLG1-BRAF fusion is novel.15 The BRAF fusions activate 
oncogenic signaling pathways in cells lines, indicating that they form genuine 
oncogenes in colon cancer, in addition to known oncogenic mutations in BRAF and 
KRAS. Although BRAF fusions are relatively rare, they may be highly relevant drug 
targets for the individual patient, similar as mutations in BRAF.40-42
An expression outlier analysis involving samples with and without fusion genes, 
revealed EML4-NTRK3, RRBP1-RET, and USPX9-ERAS fusion genes. The EML4-NTRK3 
fusion gene has not been described in colon cancer, but was reported in a single 
case of glioma.28 However separately, both the EML4 and NTRK3 gene have been 
described as part of gene fusions in various types of cancers.10 EML4 has mainly been 
described in conjunction with the ALK kinase gene in non–small cell lung cancer 
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occurring in five different variants.43 All of these contain a CCD, which is responsible 
for the dimerization and constitutive activation of its acceptor gene product. This is 
consistent with our findings that the EML4-NTRK3 fusion induces ERK1 and AKT 
phosphorylation, while expression of a truncated version of NTRK3 or the entire 
NTRK3 gene did not reveal such activity.
RET fusions have been described in up to one-third of papillary thyroid cancers, in 
2% of lung adenocarcinoma and recently in 0.2% of 3,117 advanced colorectal 
tumors.32-34 Tumors carrying a RET fusion in that colorectal cancer cohort were pan 
negative for known driver mutations such as KRAS, BRAF, PIK3CA, and EGFR, which 
was also true for the tumor carrying the RRBP1-RET fusion in our cohort. RET kinase 
inhibitors might form a promising treatment for colorectal cancers containing 
oncogenic RET fusions.33
An entirely novel fusion gene described in this work, comprises the USP9X and ERAS 
genes. Although this fusion has only been found in a single colon cancer sample in our 
study, its high expression and in vitro activity demonstrate that expression of ERAS has 
strong oncogenic capacity. We observed ERAS expression in colon cancer RNA-seq 
datasets from TCGA, suggesting that ERAS expression could be a recurrent oncogenic 
mechanism in colon cancer, similarly as has been proposed for stomach cancer.36
R-spondin fusions were described as a recurrent genomic aberration in colon cancer 
patients by Seshagiri and colleagues, whom identified seven R-spondin fusions in a 
cohort of 74 colon cancer patients (9.5%).11 In their cohort, tumors with an R-spondin 
fusion did not contain a loss of function mutation in APC or copy loss, except for one 
tumor, which contained a single APC allele. Five out of seven R-spondin fusions occurred 
in a tumor with a KRAS mutation (13.5% of all KRAS mutant tumors) and two in a tumor 
carrying a BRAF mutation (40% of all BRAF mutant tumors). In our cohort of 278 patients 
we observed only one R-spondin fusion, which was present in a tumor sample carrying 
a BRAF mutation (3.7% of all BRAF mutated tumors). However, the percentage of KRAS 
mutated tumors differed substantially between the cohort of Seshagiri and our cohort 
(KRAS 50% vs. 35.6% P = 0.024 and BRAF 6.8% vs. 9.7% P = 0.43, respectively). The 
presence of R-spondin fusions in a subset of colorectal adenomas (traditional serrated 
adenoma) with frequent KRAS mutations has been recently shown.44 These data suggest 
that differences between tumor cohorts may explain the differences in the total 
number of identified R-spondin fusions.
Our findings are in line with new insights that broader and systematic use of genetic 
profiling including DNA and RNA sequencing is needed to maximize identification of 
patients that could potentially benefit from targeted treatment.45 Sharing of datasets 
including clinical characteristics and treatment outcome, such as our dataset, may 
help to overcome sample size limitations of individual studies and improve insight 
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into the clinical merit of specific infrequent genetic aberrations and fusion genes.46 
We found that oncogenic fusion genes were present in lymph node– negative tumors, 
although this finding needs to be substantiated in larger studies. Most of the previous 
studies reporting fusion genes in colorectal cancer did not include clinical or 
histopathologic characteristics, especially not stage.
In conclusion, we have created a large and comprehensive catalog of fusion genes in 
a unique clinically well-defined prospectively collected cohort of stage I to III primary 
colorectal cancers and identified several known and novel fusion genes with biological 
activity and possible prognostic value. We anticipate that incorporating in vitro 
platforms such as (tumor)organoids may facilitate testing of fusion genes for functional 
relevance, differences in oncogenic capacity and response to antitumor drugs.5 
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SUPPLEMENTARY MATERIALS AND METHODS
SAMPLE COLLECTION
Patients were selected from the MATCH-study, a prospective multicenter cohort 
study from 2007 onwards including adult patients undergoing curative surgery in 
one of seven hospitals in the Rotterdam region, the Netherlands (MEC-2007-088). 
All patients gave written informed consent for the storage and use of tissue samples 
for research purposes, and the collection of clinical data.
The selection criteria for this study were: 55-85 years old, stage I-III colon cancer, 
treatment was either curative surgery only (stage I-II) or curative surgery combined 
with adjuvant systemic therapy (stage III), and either disease free follow-up of at least 
30 months or recurrence of disease at any point in time. 
Directly following resection of the bowel segment containing the tumor, the specimen 
was transported to the pathology lab. Then, 2 to 5 biopsies of both central and 
peripheral regions of the tumor were sampled as well as 1 to 2 nontumor colon 
tissue sampled as distant from the tumor as possible. The samples were then fresh 
frozen using liquid nitrogen or isopentane with a maximum cold ischemia time of 2 
hours. All samples were temporarily kept at -80˚C at the local centers, transported 
to the central tissue bank on dry ice and stored in liquid nitrogen. 
HISTOLOGICAL EXAMINATION OF TUMOR SAMPLES
Sections of all samples were produced using a cryostat microtome (Thermo Scientific 
Microm HM 560, Thermo Fisher Scientific, inc.) set at -20˚C. For each sample, a 
Haematoxylin-eosin (HE) stained 5 μm section was reviewed by two pathologists for 
determination of final percentage of invasive tumor cells, necrosis, infiltrative cells, 
normal cells, tumor type (adenocarcinoma or other) and grade if possible. If needed, 
the paraffin slides of the primary tumor were used to aid in the assessment of the 
fresh frozen slides. Only samples with at least 40% invasive tumor cells were included 
in the final analysis, with the number of samples per sequencing run depending 
upon this percentage (see also below). 
ISOLATION OF DNA AND RNA FROM TUMOR SAMPLES
DNA and RNA was isolated from 30 μm sections taken from the frozen tumor tissue 
obtained at primary surgery, preceded and followed by a 5 μm section for HE-staining 
and subsequent evaluation by the pathologist.
Genomic DNA was isolated using the NucleoSpin DNA Tissue kit (Macherey- Nagel; 
Bioké, Leiden, The Netherlands) according to the manufacturer’s protocol. RNA 
isolation was done using RNA-Bee® (Tel-Test inc., Bio-Connect BV, Huissen, The 
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Netherlands), chloroform, isopropanol and ethanol according to the manufacturer’s 
protocol and as described before.1 Prior to sequencing, 20 μg of the isolated RNA 
was DNase treated and cleaned using the NucleoSpin® RNA II kit (Macherey-Nagel; 
Bioké, Leiden, The Netherlands) according to the manufacturer’s protocol. 
The quality and quantity of the DNA and RNA before and after clean-up was assessed 
with the Nanodrop ND-1000 (Thermo Scientific, Bleiswijk, The Netherlands) for 
measurement of A260/280 ratio, A260/230 ratio and total nucleic acid concentration. 
In addition, DNA quality and quantity was assessed using agarose gel electrophoresis 
and the PicoGreen® dsDNA quantitation assay (Thermo Scientific), respectively. The 
MultiNA Microchip Electrophoresis system (Shimadzu, Kyoto, Japan) was used for 
assessment of RNA quality, which was reported as an in-house adapted RNA integrity 
value ranging from 2 to 10. Only samples with an RNA integrity value of at least 7.0 
were included in the final analysis. 
RNA-SEQUENC ING
500 ng of total RNA from tumor samples was used as input for the Illumina TruSeq 
stranded RNA-seq protocol. Libraries were pooled and sequenced on Illumina 
HiSeq2500 or NextSeq instruments. Pool sizes and the amount of samples per run 
were determined based on the percentage of tumor cells estimated from histological 
examination. Supplementary Table S1 provides an overview of the number of 
sequence reads generated per sample. 
BIOINFORMATIC DETECTION OF FUSION TRANSCRIPTS
We used the STAR fusion gene detection pipeline (version STAR-2.4.1) for analysis of 
RNA-seq data.2 In a first step, fastq files were merged in case tumor samples (libraries) 
had been sequenced on separate sequencing runs. A total of 348 tumor datasets 
(70 published3 and 278 generated in our work) and 74 control datasets (69 previously 
published and 5 generated in our work) were used as input. Subsequently, fastq files 
were used as input for STAR mapping and fusion detection with settings: 
-chimSegmentMin 15, chimJunctionOverhangMin 15, outSJfilterIntronMaxVsReadN 
10,000,000. The resulting splice junction (SJ) and chimeric junction files were 
annotated with ensembl gene IDs (Ensembl version 72) and the annotated junctions 
were clustered per sample based on their overlapping gene IDs, i.e. junctions with 
the same overlapping donor and acceptor genes were merged. Subsequently, the 
clustered junctions were annotated based on the longest overlapping Ensembl CCDS 
transcript. The last exon of the donor gene and the first exon of the acceptor gene 
are reported. In addition, the type of junction was indicated as intronic (if junction 
reads fall in an intron), exonic (if junction reads fall in an intron) or boundary (if the 
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junction matches an intron-exon boundary). Furthermore, the exon rank within the 
transcript and the exon phase were assigned for both the donor and acceptor gene. 
Using this analysis and annotation pipeline we obtained 3 million raw junction calls.
We applied a series of filtering steps to extract high-quality junctions from these raw 
data (Figure 1). This list of remaining junctions was annotated by adding fusion gene 
counts, donor gene counts, acceptor gene counts, overlap with protein domains and 
calculation of expression z-scores for the donor and acceptor genes relative to 
samples without the fusion. For calculation of z-scores, read counts per gene were 
calculated using HTSeq4 using settings –m union -s yes. Read counts were normalized 
for library size (total read counts per sample). Normalized read counts were used as 
input for calculating z-scores according to: 
z − score = (X − μ)/σ
where X is the normalized read count for the sample with the fusion gene, μ is the 
mean read count for all samples without fusion and σ is the standard deviation of 
the normalized read counts across all samples without the fusion gene. 
BIOINFORMATIC DETECTION OF SOMATIC VARIATIONS IN RNA-SEQ DATA
Somatic genetic variations in BRAF, HRAS, NRAS, KRAS, PIK3CA, TP53, APC, SMAD4, PTEN 
were detected in RNA-seq data using the GATK RNA-seq variant calling best practices. 
In brief, RNA-seq reads were mapped with STAR (version STAR-2.4.1) followed by a 
2-pass STAR mapping using a new index of the genome reference based on the splice 
junctions identified by STAR (SJ.out.tab). The resulting BAM files were processed by 
Picard5 to mark duplicates, sorting, indexing and adding read group information. 
Subsequently, we used GATK SplitNCigarReads to split reads in exon segments and 
hard-clip parts of reads that overlap intronic regions. Following indel realignment and 
base recalibration, variant calling and filtering was done using GATK Haplotypecaller, 
which resulted in a vcf file with indels and single-nucleotide variants. The vcf file was 
overlapped with COSMIC hotspot mutations in BRAF, KRAS, NRAS and HRAS genes. For 
variations in the remaining genes we checked for overlap with variations in 1000G 
(phase 3), TWINSUK, ALSPAC and ExAC. The non-overlapping variations were 
annotated based on variant effect and only non-synonymous, stop-gained/lost and 
frameshift variants that were flagged with PASS and SnpCluster were retained.
MATE-PAIR SEQUENCING AND ANALYSIS
Mate-pair library preparation was done using the Illumina Nextera Mate Pair library 
kit. Libraries were barcoded, pooled and sequenced on NextSeq using 2*75bp 
configuration. Mate-pair sequencing reads were mapped to the human reference 
genome (GRCh37) using BWA.6 Subsequently, discordant read pairs were detected 
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from BAM files using a custom analysis pipeline as described previously.7 To enrich 
our data for somatic rearrangements, clusters of discordant reads (rearrangement 
calls) were filtered against an in-house database of structural variation calls generated 
from mate-pair sequencing data using the same analysis pipeline. Previous work has 
shown that filtering against a large control dataset is a highly efficient approach to 
select for somatic variants.8 BAM files containing mate-pair sequencing reads were 
also used as input for calling copy number changes with the FREEC tool.9
WHOLE EXOME SEQUENCING
DNA was was sequenced by GATC Biotech (Constance, Germany) using Illumina’s 
HiSeq protocol (paired-end 100 bp, captured regions according to SureSelect v5), 
with a minimum of 60x coverage for normal DNA, and 90x or 120x for tumor DNA 
of tissues with >70% or 40-70% tumor cells, respectively. Raw sequence data for both 
normal and tumor DNA were mapped to reference genome GRCh37 using BWA (v 
0.7.5a-r405)6 after which data was sorted, indexed and duplicates marked using 
Picard (http://broadinstitute.github.io/picard/). Resulting BAM files were used for 
variant calling using two different software-packages: GATK (v3.3.0)10 and Mutect 
(v1.1.6).11 Mutations were filtered for high-quality calls and overlapping results from 
both variant callers. Next, the resulting mutations were annotated using SnpEff12 to 
judge the effect of the mutation on the coding sequence (i.e. to check e.g. if the 
mutation results in an amino-acid change) and to check if the mutation is a known 
SNP in dbSNP (138_v37). Next, these data are combined per patient; only mutations 
found in the tumor but not in the normal and unknown in dbSNP were considered 
as somatic. Finally, the list was filtered for any variant with a minimal number of 20 
reads per position and at least 15 reads having the variant.
FUSION GENE VALIDATION BY RT-PCR
We used RT-PCR as an assay to validate fusion genes. For this, 0.5μg of total RNA 
was taken as input for cDNA preparation (20 μL total reaction volume) using the High 
Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Junction PCR 
specific primers were designed based on the RNA-seq chimeric junction reads using 
primer3 software (Supplementary Table 2). PCR was performed in a final volume 
of 10 μL with 0.5 μL cDNA reaction using 50 nM junction specific PCR primers and 
0.1 μL AmpliTaq Gold polymerase (Thermo Fisher Scientific) with standard PCR cycling 
conditions. cDNA samples from matching normal tissue were used as a control to 
be able to confirm that fusion genes were tumor-specific. 
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FUSION GENE CLONING
Primers specific for the entire fusion transcripts were designed using primer3 
software. PCR products containing the entire fusion genes were cloned into the 
pBABE-puro retroviral mammalian expression vector. pBABE-puro was obtained 
through Addgene (Addgene plasmid # 1764).
FUSION GENE EXPRESSION AND WESTERN BLOTTING
HEK293T cells or NIH-3T3-A14 cells were transfected with 2μg of pBABE constructs 
containing fusion genes by the calcium phosphate method. Cells were co-transfected 
with constructs containing either myc-tagged ERK1 and GFPtagged AKT. After 48 
hours cells were serum starved for 12 hours before cells were lysed with NP40 lysis 
buffer (150 mM NaCl, 50 mM Tris pH 8, 1 mM EDTA pH 8, 5 mM NaF, 1% NP-40, 0.25%, 
Na deoxycholate, 2mM NaVO3, protease inhibitors (cOmplete, Roche)). Lysates were 
clarified by centrifugation (12,000 × g for 10 minutes at 4˚C), and the concentration 
of total protein in the supernatant fraction was quantified by the Qubit protein assay 
kit (Thermo Fisher Scientific). Samples were denatured in NuPage® LDS Sample 
buffer 4X (Invitrogen, UK) at 70˚C for 10 minutes and 30 μg of protein was loaded 
and run on commercially produced pre-cast 4–12% Bis-Tris gels (Life Technologies). 
Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon-
FL, Merck-Millipore). Membranes were blocked with 2% BSA (Sigma) for 1 hour in 
TBS-T prior to incubation with rabbit polyclonal antibodies directed against phospho-
AKT (Ser473) (D9E, Cell Signaling), phospho-p44/42 MAPK (ERK1/2, Thr202/Tyr204, 
Cell Signaling), c-MYC (910E, Santa Cruz Biotechnology) and mouse monoclonal anti-
α-Tubulin (CP06, Calbiochem, San Diego, CA) overnight at 4˚C and diluted 1:5000 in 
TBS-T. Fluorescently labeled secondary antibodies (goat-anti-rabbit IgG (H+L) 800CW 
and donkey-antimouse (680 RD) from LI-COR) were applied for 90 minutes at room 
temperature (1:5,000 in TBS-T) prior to washing with TBS-T. Blots were imaged using 
a LICOR Odyssey® Infrared Imaging System and software and scanned at a resolution 
of 169 μm.
TISSUE CULTURE
Human HEK-293T cells were maintained in DMEM supplemented with 10% (v/v) fetal 
bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 2mM UltraGlutamine. 
For analysis of the AKT/PI3K pathway, NIH-3T3-A14 cells were used.13 These cells 
overexpress the insulin receptor and were cultured in DMEM with low glucose (1000 
mg/L). All cell lines were maintained at 37˚C in a humidified atmosphere consisting 
of 5% CO2/95% air. 
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SUPPLEMENTARY F IGURES
SUPPLEMENTARY FIGURE 1.
Flow diagram showing patient inclusion in this study. Patient samples were gathered from July 2007 to July 
2012 as part of the Rotterdam MATCH study.
SUPPLEMENTARY FIGURE 2.
RT-PCR results of fusion gene verification. Primers for verification of cancer fusion genes were designed 
based on chimeric RNA-seq reads. M = marker, T = primary colon tumor with indicated fusion, N = matching 
normal colon tissue.
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SUPPLEMENTARY FIGURE 3.
Exonic and protein structure of three BRAF fusions. Exonic structure, selected split RNA-seq reads and protein 
structure of TRIM24-BRAF (A), AGAP3-BRAF (B), DLG1-BRAF (C). KD = kinase domain, L27 = L27 protein interaction 
module, PH = pleckstrin homology, RING = zinc finger domain, ring type , BBOX1 = B-box-type zinc finger 
domain.
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SUPPLEMENTARY FIGURE 4. 
Structure of an EML4-NTRK3 fusion gene and exonic expression of NTRK3. (A) Exonic structure, split-reads 
and protein structure of EML4-NTRK3 fusion gene. (B) Exonic expression of NTRK3 in 70 colorectal cancers 
published previously.1 The data represented by a red line are derived from a colorectal tumor expressing 
an ETV6-NTRK3 fusion gene. (C) Exonic expression of NTRK3 in 732 colorectal cancer RNA-seq datasets from 
TCGA data (https://tcga-data.nci.nih.gov/tcga/). Red lines indicate samples with increased expression of the 
entire NTRK3 kinase domain, possibly indicating the presence of an NTRK3 fusion gene. Both RNA-seq datasets 
were obtained from colon adenocarcinoma tissue. Data file identifiers and exonic expression values are 
shown in Supplementary Table 3.
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SUPPLEMENTARY FIGURE 5.
Structure and expression of a novel RRBP1-RET fusion. (A) Exonic structure, as subset of split-reads and 
protein structure of the RRBP1-RET fusion gene. The entire kinase domain of RET is fused to an N-terminal 
Rip-rcpt-KP and coiled-coil domain of RRBP1. (B) Expression of exons in the RET gene in 278 primary colon 
cancers from this study. The red curve indicates the sample with the RRBP1-RET fusion gene.
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SUPPLEMENTARY FIGURE 6.
Structure and expression of a novel USP9X-ERAS fusion gene. (A) Exonic structure and protein domains of 
the USP9X-ERAS fusion gene. (B) Expression of the ERAS gene across 521 TCGA RNA-seq data sets from colon 
cancer samples. (C) Expression of the ERAS gene across 407 TCGA RNA-seq datasets from stomach cancer 
samples. For (B) and (C), both raw read counts and upper quartile normalized FPKM values (FPKM UQ) are 
plotted. Datasets (x-axis) were ranked from low to high raw read count. Data were obtained from the 
Genomic Data Commons Data Portal (NIH). Plotted values and dataset identifiers are provided in 
Supplementary Table 3.
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SUPPLEMENTARY FIGURE 7.
Rspondin fusion gene detection and expression. (A) Structure of an EIF3E-RSPO2 fusion gene detected in a 
colon cancer sample in the cohort described in this paper. Note that the fusion does not lead to a fusion 
protein, since the RSPO2 start codon is present after the fusion point in exon 2. (B) Expression of RSPO2 and 
RSPO3 genes in colorectal cancer datasets from Seshagiri et al.3 (C) Expression of RSPO2 and RSPO3 genes in 
278 colon cancer datasets from this study.
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SUPPLEMENTARY TABLES
SUPPLEMENTARY TABLE S1. COLON TUMOR SAMPLE OVERVIEW, CLINICAL CHARACTERISTICS, FUSION GENES AND 
KRAS, NRAS, BRAF MUTATION STATUS AND SEQUENCING STATISTICS.
This supplementary table can be found online.
SUPPLEMENTARY TABLE S2. ANNOTATED LIST OF PREDICTED GENE FUSIONS THAT PASSED ALL FILTERING STEPS.
This supplementary table can be found online.
SUPPLEMENTARY TABLE S3. LIST OF RNA-SEQ DATASET IDENTIFIERS FROM TCGA USED FOR ANALYZING EXPRESSION 
OF ERAS AND NTRK3 IN COLON AND STOMACH CANCER SAMPLES.
This supplementary table can be found online.
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ABSTRACT
OBJECTIVE
Overall and splice specific expression of Spleen Tyrosine Kinase (SYK) has been posed 
as a marker predicting both poor and favorable outcome in various epithelial 
malignancies. However, its role in colorectal cancer is largely unknown. The aim of 
this study was to explore the prognostic role of SYK in three cohorts of colon cancer 
patients. 
METHODS
Total messenger RNA (mRNA) expression of SYK, SYK(T), and mRNA expression of its 
two splice variants SYK short (S) and SYK long (L) were measured using quantitative 
reverse transcriptase (RT-qPCR) in 240 primary colon cancer patients (n=160 patients 
with chemonaive lymph node negative [LNN] and n=80 patients with adjuvant treated 
lymph node positive [LNP] colon cancer) and related to microsatellite instability (MSI), 
known colorectal cancer mutations, and disease-free (DFS), hepatic metastasis-free 
(HFS) and overall survival (OS). Two independent cohorts of patients with respectively 
48 and 118 chemonaive LNN colon cancer were used for validation.
RESULTS
Expression of SYK and its splice variants was significantly lower in tumors with MSI, 
and in KRAS wild type, BRAF mutant and PTEN mutant tumors. In a multivariate Cox 
regression analysis, as a continuous variable, increasing SYK(S) mRNA expression was 
associated with worse HFS (Hazard Ratio[HR]=1.83; 95% Confidence 
Interval[CI]=1.08-3.12; p=0.026) in the LNN group, indicating a prognostic role for 
SYK(S) mRNA in patients with chemonaive LNN colon cancer. However, only a non-
significant trend between SYK(S) and HFS in one of the two validation cohorts was 
observed (HR=4.68; 95%CI=0.75-29.15; p=0.098).
CONCLUSION
In our cohort, we discovered SYK(S) as a significant prognostic marker for HFS for 
patients with untreated LNN colon cancer. This association could however not be 
confirmed in two independent smaller cohorts, suggesting that further extensive 
validation is needed to confirm the prognostic value of SYK(S) expression in 
chemonaive LNN colon cancer.
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INTRODUCTION
Colon cancer is the second most common malignancy in the Western World with 
close to 450,000 new cases in Europe in 2012.1 As in most solid cancers, histological 
tumor staging (TNM) is the best determinant of prognosis and as a result provides 
recommendations for treatment decisions. The current treatment for stage I-III colon 
cancer is surgery alone for stages I and II, and surgery combined with adjuvant 
chemotherapy for stage III. However, up to 21% of the patients with stage I-II and up 
to 40% of the patients with stage III colon cancer will develop metastatic disease after 
curative surgery.2,3 Therefore, prognostic biomarkers complementing the TNM 
classification are urgently needed.4,5
Tyrosine-protein kinases are key regulators of cell proliferation associated with poor 
survival and tumorigenesis, and are therefore extensively studied in the field of 
oncological biomarker research.6,7 Spleen tyrosine kinase (SYK) has been posed as 
marker predicting both poor and favorable outcome in various epithelial malignancies 
including colorectal cancer.8-11 However, most of these studies have focused on 
functional outcome in cell lines or associated tumor characteristics to the total mRNA 
or protein expression of SYK instead of linking mRNA and/or protein expression of 
SYK to long term clinical outcome. Furthermore, evidence suggesting different 
biological effects for the two known splice variants of SYK on growth properties of 
cancer cells is accumulating. In aggregate, the long isoform SYK(L) appears to be 
associated with tumor suppressive activities while the short isoform SYK(S) appears 
to be associated with tumor promoting activities. For instance, in patients with 
hepatocellular cancer, the expression of SYK(S) has been reported to be a significant 
indicator of poor prognosis.12
The significance of SYK and its isoforms in colorectal cancer is largely unknown. Yang 
et al. showed that hypermethylation of the SYK promoter region resulted in loss of 
overall SYK mRNA expression, which was associated with a higher tumor stage and 
reduced five-year overall survival in a heterogeneous group of stage I-IV colon and 
rectum carcinoma.13 In a second study by Ni et al. SYK(L) but not SYK(S) was 
downregulated in the majority of cancer and adjacent non-cancerous colon tissues.14 
Lastly, SYK is part of various prognostic gene signatures and the gene set used to 
define the consensus molecular subtypes of colorectal cancer.15,16 
We aimed to assess the association of mRNA expression of overall SYK (SYK(T)) and 
its splice variants SYK(L) and SYK(S) with disease outcome in a well-defined 
homogeneous prospectively collected set of primary tumor tissues of patients with 
stage I-III colon cancer. Patients with lymph node negative (LNN) colon cancer who 
did not receive systemic adjuvant chemotherapy (chemonaive) and patients with 
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lymph node positive (LNP) colon cancer who did receive adjuvant chemotherapy 
were analyzed separately to distinguish between pure disease prognosis and 
prognosis after adjuvant chemotherapy.
MATERIAL  AND METHODS
Where possible, the guidelines for Reporting recommendations for tumour 
MARKer (REMARK) prognostic studies were followed, and the paper was written 
accordingly.17 
PATIENT SELECTION
Patients were selected from the MATCH study, an ongoing prospective multicenter 
observational cohort study from 2007 onwards including adult patients who 
undergo curative surgery in one of seven participating hospitals in the Rotterdam 
region, the Netherlands. Patients received treatment according to the current 
national guideline.18 Patients were verbally informed about the storage and use of 
tissue samples, and the collection of clinical data for research purposes. The 
institutional review board of the Erasmus MC University Medical Center approved 
the MATCH study and specifically approved studies on (epi)genetic biomarkers to 
predict recurrence of diseases including the current study (Institutional Review 
Board number MEC 2007-088). Written informed consent was obtained from all 
patients. 
Inclusion criteria for this study were: informed consent available, inclusion date 
between 1st July 2007 and 1st July 2012 to ensure sufficient follow up, age > 55 years, 
stage I-II without adjuvant chemotherapy or stage III with adjuvant chemotherapy, 
radical surgery, fresh frozen tissue with at least 40% invasive tumor cells available, 
and either recurrence of disease or at least 30 months of disease-free follow-up. A 
diagram of the analysis workflow is shown in Figure 1.
The two independent validation cohorts consisted of 84 and 196 fresh frozen samples 
of primary colorectal cancers obtained through the Baylor Scott and White Research 
Institute and Charles A Sammons Cancer Center (Dallas, TX, USA) (cohort A and cohort 
B). Details on samples collection, processing and RNA isolation have been described 
previously.19 For 82 and 185 patients of these cohorts respectively, RNA was sent to 
our lab to perform the cDNA synthesis and mRNA transcript level quantifications 
using the methodology as was used for the discovery study (see below). In cohort A, 
34 patients were excluded (failed RNA/cDNA quality control [n=10], rectal carcinoma 
[n=23] and irradical resection [n=1]) leaving a total of 48 patients for analysis 
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(Supplementary Figure 1). In cohort B, 80 patients were excluded (failed RNA/cDNA 
quality control [n=7], rectal carcinoma [n=51] and age < 50 years [n=9] and incomplete 
survival data [n=2]) leaving a cohort of 116 patients for analysis (Supplementary 
Figure 2).
SAMPLE COLLECTION AND PROCESSING
Immediately following removal of the resection specimen during surgery, the 
specimen was transported to the pathology lab at room temperature and without 
any conservation fluids. In the pathology lab, two to four biopsies of both central 
and peripheral regions of the tumor as well as one or two adjacent non-tumor colon 
tissue samples were taken and fresh frozen with a maximum cold ischemia time of 
two hours. All samples were stored in liquid nitrogen. 
FIGURE 1. DIAGRAM OF ANALYSIS WORKFLOW OF THE MATCH COHORT
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RNA ISOLATION, CDNA SYNTHESIS AND MRNA TRANSCRIPT LEVEL 
QUANTIFICATION
Sectioning of fresh frozen colon cancer and normal colon tissue was done using a 
cryostat microtome (Thermo Scientific Microm HM 560, Thermo Fisher Scientific, 
inc.) set at -20°C. Before, during and after sectioning for RNA isolation, 3 x 5 µm 
sections were cut and after hematoxylin-eosin (HE) staining reviewed by two 
pathologists independently. For the MATCH cohort, the percentage of tumor cells, 
necrosis, infiltrate and normal cells were estimated relative to other cells (e.g. 
stromal cells, inflammatory infiltrate and pre-existing epithelial cells). The estimates 
were scored in categories of 0–5%, 6–10%, 11–20%, 21–30%, 31–40%, 41–50%, 
51–60%, 61–70%, 71–80%, 81–90%, and 91–100% tumor cells. Differentiation grade 
of the tumor was estimated according to the WHO 2010 classification for the 
carcinoma of the colon and rectum (WHO Press, World Health Organization, 20 
Avenue Appia, Geneva, Switzerland). For the validation cohorts, no HE slides were 
available for evaluation.
For the discovery cohort, RNA was isolated from 30 µm sections using RNA-Bee® 
according to the manufacturer’s instructions (Tel-Test inc., USA). For the validation 
cohorts, RNA was isolated with the RNeasy tissue kit (Qiagen, Germany). Quality and 
quantity of RNA was assessed with the Nanodrop ND-1000 (Thermo Scientific, 
Wilmington, USA) and the MultiNA Microchip Electrophoresis system (Shimadzu, 
Kyoto, Japan). Next, cDNA was generated from 2 µg of the isolated total RNA for the 
discovery cohort and from 0.1-1 µg of the isolated total RNA for the validation cohort 
using Reverse Transcriptase (RT) with the Thermo Scientific RevertAid H Minus First 
Strand cDNA Synthesis Kit (Fermentas, Thermo Scientific, USA) using the protocol 
supplied by the manufacturer, followed by an RNAse H step (Ambion, Life 
Technologies, USA) to digest any remaining RNA. Quantitative real-time PCR (qPCR) 
was performed with the Mx3000P QPCR machine (Agilent Technologies, NL) using 
ABgene Absolute Universal or Absolute SYBR Green with ROX PCR reaction mixtures 
(Thermo Scientific, USA) according the manufacturer’s instructions.20 
SYK mRNA expression levels were quantified with commercially available and 
validated TaqMan assays (Applied Biosystems, Thermo Scientific, USA) for the total 
expression of SYK (SYK(T)); Hs00374292_m1, and for its two alternative splicing variants, 
full-length SYK (SYK(L)); Hs00895384_m1 and the short gene product lacking a 23-amino 
acid insert within the “linker” region located between the second Src homology 2 and 
the catalytic domain (SYK(S)); Hs00177369_m1. SYK mRNA expression levels were 
normalized using the average of three reference genes (HMBS, HPRT1 and TBP) using 
the 2-ΔΔCq method as described in detail before by Livak and Schmittgen 21 and 
Sieuwerts et al 22, using a serially diluted pooled tumor cDNA sample as calibrator in 
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every run to allow comparisons between runs. Only cDNA samples that were at a 
100-fold final dilution in the qPCR able to generate a Cq value for the average of the 
reference genes within 28 cycles were considered of sufficient quality and quantity 
to be included in the study. Specifics of the gene assays used are provided in 
Supplementary Table 1.
MESENCHYMAL AND INFILTRATE MARKERS
To capture epithelial to mesenchymal transition (EMT), the mRNA expression levels 
of one epithelial marker (EPCAM) and the three mesenchymal markers from the 
Oncotype Dx (BGN, FAP, INHBA) were measured using RT-qPCR.23
PTPRC mRNA levels (a measure for CD45), which is present on all differentiated 
hematopoietic cells except erythrocytes and plasma cells, were used to estimate the 
contribution of infiltrate. Specifics of the gene assays to generate these indices are 
provided in Supplementary Table 1. 
MUTATION CALLING
For n=238 patients, RNA sequencing data was available.24 In short, somatic genetic 
variations were detected in RNA-seq data using the GATK RNA-seq variant calling 
tool.25 From the variant call list produced by the GATK workflow, we only retained 
calls that overlapped known cancer mutations present in the COSMIC database.26
MICROSATELLITE INSTABILITY (MSI)
MSI was analyzed with the MSI Analysis System from Promega, a fluorescent PCR-
based assay for the detection of MSI in 5 mononucleotide repeat markers (BAT-25, 
BAT-26, NR-21, NR-24 and MONO-27) and two pentanucleotide repeat markers (Penta 
C and Penta D). The mononucleotide markers were used for MSI determination, and 
the pentanucleotide markers to detect potential sample mix ups and/or 
contamination using the protocol supplied by the manufacturer. In brief, genomic 
DNA was extracted with the NucleoSpin Tissue kit (Macherey-Nagel, BIOKE, Leiden, 
NL) from 2 to 5 x 30 µm sections cut in between the sections used for the RNA 
isolation. Quality and quantity were assessed by both Nanodrop, the Quant-iT 
PicoGreen dsDNA kit (Life Technnologies) and agarose gel electrophoresis. Next, 2 
ng of PicoGreen measured DNA was used in the analysis for MSI.
The technical personnel performed all the above-mentioned analyses blinded from 
clinical outcome since they received the samples with according sample numbers 
and had no access to the patient identifying data nor the clinical data.
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SURVIVAL DATA
Disease free survival (DFS) was defined as the time elapsed between the date of 
surgery, and either the date of any recurrence of disease or the date of the last 
follow-up visit at which a patient was considered to have no recurrence. Hepatic 
metastasis free survival (HFS) was defined as the time elapsed between the date of 
surgery, and either the date of the appearance of liver metastasis or the date of the 
last follow-up visit at which a patient was considered to have no liver metastases.
Overall survival (OS) was defined as the time elapsed between the date of surgery, 
and either the date of death or the date of the last check in the Municipal Personal 
Records Database. 
STATISTICAL ANALYSES
Statistical analyses were performed using the SPSS statistical package version 21. 
mRNA expression levels of SYK(T), SYK(S) and SYK(L) were correlated with each other, 
the epithelial, mesenchymal and infiltrate markers, the clinicopathological 
characteristics and assessed CRC mutations using the Spearman Rank correlation 
test, Mann-Whitney U test, Kruskal-Wallis test and Jonckheere-Terpstra test where 
appropriate. Univariate Cox regression analysis was used to assess the association 
of the mRNA expression levels of SYK(T), SYK(S) and SYK(L) as a continuous variable 
and clinicopathological characteristics with the clinical endpoints. Kaplan Meier 
estimates were used to visualize the association between mRNA expression of SYK 
and its splice variants with the relevant clinical endpoints. To this end, mRNA 
expression levels were split at the median level. Multivariate Cox regression analysis 
was used to assess the association between mRNA expression and clinical outcome 
while correcting for other clinicopathological factors associated with the clinical 
endpoint of interest. All analyses were two-sided and P<0.05 was considered 
significant. 
RESULTS
CORRELATION OF MRNA EXPRESSION LEVELS  SYK(T)  AND ITS  SPL ICE  VARIANTS
First, we assessed the correlation between SYK(T), SYK(S) and SYK(L). SYK(T) showed a 
good correlation with both SYK(S) and SYK(L) (Spearman’s Rho (rs)=0.74, p<0.001 and 
rs=0.86 p<0.001, respectively) while SYK(S) and SYK(L) expression levels showed only 
a moderate association (rs=0.48 p<0.001) (Supplementary Figure 3). The worse 
correlation between the two splice variants suggested that a separate analysis of the 
splice variants may be of added value.
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ASSOCIATION OF SYK  MRNA EXPRESSION LEVELS WITH CLINICAL AND 
HISTOPATHOLOGICAL CHARACTERISTICS
In total, 240 patients were included in the discovery cohort. Clinical and 
histopathological characteristics, and median SYK(T), SYK(S) and SYK(L) mRNA 
expression levels and their associations for the entire group are shown in Table 1, 
for the 160 patients with lymph node negative (LNN) disease in Supplementary 
Table 2a and for the 80 patients with lymph node positive (LNP) disease in 
Supplementary Table 2b. 
A significantly lower expression of SYK(T), SYK(S) and SYK(L) was found in MSI tumors 
as compared to MicroSatellite Stable (MSS) tumors. This finding was observed in the 
total group as well as in both subgroups, except for SYK(L) in the LNP group. SYK 
expression was also significantly associated with tumor stage and location, but 
significance was dependent on the type of variant analyzed. While expression of 
SYK(S) was higher in stage I and II than in stage III, expression of SYK(T) and SYK(L) was 
not found to correlate in an unambiguous way with tumor stage. Independent of 
stage, a higher expression of SYK(T), SYK(S) and SYK(L) was found in left sided tumors, 
which was also observed for SYK(S) in the LNN group and for SYK(T) and SYK(L) in the 
LNP group. 
These data indicated a differential expression of SYK splice variants as compared to 
total SYK expression, with significant differences in mRNA expression of SYK(T), SYK(S) 
and/or SYK(L) with MSI status, stage and tumor location.
ASSOCIATION OF SYK  MRNA EXPRESSION LEVELS AND MESENCHYMAL MARKERS
To explore the association between the SYK isoform variants and features of EMT in 
our cohort, mRNA expression levels of one epithelial marker (EPCAM) and the three 
mesenchymal markers from the Oncotype Dx23 (BGN, FAP, INHBA) were measured 
using RT-qPCR (Supplementary Figure 3). mRNA expression levels of SYK(T), SYK(S) 
or SYK(L) all showed a moderate positive correlation with mRNA expression of EPCAM 
(rs=0.47 p<0.001, rs=0.58 p=0.001 and rs=0.41 p<0.001, respectively). For the stromal 
markers, only FAP showed a significant but less striking negative association with 
SYK(S) in the total group (rs=-0.13 p=0.046) and LNP group (rs=-0.24 p=0.031).
ASSOCIATION OF SYK MRNA EXPRESSION LEVELS AND INFILTRATE
As SYK is a known infiltrate marker27, we next explored the association between 
mRNA and protein expression levels of SYK and its isoform variants, and the extent 
of possible infiltrate contribution. We measured mRNA expression levels of an 
infiltrate marker (PTPRC/CD45) using RT-qPCR and scored the percentage of infiltrate 
on H&E slides. Although mRNA expression levels of SYK(S) correlated moderately 
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negatively with the percentage of infiltrate as scored by a pathologist in the total 
group (rs=-0.14 p=0.043), we did not observe a significant association between 
PTPRC/CD45 and mRNA expression of SYK or its splice variants (Supplementary 
Table 4). 
ASSOCIATION OF SYK  MRNA EXPRESSION LEVELS WITH KNOWN CRC MUTATIONS
Because of the correlation of SYK mRNA expression with MSI and a previous study 
which showed that SYK is differentially expressed in KRAS-dependent and KRAS-
independent cancer cell lines28, we explored the association between known CRC 
mutations and SYK expression in our MATCH cohort and TCGA (Figure 2). The 
mutation rates were: APC 90.4%, TP53 83.3%, KRAS 35.4%, BRAF 7.9%, PTEN 3.8%, 
SMAD4 3.3% and NRAS 1.7% (Figure 2a). mRNA expression of SYK(T) was significantly 
higher in KRAS mutant (mt), and lower in BRAF mt and PTEN mt tumors compared to 
wild type (wt) tumors (p=0.021, p=0.01 and p=0.031, respectively) (Figure 2b). 
A similar association was observed for SYK(S) (BRAF p<0.001 and PTEN p=0.002, 
respectively), while no significant associations were found for SYK(L) (Figure 2c-d). 
In line with literature29, these mutations were more prevalent in MSI tumors than in 
MSS tumors (BRAF 30.6% vs 2.1%, p<0.001 and PTEN 10.2% vs 2.1% p=0.008). No 
significant differences in mRNA expression for SYK(T), SYK(S) and SYK(L) were observed.
Next, we analyzed all cases of stage I-III colon cancer in the TCGA for which both the 
known CRC mutations and SYK(T) expression levels were available (n=108) (Figure 
2e). In this cohort, SYK(T) expression was significantly lower in BRAF mt tumors 
compared to wild type tumors (p=0.0018) and significantly lower in APC mt tumors 
compared to wild type tumors (p=0.009) (Figure 2f).
ASSOCIATION OF SYK  MRNA EXPRESSION LEVELS WITH SURVIVAL
First, associations between basic patient characteristics and survival outcome were 
assessed using Cox regression analysis. In the total MATCH cohort, having a stage 
III tumor or more than three positive lymph nodes (N2 versus N0) was significantly 
associated with an adverse DFS. Age, gender and more than three positive lymph 
nodes were significantly associated with poor OS (Supplementary Table 5a). In the 
LNN subgroup, less than ten lymph nodes assessed in total was associated with an 
adverse HFS. In this sub group, only age at time of surgery was significantly associated 
with OS (Supplementary Table 5b). In the LNP group, more than three positive 
lymph nodes was significantly associated with an adverse DFS. Also, the presence of 
more than three positive lymph nodes and increasing age were significantly 
associated with poor OS in the LNP subgroup of the MATCH cohort (Supplementary 
Table 5c).
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Subsequently, the associations between mRNA expression levels of SYK and its splice 
variants with DFS, HFS and OS were assessed using Cox regression analysis. For the 
whole MATCH cohort (n=240), no significant associations were found between mRNA 
expression of SYK(T), SYK(S) and SYK(L), and the clinical endpoints (Supplementary 
Table 5a). Next, the LNN chemonaive group (n=160) and the LNP group who had 
received adjuvant therapy (n=80) were analyzed separately.
FIGURE 2. THE ASSOCIATION BETWEEN SYK MRNA EXPRESSION AND KNOWN CRC MUTATIONS
Mutation rates in the MATCH cohort (n=240)(a); differences in mRNA expression of SYK(T) (b), SYK(S) (c) and 
SYK(L) (d) in the MATCH cohort; mutation rates in the TCGA (n=108)(e); differences in mRNA expression of 
SYK(T) in the TCGA cohort (f).
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In the LNN group, higher mRNA expression levels of SYK(T) and SYK(S) (continuous 
variables) were significantly associated with poor HFS (Hazard Ratio [HR]=2.05; 95% 
Confidence Interval [CI]=1.01-4.17; p=0.047 and HR=2.14; 95% CI=1.14-4.01; p=0.018, 
respectively) (Supplementary Table 5b). The association of mRNA expression of 
SYK(T) and SYK(S) split into four quartiles (Q1 with lowest mRNA expression levels 
through Q4 with the highest mRNA expression levels) with HFS was visualized by 
Kaplan-Meier curves (Figures 3a and 3b), which suggested an impaired HFS 
particularly for patients with SYK(S) mRNA expression levels of the tumor in Q4. These 
findings were confirmed in an exploratory analysis with Cox regression analysis 
showing a significantly worse HFS for Q4 versus Q1-Q3 (HR=3.83; 95%CI=1.23-11.86; 
p=0.02). To explore the prognostic role of SYK(S) for HFS independent of other 
significantly associated factors in the LNN group, we performed a multivariate Cox 
regression model including N-status, the only other factor significantly related to HFS 
in the LNN group, and SYK(S) mRNA expression level. In this analysis, both continuous 
mRNA expression levels of SYK(S) and nodal status remained significantly associated 
with HFS (HR=1.83; 95% CI=1.08-3.12; p=0.026 and HR=1.27; 95%CI=1.01-1.60; 
p=0.042) (Table 2). However, since the total number of events in this low-risk group 
was only 12, these results should be interpreted with caution.
In the LNP group, no significant associations between any of the SYK mRNA expression 
levels and clinical endpoints were observed (Supplementary Table 5c).
FIGURE 3. SURVIVAL CURVES FOR HFS IN THE LNN SUBGROUP OF THE MATCH COHORT FOR SYK(T) SPLIT IN 
QUARTILES (A) AND FOR SYK(S) SPLIT IN QUARTILES (B)
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VALIDATION COHORTS
Details on patient and tumor characteristics for both cohorts can be found in Table 
3. More patients in cohort A and B had a T1/T4 tumor compared to patients in the 
LNN subgroup of the MATCH cohort (14.6% and 8.6% vs 0%, p<0.001 respectively). 
The total number of assessed lymph nodes was less often below the cut-off of 10 
lymph nodes (cohort A 4.2% and cohort B 12.9% vs 18.1% in the LNN subgroup of 
the MATCH cohort, p<0.001). Both cohort A and B contained more well differentiated 
tumors compared to the LNN MATCH cohort (83.3% and 93.1% vs 8.1%, p<0.001 
TABLE 2. UNIVARIATE AND MULTIVARIATE COX REGRESSION ANALYSIS FOR THE LNN MATCH COHORT
HFS (EVENTS=12)
HR (95%CI) P VALUE HR (95%CI) P VALUE
n %
mRNA expression
SYK(S) 160 100% 2.14 (1.14 • 4.01) 0.018 1.83 (1.08 • 3.12) 0.026
Gender
Female 78 48.8% 1
Male 82 51.3% 1.97 (0.59 • 6.53) 0.27
Age 160 100% 1.01 (0.94 • 1.08) 0.79
Tumor stage
Stage I 60 37.5% 1
Stage II 100 62.5% 1.21 (0.36 • 4.02) 0.76
Stage III -
T status
T2 60 37.5% 1
T3 100 62.5% 1.21 (0.36 • 4.02) 0.76
Nodal status
N0 ≥ 10 nodes assessed 131 81.9% 1
N0 < 10 nodes assessed 29 18.1% 3.42 (1.09 • 10.78) 0.04 1.27 (1.01 • 1.60) 0.042
N1 -
N2 -
Tumor grade
Good 13 8.1% 1
Moderate 135 84.4% 0.88 (0.11 • 6.91) 0.27
Poor 9 5.6% 2.85 (0.26 • 31.39) 0.39
Othera 3 1.9% - -
Location
Right 82 51.3% 1
Left 78 48.8% 1.09 (0.35 • 3.38) 0.88
MSI statusb
MSI 37 23.1% 1
MSS 122 76.1% 31.28 (0.12 • 8430.24) 0.23
a there were no events in this subgroup; b n=1 missing 
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respectively). In cohort A, more tumors were right-sided compared to the LNN 
subgroup of the MATCH cohort (79.2% vs 51.3%, p>0.001). In cohort B, less tumors 
for which MSI status was known were MSI compared to the LNN subgroup of the 
MATCH cohort (9.5% vs 23.3%, p=0.019). No differences for the distribution of gender, 
age, tumor stage, or location of recurrence between the validation cohorts and the 
LNN subgroup of the MATCH cohort were observed (Table 3). No significant 
association between mRNA expression of SYK(T) or its splice variants with any of 
these characteristics were observed.
TABLE 3. BASIC CHARACTERISTICS OF THE LNN MATCH COHORT, AND VALIDATION COHORTS A AND B
MATCH COHORT COHORT A COHORT B P VALUE
Gender
Female 78 (48.8%) 24 (50.0%) 51 (44.0%) 0.67
Male 82 (51.3%) 24 (50.0%) 65 (56.0%)
Age 68 (62-75) 69 (61-78) 0.89
Tumor stage
Stage I 60 (37.5%) 16 (33.3%) 37 (31.9%) 0.61
Stage II 100 (62.5%) 32 (66.7%) 79 (68.1%)
T status
T1 0 (0.0%) 3 (6.3%) 10 (8.6%) <0.001
T2 60 (37.5%) 13 (27.1%) 27 (23.3%)
T3 100 (62.5%) 28 (58.3%) 79 (68.1%)
T4 0 (0.0%) 4 (8.3%) 0 (0.0%)
Nodal status
N0 ≥ 10 nodes assessed 131 (81.9%) 46 (95.8%) 101 (87.1%) 0.046
N0 < 10 nodes assessed 29 (18.1%) 2 (4.2%) 15 (12.9%)
Tumor grade
Good 13 (8.1%) 40 (83.3%) 108 (93.1%) <0.001
Moderate 135 (84.4%) 5 (10.4%) 0 (0.0%)
Poor 9 (5.6%) 2 (4.2%) 8 (6.9%)
Other 3 (1.9%) 1 (2.1%) 0 (0.0%)
Location
Right 82 (51.3%) 38 (79.2%) 53 (45.7%) <0.001
Left 78 (48.8%) 10 (20.8%) 63 (54.3%)
MSI statusa
MSI 37 (23.1%) - 6 (9.5%) 0.019
MSS 122 (76.3%) - 57 (90.5%)
Location of recurrence
No recurrence 133 (83.1%) 41 (85.4%) 105 (90.5%) 0.65
Local 2 (1.3%) 1 (2.1%) 2 (17%)
Hepatic 11 (6.9%) 2 (4.2%) 5 (4.3%)
Non hepatic 11 (6.9%) 3 (6.3%) 4 (3.4%)
Combined 3 (1.9%) 1 (2.1%) 0 (0.0%)
a n=1 missing in the MATCH cohort and n=53 missing in cohort B
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In both cohorts, no significant associations were observed between mRNA expression 
of SYK(T) nor the splice variants with DFS or HFS, although a non-significant trend 
between mRNA expression levels SYK(S) and HFS was observed in cohort A (HR=4.68; 
95%CI=0.75-29.15; p=0.098).
DISCUSSION
In epithelial malignancies, both tumor promoting and tumor suppressing roles have 
been ascribed to SYK. Evidence suggesting different effects of the SYK splice variants 
on growth properties of cancer cells is accumulating.10 The dual role of SYK in 
epithelial cancers combined with the scarce literature on the role of SYK and its splice 
variants in colorectal cancer provided a rationale to assess their prognostic value in 
primary tumors of colon cancer patients. This study showed that high mRNA 
expression level of SYK(S) is associated with short HFS in our MATCH cohort of 
chemonaive LNN colon cancer patients, although these findings could not be 
validated in two independent clinically less well-defined and smaller cohorts of 
patients with chemonaive LNN colon cancer.
Three major mechanisms through which SYK may affect cancer cell properties have 
been identified: SYK promoting cell survival through anti-apoptotic factors, SYK 
altering cellular differentiation programs regulating EMT and SYK altering cell motility. 
Importantly, SYK has two alternatively spliced variants, SYK(L) and SYK(S). In the short 
splice variant which a stretch of 23 amino acids in linker B (Exon 7) is spliced out. In 
normal hematopoietic cells, SYK(S) is intrinsically less active compared to SYK(L). In 
most epithelial cancers, overall SYK mRNA levels are higher in cancerous cells 
compared to normal cells of the same organ, including colon, suggesting a tumor 
promotor role of SYK in tumorigenesis.10 
However, SYK mRNA or SYK protein expression have been both positively and 
negatively associated with tumor characteristics such as tumor grade and tumor 
stage. This paradoxical association may be explained by the accumulating 
observations that SYK(S) and SYK(L) both have an active but opposing role in solid 
cancers.30,31 These opposing effects are generally attributed to a different location 
within the cell with SYK(L) being present in both the nucleus and cytoplasm, and 
SYK(S) being confined to the cytoplasm.12,30,32 Wang and co-workers showed that 
SYK(L) was present in both normal and cancerous cells, and suppressed cell 
invasiveness in breast cancer cell lines. In contrast, SYK(S) was present only present 
in cancerous cells, but did not affect cell invasiveness.30 Hong et al. observed similar 
differential expression patterns in hepatocellular carcinoma (HCC) as SYK(L) mRNA 
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expression was downregulated in 38% of the tumor samples while SYK(S) mRNA 
expression was detectable in 40% of the tumor samples and none of the normal liver 
tissue samples. Furthermore, SYK(S) mRNA expression levels were higher in poorly 
differentiated tumors compared to well differentiated tumors, while SYK(L) was 
expressed vice versa.12 Ni et al. showed that overexpression of SYK(L) significantly 
reduced cell proliferation in vitro while SYK(S) overexpression did not in the human 
colorectal cancer HCT116 cell line. They also observed downregulation of SYK(L) but 
not SYK(S) 69% of tumor tissue samples compared to adjacent non-cancerous 
tissues.14 In the current study we observed an decreased mRNA expression of SYK(S) 
in stage III compared to stage I-II colon cancers, but no association between mRNA 
expression of the splice variants with tumor grade. The latter may be explained by 
the large portion (88.3%) of well to moderately differentiated tumors in our cohort. 
Overall, the findings in literature and the current study suggest that SYK(S) is 
associated with tumor promoting activities while SYK(L) is associated with tumor 
suppressing activities. 
We also observed differential expression between left and right-sided tumors, MSI 
and MSS tumors, and between tumors with and without known CRC mutations. 
Right-sided tumors, MSI tumors, BRAF mt tumors and PTEN mt tumors expressed 
SYK(T) and SYK(S) at a significantly lower level compared to left-sided tumors, MSS 
tumors, and wild type tumors in both the total and LNN subgroup, respectively. The 
lower expression of SYK(T) and SYK(S) in tumors harboring a PTEN mutation supports 
the findings of a previous study on diffuse large B-cell lymphomas in which a subset 
of samples exhibited an increase in the SYK gene copy number variation while a 
different subset exhibited loss of PTEN suggesting two independent mechanisms to 
promote cell survival.33 The association between high mRNA expression of SYK(T) and 
both splice variants and microsatellite stability is interesting, as microsatellite stability 
is considered to be a phenotype associated with poor prognosis.34 In aggregate, these 
findings may suggest a different role for SYK in hypermutated versus non-
hypermutated tumors, although these findings should be verified in independent 
cohorts. We also observed a higher expression of SYK(T) in KRAS mt compared to KRAS 
wt tumors in our own cohort. These findings were in line with a previous study 
reporting higher expression KRAS-dependent compared to KRAS-independent 
pancreatic and lung cancer cell lines.28 Thus, SYK may play a different role in KRAS mt 
and KRAS wt tumors. Functional studies should be conducted in colorectal cancer 
cell lines and/or samples to confirm this assumption.
Next to the associations with tumor characteristics, we showed that high SYK(S) 
mRNA expression is associated with short HFS in our MATCH cohort of chemonaive 
LNN colon cancer patients. To our knowledge, one previous study of colorectal 
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cancer patients explored the prognostic role of SYK. Yang et al. showed that 
methylation of the SYK gene promoter region was associated with decreased SYK 
mRNA and SYK protein expression, and subsequently showed a significantly worse 
five-year OS in the group with methylated SYK gene promoter region compared to 
the group with unmethylated SYK gene promoter region (5-year overall survival 
59% vs 80% p<0.001, respectively.13 However, the cohort consisted of stage I to IV 
colon and rectum carcinoma, and no details regarding neoadjuvant or adjuvant 
therapy and DFS were provided. Furthermore, only total expression of SYK was 
measured leaving questions regarding the prognostic value of the splice variants 
in their cohort unanswered. Interestingly, the prognostic role of the splice variants 
of SYK was investigated by Hong et al., who showed that patients with a SYK(S)-
positive HCC were more likely to develop early and late recurrence (80.3% vs 53.8% 
P=0.001 and 66.7% vs 16.7%; P=0.002 respectively) compared to patients with a 
 SYK(S)-negative HCC, which supports the findings in the MATCH cohort. Hong et al. 
also showed that patients with a SYK(S)-positive HCC had a worse OS compared to 
patients with a SYK(S)-negative HCC.12 We did not observe an association between 
SYK mRNA expression and OS in our cohort. Furthermore, we did not find evidence 
supporting a tumor suppressor role for SYK(L). 
Unfortunately, the findings in the MATCH cohort could not be confirmed in two 
independent cohorts of patients with chemonaive LNN colon cancer and therefore 
warrant further investigation. The different observations in the MATCH cohort and 
the two validation cohorts with regard to clinical outcome may be explained by the 
limited number of patients and events (especially in cohort A with 48 patients and 
only 3 events for HFS). Second, the observed differences may be explained by 
differences in tumor biology. The large majority of tumors in both validation cohorts 
were well-differentiated compared to a large majority of moderately differentiated 
tumors in the MATCH cohort. Furthermore, Cohort A contained significantly more 
right-sided tumors while cohort B contained significantly less MSI tumors compared 
to the LNN subgroup of the MATCH cohort. Beside the biological differences 
associated with these tumor characteristics, we showed that expression of SYK(T) 
and its splice variants was significantly different for left- vs right-sided tumors and 
for MSS vs MSI tumors in the MATCH cohort. Lastly, the two validation cohorts 
originated from Japan, which may account for some of the observed differences as 
worldwide variations in clinical outcome in colorectal cancer patients have been 
shown.35 
In conclusion, the differential expression of SYK(T) and its splice variants between 
left and right-sided tumors, MSI and MSS tumors, and tumors with and without a 
BRAF and/or PTEN mutation suggest a different role for SYK in hypermutated and 
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non-hypermutated tumors. Furthermore, high SYK(S) was associated with poor HFS 
in the prospectively collected MATCH cohort of patients with chemonaive LNN 
colon cancer. However, the association was not confirmed in two independent, 
clinically less well-defined and smaller cohorts of patients with chemonaive LNN 
colon cancer. Further research is warranted to elucidate the role of SYK and its 
splice variants in colorectal cancer.
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SUPPLEMENTARY F IGURES
SUPPLEMENTARY FIGURE 1. DIAGRAM OF ANALYSIS WORKFLOW OF VALIDATION COHORT A
SUPPLEMENTARY FIGURE 2. DIAGRAM OF ANALYSIS WORKFLOW OF VALIDATION COHORT B
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SUPPLEMENTARY FIGURE 3. CORRELATION PLOTS AND PEARSON CORRELATION COEFFICIENTS OF THE CORRELATION 
BETWEEN SYK(T), SYK(S) AND SYK(L)
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SUPPLEMENTARY TABLE 3.
The association between epithelial and mesenchyal markers and SYK(T), SYK(S) and SYK(L) for the total 
MATCH cohort, and the LNN and LNP subgroups of the MATCH cohort. 
EPCAM BGN FAP INHBA
rs P value rs P value rs P value rs P value
Total MATCH cohort
SYK(T) 0.47 <0.001 0.00 0.97 -0.08 0.22 -0.01 0.86
SYK(S) 0.58 <0.001 -0.06 0.40 -0.13 0.046 -0.07 0.31
SYK(L) 0.41 <0.001 0.12 0.07 0.03 0.65 0.08 0.24
LNN cohort
SYK(T) 0.47 <0.001 0.02 0.83 -0.06 0.46 -0.02 0.80
SYK(S) 0.55 <0.001 0.02 0.80 -0.06 0.43 -0.05 0.53
SYK(L) 0.36 <0.001 0.10 0.20 0.03 0.75 0.04 0.60
LNP cohort
SYK(T) 0.51 <0.001 -0.01 0.91 -0.13 0.27 -0.00 0.99
SYK(S) 0.59 <0.001 -0.21 0.07 -0.24 0.031 -0.17 0.14
SYK(L) 0.39 <0.001 0.16 0.16 0.06 0.58 0.12 0.29
SUPPLEMENTARY TABLE 4.
The association between infiltrate markers and SYK(T), SYK(S) and SYK(L) for the total MATCH cohort, and 
the LNN and LNP subgroups of the MATCH cohort. 
PTPRC/CD45 VEGFA % OF INFILTRATING 
CELLS
% OF INVASIVE 
TUMOR CELLS
rs P value rs P value rs P value rs P value
Total MATCH cohort
SYK(T) 0.09 0.18 0.16 0.012 -0.04 0.56 -0.10 0.14
SYK(S) 0.12 0.07 0.16 0.015 -0.14 0.043 0.03 0.64
SYK(L) 0.08 0.21 0.12 0.06 0.04 0.56 -0.09 0.18
LNN cohort
SYK(T) 0.02 0.81 0.16 0.05 -0.04 0.63 -0.10 0.19
SYK(S) 0.09 0.26 0.19 0.017 -0.24 0.007 0.04 0.59
SYK(L) 0.01 0.93 0.13 0.09 0.05 0.62 -0.14 0.07
LNP cohort
SYK(T) 0.18 0.11 0.18 0.11 -0.03 0.80 -0.10 0.38
SYK(S) 0.10 0.38 0.09 0.42 0.02 0.87 -0.14 0.21
SYK(L) 0.08 0.48 0.10 0.39 0.07 0.57 -0.13 0.24
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ABSTRACT
The identification of patients with high-risk stage II colon cancer who may benefit 
from adjuvant therapy remains an unmet need. Understanding of tumour biology 
may be used to tailor the clinical approach for these patients. MicroRNAs have been 
proposed as markers for prognosis or treatment response in colorectal cancer. 
Recently, a 2-microRNA signature (let-7i and miR-10b) was proposed to identify 
colorectal cancer patients at risk of developing distant metastasis. We assessed the 
prognostic value of this signature and additional candidate microRNAs in an 
independent clinically well-defined prospectively collected cohort of primary colon 
cancers including stage I-II colon cancer without and stage III colon cancer with 
adjuvant treatment. The 2-microRNA signature predicted specifically hepatic 
recurrence in the stage I-II group, but not overall the ability to develop distant 
metastasis. Addition of miR-30b to the 2-microRNA signature allowed prediction of 
both distant metastasis and hepatic recurrence in patients with stage I-II colon cancer 
who did not receive adjuvant chemotherapy. Available gene expression data allowed 
us to associate miR-30b expression with axon guidance and let-7i expression with 
cell adhesion, migration and motility.
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INTRODUCTION
Colorectal cancer (CRC) is the second most common malignancy in the Western World 
with close to 450,000 new cases in Europe in 2012.1 As in most solid cancers, histologic 
tumour staging (TNM) is to date the best determinant for prognosis and treatment. 
The current treatment for stage I-III colon cancer is surgery alone for stages I and II, 
and surgery followed by adjuvant chemotherapy for stage III. Despite treatment, up 
to 21% of the patients with stage I-II and up to 40% of the patients with stage III colon 
cancer will develop metastatic disease after curative surgery.2,3 Therefore, prognostic 
biomarkers complementing the TNM classification are urgently needed.4,5 The only 
biomarker that is currently used to predict prognosis and response to therapy in 
resectable colon cancer is microsatellite instability (MSI), a phenotype associated with 
a favourable prognosis compared to microsatellite stable (MSS) tumours.6 
MicroRNAs (miRNAs) are a group of short noncoding RNAs that regulate gene 
expression at the post-transcriptional level.7 In cancer, miRNAs are known to play a 
central role in key pathways. In CRC, a growing number of miRNAs has been connected 
to different steps of tumorigenesis and has been proposed as markers for prognosis 
or treatment response.8 Recently, Hur et al. identified six miRNAs as potential markers 
for the development of metastases in CRC patients (miR-320, miR-221, miR-30b, miR-
10b, miR-885-5p, let-7i) through a metastasis-specific miRNA biomarker discovery 
approach showing differential expression of these six miRNAs between primary CRC 
and paired liver metastases tissues.9 Two of these miRNAs (miR-10b and let-7i), 
measured in primary tumours, were associated with the development of distant 
metastases. The combination of the expression of these two miRNAs identified a 
group of patients which remained entirely free of distant metastases.
In this study, we aimed to assess the prognostic value of the above-mentioned 
miRNAs and the 2-miRNA metastasis-specific signature in a clinically well-defined 
independent prospectively collected cohort of primary colon cancers. Patients with 
lymph node negative (LNN) colon cancer who did not receive systemic adjuvant 
chemotherapy (untreated) and patients with lymph node positive (LNP) colon cancer 
who did receive adjuvant chemotherapy were analysed separately to distinguish 
between the natural course of the disease (pure prognosis) and prognosis while 
receiving adjuvant chemotherapy. 
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METHODS
All aspects of the guidelines for REporting recommendations for tumour MARKer 
(REMARK) prognostic studies were followed, and the paper was written accordingly.10 
The study was conducted according to Declaration of Helsinki. All procedures 
involving human subjects were approved by the Erasmus MC University Medical 
Centre Institutional Review Board (MEC 2007-088).
PATIENT SELECTION
Patients were selected from the MATCH-cohort, an observational prospective 
multicentre cohort study from 2007 onwards including patients who undergo curative 
surgery for CRC in one of seven participating hospitals in the Rotterdam region, the 
Netherlands. Patients gave written informed consent for the storage and use of 
biobank samples for research purposes, and the collection of clinical data 
(Institutional Review Board number MEC 2007-088).
Inclusion criteria for this study were: informed consent available, inclusion date between 
1st July 2007 and 1st July 2012, age 55-85 years, stage I-II without adjuvant chemotherapy 
or stage III with adjuvant chemotherapy, fresh frozen tissue with at least 40% invasive 
tumour cells available, and either recurrence of disease or at least 30 months of disease-
free follow-up. A diagram of patient selection is shown in Figure 1. 
SAMPLE COLLECTION AND PROCESSING
The resection specimens were transported to the pathology laboratory immediately 
following removal during surgery. In the pathology laboratory, two to four samples of 
both central and peripheral regions of the tumour, and one or two adjacent non-tumour 
colon tissue samples were taken. These samples were fresh frozen with a maximum 
cold ischemia time of two hours. All samples have been stored in liquid nitrogen. 
RNA ISOLATION, CDNA SYNTHESIS AND MRNA TRANSCRIPT LEVEL 
QUANTIFICATION
A cryostat microtome set at -20°C was used to cut the fresh frozen colon cancer and 
normal colon tissues (Thermo Scientific Microm HM 560, Thermo Fisher Scientific, 
inc.). Before, in the middle and after sectioning for RNA isolation, a 5 µm section was 
cut. After hematoxylin-eosin (HE) staining the sections were reviewed by two 
pathologists independently. The percentage of neoplastic cells, infiltrating immune 
cells, necrosis and normal mucosa was scored in categories of 0–5%, 6–10%, 11–20%, 
21–30%, 31–40%, 41–50%, 51–60%, 61–70%, 71–80%, 81–90%, and 91–100% tumour 
cells, relative to other cells. Classification and grading of the tumour was determined 
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using the WHO 2010 classification for the carcinoma of the colon and rectum (WHO 
Press, World Health Organization, 20 Avenue Appia, Geneva, Switzerland).
Total RNA was isolated from 30 µm sections using RNA-Bee® according the 
manufacturer’s instructions (Tel-Test inc., USA). Quality and quantity of RNA was 
assessed with the MultiNA Microchip Electrophoresis system (Shimadzu, Kyoto, Japan) 
and the Nanodrop ND-1000 (Thermo Scientific, Wilmington, USA), respectively.
Expression levels of the six miRNAs were quantified in a 9-plex miRNA Assay Protocol 
utilizing commercially available and validated Taqman miRNA assays (Applied 
Biosystems, Thermo Scientific, USA) relative to the average level of reference genes 
miRNA-16, RNU6B and RNU44 measured in the same total RNA sample. 
In brief, 5 μL sample containing 20 ng/μL total RNA was reverse transcribed for 30 
min at 16°C, 30 min at 42°C, 5 min at 85°C and stopped at 4°C in the presence of 18 
nM final of each of the 9 Taqman RT-primers in 1x RT buffer [Fermentas] supplemented 
with 0.65 mM each dNTP [Fermentas], 0.25 U/μL RNAseout [Fermentas], 3.8 mM 
MgCl2 [Invitrogen) in the absence (negative control) or presence of 15 U/μL revertAid 
MLV H-minus RT [Fermentas]. After the RT-reaction samples were diluted 20-fold in 
LoTE (3 mM Tris-HCl/0.2 mM EDTA, pH 8.0) prior to performing 40 cycles of individual 
qPCR reactions for each of the 9 miRNA assays in the presence of Taqman Master 
mix without UNG as advised by the manufacturer (Applied Biosystems, Thermo 
Scientific, USA). Specifics of the 6 target miRNA assays and 3 reference miRNA assays 
used to normalize the data are provided in Supplementary Table 1.
FIGURE 1. DIAGRAM OF THE PATIENT SELECTION
201748 Robert Coebergh_binnenwerk.indd   171 12-12-17   15:41
CHAPTER 7
172
MICROSATELLITE INSTABILITY (MSI)
In short, genomic DNA was extracted from 2 to 5 x 30 µm sections cut in between 
the sections used for RNA isolation (NucleoSpin Tissue kit, Macherey-Nagel, BIOKE, 
Leiden, the Netherlands). MSI status was determined with a fluorescent PCR-based 
assay in five mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24 and 
MONO-27 (Promega MSI Analysis System) using 2 ng of PicoGreen measured DNA. 
Quality and quantity were assessed by both agarose gel electrophoresis, Nanodrop 
and the Quant-iT PicoGreen dsDNA kit (Life Technnologies). Two pentanucleotide 
repeat markers (Penta C and Penta D) were also included to detect potential 
sample mix ups and/or contamination using the protocol as supplied by the 
manufacturer. 
PATHWAY ANALYSIS
For n=231 patients, RNA sequencing data were available.11 In short, we used the 
STAR12 algorithm (version 2.4.2a) to align the RNA-seq data with the GRCh38 reference 
using the ‘--quantmode Genecounts’ option to obtain the raw readcounts for each 
gene. Gene annotation was derived from gencode v23 (https://www.gencodegenes.
org/). Next, the Trimmed Mean of M-values normalization13 - as implemented in 
EdgeR14 - was used to normalize the raw read count data. These data were used as 
input for the pathway analysis.
For the miRNAs associated with long-term clinical outcome in our cohort, the 50 
tumours with the highest expression and 50 tumours with the lowest expression per 
miRNA were grouped and used as input. Pathway analyses were performed using 
the R-package ‘global test’ using KEGG.15 Importantly, only genes for which expression 
data was available were used as input. The Bonferroni-Holm method was used to 
correct all p values for multiple testing. Re-sampling (n=1,000) was performed to 
determine the number of times a randomly selected group of genes of equal size 
was at least as significant as the true set of genes assigned to a pathway. The gene 
plots of pathways with a corrected p value < 0.05 and a re-sampling probability <0.05 
were reviewed. Three target gene prediction databases were used to identify which 
genes within the selected pathways were predicted to be potential targets of the 
respective miRNAs (Targetscan version 7.1, http://www.targetscan.org16; MicroRNA 
Target Prediction and Functional Study Database [miRDB], http://mirdb.org/miRDB17; 
RNA22 version 2.0, https://cm.jefferson.edu/rna22/18).We considered genes to be a 
potential target of a miRNA when predicted by all three databases and when the 
binding site was a conserved site within the 3’ UTR region.
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SURVIVAL DATA
Metastasis free survival (MFS) was defined as the time elapsed between date of 
surgery, and either date of the appearance of distant metastasis or date of the last 
follow-up visit at which a patient was considered to have no recurrence.
Hepatic metastasis free survival (HFS) was defined as the time elapsed between date 
of surgery, and either date of the appearance of liver metastasis or date of the last 
follow-up visit at which a patient was considered to have no liver metastases.
Overall survival (OS) was defined as the time elapsed between date of surgery, and 
either date of death or date of the last check in the Municipal Personal Records 
Database. 
STATISTICAL ANALYSES
Statistical analyses were performed using the SPSS statistical package version 21. 
Associations between the expression of the six miRNAs as a continuous variable, 
and clinical and histopathological characteristics were assessed using the Mann-
Whitney U test, Spearman Rank correlation test, Kruskal-Wallis test and Jonckheere-
Terpstra test where appropriate. Cox regression analysis was used to assess the 
association between the expression of the six miRNAs as a continuous variable, and 
MFS, HFS and OS. A one-way ANOVA was used to assess the difference between the 
two log likelihood estimates of the Cox regression models when adding a variable 
to the model. Kaplan Meier estimates were used to visualize the relevant associations 
between miRNAs and long-term clinical outcome. The Youden’s index was calculated 
as previously described.19 All analyses were two-sided and p<0.05 was considered 
significant.
DATA AVAILABILITY
All data generated or analyzed during this study are included in this published article 
(and its Supplementary Information files). The RNA sequencing data have already 
been published and made available elsewhere.11 
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RESULTS
ASSOCIATION OF MIRNA EXPRESSION LEVELS WITH CLINICAL AND 
HISTOPATHOLOGICAL CHARACTERISTICS
The total cohort consisted of 232 patients, 155 patients with LNN primary colon 
cancer and 77 patients with LNP primary colon cancer. 
First, the distribution of the mRNA expression levels for each miRNA, and the correlation 
between the expression levels of the miRNAs were assessed (Supplementary Figure 
1). The only miRNA for which the expression levels did not follow a normal distribution 
was miR-885-5p (p<0.001). Furthermore, the Spearman correlation between the six 
miRNAs was assessed. All miRNAs were significantly and positively correlated with 
three or more of the six assessed miRNAs. However, only poor to moderate associations 
were observed (spearman’s rho 0.13 - 0.33, p<0.001 - p=0.044) (Supplementary Figure 
1). Then, possible associations between miRNA expression levels and clinical and 
histopathological characteristics were assessed. Importantly, most of the significant 
differences in miRNA expression observed in the total group derived from differences 
in the LNN group and not the smaller LNP group. Since we were primarily interested 
in the association with pure disease prognosis, the LNN subgroup was the main focus 
for further analyses. The associations between clinical and histopathological features 
for the LNN group are shown in Table 1, for the total group in Supplementary Table 
2A and for the LNP group in Supplementary Table 2B. 
Expression of miR-221, miR-30b and miR-885-5p was significantly lower while 
expression of miR-10b was significantly higher in MSI tumours compared to 
Microsatellite Stable (MSS) tumours (Table 1). Expression of miR-221 and miR-30b 
was significantly lower and miR-10b significantly higher in left-sided tumours 
compared to right-sided tumours. Besides the associations of the miRNAs with these 
two clinically important characteristics, expression of let-7i was significantly lower in 
stage II compared to stage I tumours.
LET-7 I ,  MIR-30B  AND MIRNA S IGNATURE AS  PROGNOSTIC  MARKERS FOR 
CLINICAL OUTCOME
First the prognostic value of the six miRNAs was assessed using the expression levels 
as a continuous variable in a univariate Cox regression model (Table 2). Let-7i 
expression levels were significantly associated with HFS (Hazard Ratio [HR]=0.32, 
95% Confidence Interval [CI]=0.17-0.60, p<0.001). In contrast to the findings of Hur 
et al., miR-10b was not significantly associated with any of the clinical endpoints. The 
expression of miR-30b however was significantly associated with MFS and HFS 
(HR=2.13, 95%CI=1.22-3.72, p=0.008 and HR=2.77, 95%CI=1.24-6.18, p=0.013, 
respectively). None of the other miRNAs were associated with MFS and HFS, and 
none of the miRNAs were significantly associated with OS.
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The significant associations were visualised using Kaplan Meier analysis dividing the 
expression levels of let-7i and miR-30b into quartiles (Figure 2) showing a split course 
for Q1-2 (below median) and Q3-4 (above median). The median expression levels 
were used to assess the prognostic value of the original 2-miRNA signature in our 
cohort (Let-7i high and miR-10b low vs. Let-7i low and/or miR-10b high). The 2-miRNA 
signature was significantly associated with HFS (5-year survival 100% vs 89.3%, 
p=0.04)(Figure 3A), but did not show a significant difference for MFS (Figure 3B) or 
OS (Figure 3C).
Since miR-30b was significantly associated with MFS and HFS (Figure 2B and Figure 
2C, respectively) in our cohort, we explored whether miR-30b could contribute to the 
discriminating value of the signature. In a multivariate Cox regression model including 
the 2-miRNA signature and miR-30b expression split at the median level, miR-30b was 
significantly associated with MFS (HR=3.65, 95%CI=1.44-9.27, p=0.007) and HFS 
FIGURE 2.
Kaplan Meier estimates for the correlation between 
let-7i with HFSa, and miR-30b with MFSb and HFSc in 
the LNN group (Q1=lowest quartile; Q4=highest 
quartile).
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(HR=10.04, 95%CI=1.30-77.78, p=0.027) independent of the original signature. For both 
models, the log likelihood significantly increased when adding miR-30b expression split 
at the median level (D log likelihood=4.36, p=0.003 and D log likelihood=4.43, p=0.003). 
We therefore added miR-30b split at the median expression level to the original 
metastasis-specific miRNA signature (modified 3-miRNA signature), in which patients 
were categorized as low risk when having a tumour with two or three of the following: 
let-7i high, miR-10b low and miR-30b low. All other patients were categorized as high 
risk. The modified 3-miRNA signature showed a significant difference in MFS (5-year 
survival 90.2% vs 75.5%, p=0.019) and HFS (5-year survival 98.6% vs 85.6%, p=0.004) 
(Figure 3A and Figure 3B, respectively). In the total group, this modified signature also 
showed a significant difference between patients in the ‘low risk’ vs ‘high risk’ group 
for both MFS (5-year survival 86.8% vs 73.8%, p=0.018) and HFS (5-year survival 97.0% 
vs 86.2%, p=0.004). Still, the modified 3-miRNA signature did not correlate with OS in 
these groups, or with any of the clinical endpoints in the LNP group.
FIGURE 3.
Kaplan Meier estimates for the correlation 
between the original metastasis-specific 
signature (dashed line) and modified 
metastasis-specific signature (continuous line) 
for MFSa, HFSb and OSc.
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Nodal status was the only traditional clinical factor significantly associated with 
disease outcome in univariate Cox regression analysis in both the LNN and total 
group (Table 2 and Supplementary Table 3, respectively). When adjusting for lymph 
node status in a multivariate Cox regression model (which in the LNN group stratifies 
in two groups based on the total number of assessed lymph nodes with a cut-off of 
10), the modified metastasis-specific 3-miRNA signature was still significantly 
associated with MFS (HR=2.72, 95%CI=1.13-6.53, p=0.025) and HFS (HR=10.30, 
95%CI=1.33-79.99, p=0.026) in the LNN group, and HFS in the total group (HR=5.07, 
95%CI=1.46-17.59, p=0.011) (Table 2 and Supplementary Table 3, respectively). 
PATHWAY ANALYSIS
Pathway analysis showed that let-7i expression was associated with axon guidance, 
glycosphingolipid and glycosaminoglycan biosynthesis, focal adhesion, extracellular 
matrix (ECM) receptor interaction and regulation of the actin cytoskeleton which are 
all related to cell adhesion, migration and motility. Furthermore, we observed an 
association with the hedgehog, WNT and Transforming Growth Factor (TGF)-β 
signalling pathways (Supplementary Table 4 and 5). Combined use of 3 independent 
target prediction algorithms did not reveal any overlapping let-7i target genes 
involved in glycosphingolipid biosynthesis, glycosaminoglycan biosynthesis, or the 
hedgehog signalling pathway. However, the axon guidance, focal adhesion, ECM 
receptor interaction, regulation of actin cytoskeleton TGF beta signalling and WNT 
signalling pathways do contain a number of genes predicted to be let-7i targets by 
all 3 algorithms (Supplementary Table 6). mRNA Expression of COL4A6 and FNDC3A, 
involved in focal adhesion and ECM receptor interactions, was significantly negatively 
correlated to let-7i expression in our samples (both in LNN and LNP samples). 
Expression of ACVR1C, part of the TGF-β signalling pathway, showed a borderline 
significant negative correlation with let-7i only in LNP samples (p=0.056). 
Expression of miR-30b was associated with axon guidance and showed a significant 
negative correlation with expression of PPP3R1, NFAT5, and SEMA6B in this pathway 
(Supplementary Table 4-6).
Noteworthy, we observed more significant positive correlations between let-7i 
expression and its predicted targets in all significantly associated pathways, 
suggesting the effect of let-7i on genes in these pathways are mostly indirect. 
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DISCUSSION
Our study confirmed the clinical significance of measuring let-7i and the miRNA-
signature as suggested by Hur et al, and have extended these findings to a well-
defined independent cohort of patients with colon cancer. We showed that the 
expression of most of these miRNAs was different for MSI and MSS tumours, and 
for left and right-sided tumours. Furthermore, let-7i was expressed at a lower level 
in stage II compared to stage I colon cancers. We validated let-7i as a prognostic 
marker, but could not confirm miR-10b as a prognostic factor. In contrast, miR-30b 
was prognostic with regard to MFS and HFS. The original metastasis-specific 2-miRNA 
signature was significantly associated with HFS but not MFS. We therefore propose 
a modified metastasis-specific 3-miRNA signature combining miR-10b, miR-30b and 
let-7i which identified a group with low and high risk in terms of MFS and HFS. 
Subsequent pathway analysis suggested an association between let-7i expression 
and cell adhesion, migration and motility, and the hedgehog, WNT and Transforming 
Growth Factor (TGF)-β signalling pathways. miR-30b expression was associated to 
axon guidance.
The findings with regard to the differential expression of the miRNAs in MSI versus 
MSS and left-sided versus right-sided tumours suggest a different role for these 
miRNAs in hyper and non-hypermutated tumours, and add to the understanding of 
these biologically different entities. Although these characteristics were not included 
in the differential miRNA expression analysis by Hur et al., the findings are in line 
with accumulating evidence that supports the role of miRNAs in the pathogenesis 
of MSI tumours, such as the involvement miR-21 and miR-155 in the regulation of 
mismatch repair gene and protein expression.20 Similarly, left- and right-sided 
tumours are reported to express miRNAs at different levels.21,22 Our findings add to 
the fast expanding knowledge on the different roles of miRNAs in these biologically 
different entities. Furthermore, we found that let-7i expression was lower in stage II 
compared to stage I tumours, which is line with the findings by Hur et al. and the 
tumour suppressing role of the let-7 family as described in literature.23 
Furthermore, low expression of let-7i was associated with poor HFS in our cohort of 
patients with lymph node negative colon cancer who did not receive adjuvant 
chemotherapy which confirmed the findings of Hur et al. We also found that high 
expression of miR-30b was associated with poor MFS and HFS, which was not 
observed by Hur et al., since miR-30b was not validated in the comparative analysis 
of primary CRC and matched liver metastases (LM) tissues used for the identification 
of miRNAs that may hold prognostic potential in primary tumours. In our cohort, all 
patients had colon cancer which may explain the different observations in our cohort. 
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In contrast to Hur et al., we did not find a significant association or even trend 
between expression of miR-10b and any of the long term clinical endpoints. 
Interestingly, Hur et al. showed that miR-10b was downregulated in LM tissue 
compared to primary CRC tissue while it was upregulated in primary CRC versus 
normal tissue, and high expression of miR-10b was associated with poor MFS. This 
suggests that differential expression between primary and metastatic lesions does 
not always reflect prognostic and/or predictive value in primary tumour lesions.24-29 
This may also explain the discrepancy for miR-30b between absence of differential 
expression in their comparative analysis and the association with MFS/HFS in our 
cohort, although further studies should be conducted to confirm the latter. 
Hur et al. also showed that their signature (consisting of miR-10b and let-7i) was 
associated with MFS in one cohort of primary colorectal cancers. Although this 
signature did segregate our cohort of patients with LNN colon cancer in two groups 
with significantly different outcome in terms of HFS, we did not find a significant 
difference in terms of MFS. Incorporation of miR-30b (modified signature) did identify 
a low and high risk group were clearly distinctive with regard to MFS and HFS. These 
results remained significant when correcting for nodal status. Next to nodal status, 
MSI was significantly associated with HFS in the LNN group. Still, when correcting for 
MSI alone or together with nodal status in the LNN group, the modified metastasis-
specific signature remained significantly associated with MFS and HFS (data not 
shown). However, due to the low number of events, these multivariable analyses 
should be interpreted with caution. In conclusion, our results underline the prognostic 
value of let-7i and provide support for the prognostic value of the modified miRNA 
signature.
The different observations may be explained by differences in the patient cohorts 
used in the study by Hur et al and the current study. The cohorts used by Hur et al 
were heterogeneous with regard to tumour stage and tumour location (both colon 
and rectum were included), and no information on pre and postoperative local and 
systemic treatment was provided.9 This heterogeneity may for instance explain the 
failure of validating miR-30b in the comparative analysis since expression levels of 
miR-30b are different between colon and rectal cancers.22 In the current study, a 
well-defined prospectively included cohort of patients with colon cancer was used. 
Another explanation for the observed differences may be the cut-off used to 
dichotomize expression levels. Hur et al. used the Youden’s index (i.e. the most 
optimal combination of sensitivity and specificity) to determine the cut-off value for 
which the miRNAs had the maximum potential effectiveness based on a specific 
outcome parameter.19 Inherent to the dependency of the cut-off to the outcome 
parameter, patients may change from the low risk to the high risk group depending 
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on the outcome of interest. In our cohort, the cut-off value based on the Youden’s 
index was nearly identical to the median expression level, which is independent of 
the outcome parameter of interest and per definition gives two equally sized 
subgroups (data not shown). In their cohort, the Youden’s index stratified the patients 
in two unequally sized groups (4.8% low let-7i expression and 21% low miR-10b 
expression) meaning the cut-off value based on the Youden’s index was quite 
different from the median expression level. Therefore, future studies may explore 
the median expression level to assign patients to a low or high risk group. Lastly, 
differences in the used material (formalin-fixed paraffin embedded versus fresh 
frozen), RNA isolation and/or the assays used to measure the miRNA expression may 
also account for part of the observed differences.
The pathway analysis for let-7i and miR-30b revealed several interesting associations. 
Let-7i expressionwas associated with several pathways related to cell adhesion, 
migration and motility. This is in line with literature that associates the expression 
of this miRNA with the expression of genes involved in these pathways that are to 
known to be altered in carcinogenesis and involved in progression.30,31 Activation of 
either LIN28A or LIN28B is thought to responsible for global post-transcriptional 
downregulation of the let-7 family in cancers.32 Furthermore, let-7i expression was 
associated with the among others hedgehog, WNT and Transforming Growth Factor 
(TGF)-β signalling pathways. Interestingly, the let-7 family was shown to be involved 
in hedgehog-mediated drug resistance in lung cancer which supports the observed 
association in our cohort.33 Similarly, the let-7 family was shown to be involved in 
both the Wnt signalling in breast cancer which again involved LIN28.34 Lastly, high 
expression of let-7i was associated with increased TGF-β signalling. TGF-β is known 
to play a major role in the tumorigenesis of at least half of all CRCs in which 
inactivating mutations abolish the tumour suppressing effect of TGF-β signalling 
pathway. Furthermore, decreased SMAD4 expression, a downstream target of TGF-β, 
is associated with poor prognosis in colon cancer providing indirect evidence that 
inactivation of TGF-β signalling leads to invasive behaviour of colon cancer.35 
Interestingly, TGF-β appears to convert from a tumour suppressor to a tumour 
promotor in more advanced stages of cancers, which is known as the TGF-β paradox.6 
A few studies have specifically addressed the association between let-7 and TGF-β 
expression showing an inverse correlation.37,38 However, these studies were 
performed in cell lines and a melanoma xenograft model, which may preclude 
extrapolating these results to CRC in a clinical setting. In our study, 6% of the genes 
in the ‘TGF-β signalling pathway’ were considered to be a potential target of let-7i 
using three prediction algorithms. The positive correlation between tumour 
suppressor let-7i and genes involved in the TGF-β signalling pathway in this study 
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suggests that TGF-β has yet to go through this conversion, and both TGF-β and let-7i 
act as a tumour suppressor in our homogeneous prospectively collected cohort of 
early stage colon cancers. Interestingly, expression of ACVR1C was negatively 
associated with let-7i expression in only the LNP group, suggesting these tumours 
may have gone through the conversion. The association with the above-mentioned 
pathways may also suggest that let-7i is linked to stromal content and has an indirect 
role in TGF-β signalling in stromal cells, which is known to play a role in metastasis 
initiation.39 
The miR-30 family has been extensively studied in the field of cancer research. In 
vitro, miR-30 family members have been associated with several aspects of 
tumorigenesis such as cell migration, cell growth, cell invasiveness and apoptosis.40-48 
Interestingly, both negative and positive associations with tumorigenesis have been 
described for miR-30 family members including miR-30b which precludes definitive 
conclusions. Contrasting associations have also been reported between the miR-30 
family and tumour characteristics such as tumour stage and tumour grade.40,46,47,49-52 
In terms of clinical outcome defined as MFS and/or OS, miR-30 family members have 
been described as markers of poor outcome in melanoma49, ovarian cancer41, 
prostate cancer44 and oesophageal cancer53, and as a tumour suppressive miRNA in 
breast cancer51, lung cancer54, CRC42, prostate cancer40 and ovarian cancer.55 In our 
study, high miR-30b was associated with poor MFS and HFS. The pathway analysis 
mainly revealed a positive association between miR-30b expression and axon 
guidance. The genes traditionally described for their roles in axon guidance are 
important regulators of neuronal migration and positioning during embryonic 
development. However, they have been implicated in cancer cell survival, growth, 
invasion and angiogenesis.56,57 Very little is known about the direct association 
between miR-30b and axon guidance in current literature. However, the target gene 
prediction we performed subsequently to the pathway analysis showed that >11% 
of the genes listed in the ‘axon guidance’ pathway in KEGG were predicted to be 
direct targets of miR-30b. In support of this direct interaction, significant negative 
correlations between expression of miR-30b and axon-guidance genes PPP3R1, NFAT5, 
SEMA6B was observed in our cohort. Further research may be directed to investigate 
the possible role of miR-30b in axon guidance. These insights combined with the fact 
that miR-30b was upregulated in patients with a poor prognosis in our cohort, may 
provide a rationale to investigate the miRNA as a therapeutic target.
Although overlapping predicted targets were found for the majority of let-7i and 
miR-30b associated pathways in 3 prediction algorithms, we observed many 
significantly positive correlations between particularly let-7i and its predicted targets 
in our cohort. This suggests that effects of let-7i on the associated pathways is 
201748 Robert Coebergh_binnenwerk.indd   183 12-12-17   15:41
CHAPTER 7
184
(partially) indirect , although functional studies are needed to confirm this. All in all, 
the observed associations suggest that let-7i and miR-30b may be a relevant factor 
for cancer cells in their ability to move potentially also involving their stromal 
component together increasing their metastatic potential.
Our data suggest that let-7i and miR-30b, and a 3-miRNA signature hold prognostic 
value in lymph node negative colon cancers, although independent validation in a 
large cohort is needed. Further studies should ideally include an analysis of circulating 
serum levels of these miRNAs.
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SUPPLEMENTARY F IGURES
SUPPLEMENTARY FIGURE 1. THIS FIGURE DISPLAYS THE CORRELATION BETWEEN THE MIRNAS (SCATTER PLOTS) 
WITH THEIR RESPECTIVE SPEARMAN’S CORRELATION COEFFICIENT AND P VALUES
The distribution of the expression levels of the six miRNAs are displayed on the diagonal with their respective 
p values (Shapiro-Wilk test).
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SUPPLEMENTARY TABLES
SUPPLEMENTARY TABLE 1. GENE ASSAYS USED TO MEASURE MRNA EXPRESSION OF THE SIX MIRNAS AND 3 
REFERENCE GENES
INDEX GENE 
SYMBOL
GENE NAME QPCR DETECTION METHOD ASSAY ID 
THERMOFISHER 
SCIENTIFIC
Candidate miR MIR320 microRNA 320 TaqMan® MicroRNA Assay 384
Candidate miR MIR221 microRNA 221 TaqMan® MicroRNA Assay 2277
Candidate miR MIR30B microRNA 30b TaqMan® MicroRNA Assay 2218
Candidate miR MIR10B microRNA 10b TaqMan® MicroRNA Assay 524
Candidate miR MIR885 microRNA 885 TaqMan® MicroRNA Assay 602
Candidate miR MIRLET7I microRNA let-7i TaqMan® MicroRNA Assay 2296
Reference miR MIR16-1 microRNA 16-1 TaqMan® MicroRNA Assay 391
Reference miR RNU6B RNA, U6 small nuclear 6, 
pseudogene
TaqMan® MicroRNA Assay 1093
Reference miR SNORD44 small nucleolar RNA, C/D box 44 TaqMan® MicroRNA Assay 1094
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SUPPLEMENTARY TABLE 2A. CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF THE TOTAL GROUP
MIR-320 MIR-221 MIR-30B MIR-10B MIR-885-5P LET-7I
n % median (IQR) P value median (IQR) P value median (IQR) P value median (IQR) P value median (IQR) P value median (IQR) P value
Gender
Female 104 44.8% -4.52 (-5.07 • -4.10) 0.82 -1.84 (-2.49 • -1.05) 0.64 -1.67 (-2.12 • -1.19) 0.008 -2.49 (-3.07 • -1.90) 0.26 -11.10 (-13.00 • -10.16) 0.30 -2.88 (-3.44 • -2.37) 0.14
Male 128 55.2% -4.56 (-4.94 • -4.03) -1.77 (-2.35 • -1.08) -1.47 (-1.92 • -1.03) -2.64 (-3.15 • -2.03) -10.93 (-12.29 • -10.20) -3.10 (-3.71 • -2.50)
Age 232 100.0% -0.04 0.52 -0.09 0.20 -0.07 0.26 .01 0.94 -0.03 0.70 0.03 0.61
Tumor stage
Stage I 57 24.6% -4.61 (-5.01 • -4.03) 0.62 -1.78 (-2.45 • -0.88) 0.92 -1.55 (-1.97 • -1.07) 0.002 -2.62 (-3.29 • -1.90) 0.27 -11.21 (-12.88 • -10.09) 0.041 -2.59 (-3.55 • -2.09) 0.47
Stage II 98 42.2% -4.49 (-4.99 • -4.08) -1.77 (-2.51 • -1.16) -1.75 (-2.17 • -1.35) -2.66 (-3.13 • -2.02) -11.39 (-13.00 • -10.52) -3.15 (-3.61 • -2.66)
Stage III 77 33.2% -4.61 (-5.08 • -4.11) -1.82 (-2.33 • -1.01) -1.33 (-1.62 • -1.01) -2.45 (-2.97 • -1.98) -10.52 (-11.46 • -9.86)
T status
T2 68 29.3% -4.58 (-4.93 • -4.03) 0.61 -1.78 (-2.39 • -0.99) 0.52 -1.48 (-1.92 • -0.99) 0.33 -2.58 (-3.17 • -1.89) 0.93 -10.79 (-12.58 • -9.99) 0.20 -2.65 (-3.54 • -2.12) 0.054
T3 164 70.7% -4.51 (-5.05 • -4.10) -1.80 (-2.37 • -1.13) -1.59 (-1.97 • -1.14) -2.59 (-3.08 • -2.01) -11.11 (-13.00 • -10.26) -3.09 (-3.56 • -2.62)
Nodal status
N0 127 54.7% -4.47 (-4.95 • -4.01) 0.38 -1.77 (-2.51 • -1.13) 0.48 -1.75 (-2.13 • -1.32) <0.001 -2.61 (-3.11 • -1.91) 0.54 -11.34 (-13.00 • -10.48) 0.002 -3.05 (-3.54 • -2.38) 0.87
N0 <10 nodes 28 12.1% -4.72 (-5.14 • -4.13) -1.71 (-2.46 • -0.67) -1.40 (-1.99 • -0.91) -2.73 (-3.37 • -2.06) -11.28 (-12.94 • -9.50) -3.12 (-3.96 • -2.36)
N1 52 22.4% -4.69 (-5.06 • -4.16) -1.89 (-2.32 • -1.15) -1.32 (-1.64 • -0.92) -2.46 (-3.13 • -2.03) -10.62 (-11.49 • -9.89) -2.86 (-3.39 • -2.46)
N2 25 10.8% -4.41 (-5.19 • -3.83) -1.42 (-2.35 • -0.52) -1.38 (1.53 • -1.01) -2.36 (-2.84 • -1.95) -10.41 (-12.12 • -9.66) -3.08 (-3.73 • -2.65)
Tumor grade
Good 20 8.6% -4.61 (-5.12 • -4.11) 0.41 -1.61 (-2.24 • -1.12) 0.72 -1.58 (-1.98 • -1.22) 0.056 -2.73 (-3.13 • -2.31) 0.56 -11.36 (-11.85 • -10.26) 0.14 -3.08 (-3.72 • -2.68) 0.34
Moderate 184 79.3% -4.55 (-5.05 • -4.04) -1.81 (-2.40 • -1.06) -1.58 (-1.99 • -1.16) -2.58 (-3.11 • -1.95) -11.11 (-13.00 • -10.24) -3.06 (-3.56 • -2.44)
Poor 20 8.6% -4.38 (-4.84 • -4.14) -1.58 (-2.50 • -0.83) -1.24 (-1.71 • -0.92) -2.84 (-3.28 • -2.28) -10.51 (-12.52 • -9.94) -2.95 (-3.72 • -2.44)
Other 8 3.4% -4.36 (-5.14 • -3.68) -2.21 (-2.35 • -1.85) -1.49 (-1.61 • -0.80) -1.79 (-2.55 • -1.17) -9.98 (-10.94 • -9.19) -2.86 (-3.04 • -2.24)
Location
Right 115 49.6% -4.41 (-4.84 • -4.03) 0.036 -2.11 (-2.56 • -1.17) 0.006 -1.62 (-2.01 • -1.23) 0.016 -2.25 (-2.72 • -1.71) <0.001 -11.10 (-13.00 • -10.10) 0.98 -2.99 (-3.55 • -2.38) 0.48
Left 117 50.4% -4.67 (-5.15 • -4.11) -1.60 (-2.23 • -0.97) -1.41 (-1.91 • -1.04) -2.88 (-3.39 • -2.34) -11.01 (-12.62 • -10.21) -3.09 (-3.59 • -2.50)
MSI-statusa
MSI 46 19.8% -4.38 (-4.86 • -3.90) 0.18 -2.45 (-3.05 • -2.10) <0.001 -1.88 (-2.14 • -1.52) <0.001 -2.12 (-2.59 • -1.64) <0.001 -11.65 (-13.00 • -10.53) 0.001 -2.79 (-3.26 • -2.38) 0.09
MSS 185 79.7% -4.55 (-5.08 • -4.09) -1.65 (-2.24 • -0.96) -1.48 (-1.91 • -1.06) -2.65 (-3.19 • -2.13) -10.92 (-12.15 • -10.10) -3.08 (-3.65 • -2.46)
a n=1 missing
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Left 117 50.4% -4.67 (-5.15 • -4.11) -1.60 (-2.23 • -0.97) -1.41 (-1.91 • -1.04) -2.88 (-3.39 • -2.34) -11.01 (-12.62 • -10.21) -3.09 (-3.59 • -2.50)
MSI-statusa
MSI 46 19.8% -4.38 (-4.86 • -3.90) 0.18 -2.45 (-3.05 • -2.10) <0.001 -1.88 (-2.14 • -1.52) <0.001 -2.12 (-2.59 • -1.64) <0.001 -11.65 (-13.00 • -10.53) 0.001 -2.79 (-3.26 • -2.38) 0.09
MSS 185 79.7% -4.55 (-5.08 • -4.09) -1.65 (-2.24 • -0.96) -1.48 (-1.91 • -1.06) -2.65 (-3.19 • -2.13) -10.92 (-12.15 • -10.10) -3.08 (-3.65 • -2.46)
a n=1 missing
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SUPPLEMENTARY TABLE 2B. CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF THE LYMPH NODE POSITIVE GROUP
MIR-320 MIR-221 MIR-30B MIR-10B MIR-885-5P LET-7I
n % median (IQR) P value median (IQR) P value median (IQR) P value median (IQR) P value median (IQR) P value median (IQR) P value
Gender
Female 31 40.3% -4.73 (-5.18 • -4.11) 0.61 -2.10 (-2.37 • -0.79) 0.84 -1.47 (-1.77 • -1.06) 0.22 -2.46 (-2.97 • -2.13) 0.57 -11.03 (-13.00 • -10.06) 0.09 -2.80 (-3.39 • -2.56) 0.57
Male 46 59.7% -4.59 (-4.93 • -4.11) -1.81 (-2.25 • -1.19) -1.32 (-1.57 • -0.94) -2.39 (-2.98 • -1.92) -10.47 (-11.13 • -9.62) -3.06 (-3.57 • -2.51)
Age 77 100% -0.06 0.60 0.01 0.91 -0.09 0.43 -0.15 0.19 -0.02 0.87 -0.05 0.70
Tumor stage
Stage I 0 0.0% - - - - - - -
Stage II 0 0.0% - - - - - - -
Stage III 77 100% -4.61 (-5.08 • -4.11) -1.82 (-2.33 • -1.01) -1.33 (-1.62 • -1.01) -2.45 (-2.97 • -1.98) -10.52 (-11.46 • -9.86) -2.99 (-3.52 • -2.52)
T status
T2 11 14.3% -4.52 (-4.83 • -3.90) 0.38 -1.71 (-2.20 • -1.02) 0.44 -1.20 (-1.37 • -0.74) 0.128 -2.41 (-2.97 • -1.66) 0.71 -10.23 (-10.52 • -9.47) 0.10 -3.04 (-3.20 • -2.45) 0.81
T3 66 85.7% -4.65 (-5.09 • -4.13) -1.84 (-2.36 • -0.99) -1.38 (-1.66 • -1.02) -2.46 (-2.98 • -1.98) -10.65 (-11.64 • -9.90) -2.97 (-3.53 • -2.53)
Nodal status
N0 0 0.0% - - - - - - -
N0 <10 nodes 0 0.0% - - - - - - -
N1 52 67.5% -4.69 (-5.06 • -4.16) 0.38 -1.89 (-2.32 • -1.15) 0.44 -1.32 (-1.64 • -0.92) 0.13 -2.46 (-3.13 • -2.03) 0.71 -10.62 (-11.49 • -9.89) 0.10 -2.86 (-3.39 • -2.46) 0.81
N2 25 32.5% -4.41 (-5.19 • -3.83) -1.42 (-2.35 • -0.52) -1.38 (1.53 • -1.01) -2.36 (-2.84 • -1.95) -10.41 (-12.12 • -9.66) -3.08 (-3.73 • -2.65)
Tumor grade
Good 7 9.1% -4.88 (-5.44 • -4.25) 0.11 -2.20 (-2.34 • -1.36) 0.57 -1.79 (-2.09 • -1.17) 0.11 -2.72 (-2.96 • -2.47) 0.52 -10.26 (-11.52 • -9.82) 0.61 -3.08 (-3.72 • -2.80) 0.50
Moderate 54 70.1% -4.69 (-5.07 • -4.09) -1.80 (-2.36 • -0.99) -1.32 (-1.60 • -0.99) -2.35 (-2.94 • -1.89) -10.74 (-11.79 • -10.01) -2.92 (-3.53 • -2.49)
Poor 11 14.3% -4.28 (-4.61 • -4.11) -1.11 (-1.82 • -0.78) -1.09 (-1.38 • -0.78) -2.78 (-3.29 • -2.17) -10.30 (-10.52 • -9.73) -3.11 (-3.80 • -2.38)
Other 5 6.5% -4.39 (-5.33 • -3.59) -2.32 (-2.57 • -2.18) -1.60 (-1.68 • -1.05) -1.99 (-2.81 • -1.06) -10.63 (-12.02 • -9.39) -2.93 (-3.22 • -2.47)
Location
Right 36 46.8% -4.31 (-4.80 • -3.80) 0.00 -1.94 (-2.36 • -0.90) 0.96 -1.47 (-1.65 • -1.03) 0.36 -2.06 (-2.53 • -1.57) <0.001 -10.54 (-11.39 • -9.62) 0.36 -2.78 (-3.11 • -2.39) 0.028
Left 41 53.2% -4.82 (-5.24 • -4.45) -1.80 (-2.27 • -1.27) -1.27 (-1.61 • -0.91) -2.74 (-3.31 • -2.34) -10.52 (-11.67 • -10.11) -3.12 (-3.68 • -2.68)
MSI-status
MSI 12 15.6% -4.31 (-5.23 • -3.55) 0.33 -2.37 (-2.86 • -1.68) 0.015 -1.58 (-1.89 • -1.47) 0.009 -2.06 (-2.52 • -1.82) 0.049 -11.45 (-13.00 • -9.79) 0.11 -2.71 (-2.87 • -2.20) 0.018
MSS 65 84.4% -4.65 (-5.07 • -4.12) -1.77 (-2.21 • -0.98) -1.20 (-1.60 • -0.94) -2.47 (-3.06 • -2.10) -10.45 (-11.21 • -9.86) -3.08 (-3.62 • -2.55)
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SUPPLEMENTARY TABLE 2B. CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF THE LYMPH NODE POSITIVE GROUP
MIR-320 MIR-221 MIR-30B MIR-10B MIR-885-5P LET-7I
n % median (IQR) P value median (IQR) P value median (IQR) P value median (IQR) P value median (IQR) P value median (IQR) P value
Gender
Female 31 40.3% -4.73 (-5.18 • -4.11) 0.61 -2.10 (-2.37 • -0.79) 0.84 -1.47 (-1.77 • -1.06) 0.22 -2.46 (-2.97 • -2.13) 0.57 -11.03 (-13.00 • -10.06) 0.09 -2.80 (-3.39 • -2.56) 0.57
Male 46 59.7% -4.59 (-4.93 • -4.11) -1.81 (-2.25 • -1.19) -1.32 (-1.57 • -0.94) -2.39 (-2.98 • -1.92) -10.47 (-11.13 • -9.62) -3.06 (-3.57 • -2.51)
Age 77 100% -0.06 0.60 0.01 0.91 -0.09 0.43 -0.15 0.19 -0.02 0.87 -0.05 0.70
Tumor stage
Stage I 0 0.0% - - - - - - -
Stage II 0 0.0% - - - - - - -
Stage III 77 100% -4.61 (-5.08 • -4.11) -1.82 (-2.33 • -1.01) -1.33 (-1.62 • -1.01) -2.45 (-2.97 • -1.98) -10.52 (-11.46 • -9.86) -2.99 (-3.52 • -2.52)
T status
T2 11 14.3% -4.52 (-4.83 • -3.90) 0.38 -1.71 (-2.20 • -1.02) 0.44 -1.20 (-1.37 • -0.74) 0.128 -2.41 (-2.97 • -1.66) 0.71 -10.23 (-10.52 • -9.47) 0.10 -3.04 (-3.20 • -2.45) 0.81
T3 66 85.7% -4.65 (-5.09 • -4.13) -1.84 (-2.36 • -0.99) -1.38 (-1.66 • -1.02) -2.46 (-2.98 • -1.98) -10.65 (-11.64 • -9.90) -2.97 (-3.53 • -2.53)
Nodal status
N0 0 0.0% - - - - - - -
N0 <10 nodes 0 0.0% - - - - - - -
N1 52 67.5% -4.69 (-5.06 • -4.16) 0.38 -1.89 (-2.32 • -1.15) 0.44 -1.32 (-1.64 • -0.92) 0.13 -2.46 (-3.13 • -2.03) 0.71 -10.62 (-11.49 • -9.89) 0.10 -2.86 (-3.39 • -2.46) 0.81
N2 25 32.5% -4.41 (-5.19 • -3.83) -1.42 (-2.35 • -0.52) -1.38 (1.53 • -1.01) -2.36 (-2.84 • -1.95) -10.41 (-12.12 • -9.66) -3.08 (-3.73 • -2.65)
Tumor grade
Good 7 9.1% -4.88 (-5.44 • -4.25) 0.11 -2.20 (-2.34 • -1.36) 0.57 -1.79 (-2.09 • -1.17) 0.11 -2.72 (-2.96 • -2.47) 0.52 -10.26 (-11.52 • -9.82) 0.61 -3.08 (-3.72 • -2.80) 0.50
Moderate 54 70.1% -4.69 (-5.07 • -4.09) -1.80 (-2.36 • -0.99) -1.32 (-1.60 • -0.99) -2.35 (-2.94 • -1.89) -10.74 (-11.79 • -10.01) -2.92 (-3.53 • -2.49)
Poor 11 14.3% -4.28 (-4.61 • -4.11) -1.11 (-1.82 • -0.78) -1.09 (-1.38 • -0.78) -2.78 (-3.29 • -2.17) -10.30 (-10.52 • -9.73) -3.11 (-3.80 • -2.38)
Other 5 6.5% -4.39 (-5.33 • -3.59) -2.32 (-2.57 • -2.18) -1.60 (-1.68 • -1.05) -1.99 (-2.81 • -1.06) -10.63 (-12.02 • -9.39) -2.93 (-3.22 • -2.47)
Location
Right 36 46.8% -4.31 (-4.80 • -3.80) 0.00 -1.94 (-2.36 • -0.90) 0.96 -1.47 (-1.65 • -1.03) 0.36 -2.06 (-2.53 • -1.57) <0.001 -10.54 (-11.39 • -9.62) 0.36 -2.78 (-3.11 • -2.39) 0.028
Left 41 53.2% -4.82 (-5.24 • -4.45) -1.80 (-2.27 • -1.27) -1.27 (-1.61 • -0.91) -2.74 (-3.31 • -2.34) -10.52 (-11.67 • -10.11) -3.12 (-3.68 • -2.68)
MSI-status
MSI 12 15.6% -4.31 (-5.23 • -3.55) 0.33 -2.37 (-2.86 • -1.68) 0.015 -1.58 (-1.89 • -1.47) 0.009 -2.06 (-2.52 • -1.82) 0.049 -11.45 (-13.00 • -9.79) 0.11 -2.71 (-2.87 • -2.20) 0.018
MSS 65 84.4% -4.65 (-5.07 • -4.12) -1.77 (-2.21 • -0.98) -1.20 (-1.60 • -0.94) -2.47 (-3.06 • -2.10) -10.45 (-11.21 • -9.86) -3.08 (-3.62 • -2.55)
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SUPPLEMENTARY TABLE 3. UNIVARIATE AND MULTIVARIATE COX REGRESSION ANALYSIS FOR THE TOTAL GROUP
UNIVARIATE MULTIVARIATE
MFS (events=44) HFS (events=12) OS (events=23) MFS (events=25) HFS (events=12) OS (events=23)
n % HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value
mRNA expression
MiR-320 232 100% 0.88 (0.60 • 1.30) 0.53 0.95 (0.53 • 1.71) 0.87 0.96 (0.64 • 1.45) 0.86
MiR-221 232 100% 1.36 (1.01 • 1.82) 0.041 1.24 (0.79 • 1.94) 0.35 1.02 (0.74 • 1.41) 0.89
MiR-30b 232 100% 1.93 (1.24 • 3.01) 0.004 2.37 (1.20 • 4.66) 0.013 1.35 (0.84 • 2.17) 0.22
MiR-10b 232 100% 1.03 (0.71 • 1.49) 0.87 0.65 (0.37 • 1.13) 0.13 1.02 (0.70 • 1.50) 0.92
MiR-885-5p 232 100% 0.98 (0.80 • 1.20) 0.85 0.89 (0.64 • 1.22) 0.45 0.94 (0.76 • 1.16) 0.57
Let-7i 232 100% 0.86 (0.62 • 1.19) 0.36 0.42 (0.27 • 0.64) <0.001 0.92 (0.66 • 1.27) 0.60
Gender
Female 73 47.1% 1 1 1
Male 82 52.9% 1.19 (0.65 • 2.18) 0.57 1.14 (0.46 • 2.82) 0.78 2.23 (1.15 • 4.59) 0.018
Age 232 100% 1.0002 (0.96 • 1.04) 0.99 1.003 (0.95 • 1.06) 0.92 1.06 (1.02 • 1.11) 0.003
Tumor stage
Stage I 57 36.8% 1 1 1
Stage II 98 63.2% 1.51 (.63 • 3.61) 0.36 1.17 (0.35 • 3.90) 0.79 1.08 (0.46 • 2.54) 0.87
Stage III 2.18 (0.92 • 5.18) 0.08 1.40 (0.41 • 4.79) 0.59 1.80 (0.78 • 4.15) 0.17
T status
T2 57 36.8% 1 1 1
T3 98 63.2% 1.97 (0.92 • 4.24) 0.08 1.22 (0.44 • 3.38) 0.71 1.87 (0.86 • 4.07) 0.11
Nodal status
N0 127 81.9% 1 1 1 1 1 1
N0 <10 nodes 28 18.1% 1.20 (0.45 • 3.20) 0.72 3.41 (1.08 • 10.75) 0.036 1.53 (0.6 • 3.88) 0.38 1.16 (0.43 • 3.08) 0.77 3.18 (1.01 • 10.02) 0.049 1.44 (0.56 • 3.68) 0.45
N1 0.99 (0.44 • 2.26) 0.99 1.79 (0.57 • 5.65) 0.32 1.01 (0.42 • 2.45) 0.98 0.90 (0.39 • 2.05) 0.80 1.43 (0.45 • 4.54) 0.54 0.94 (0.39 • 2.29) 0.89
N2 3.57 (1.71 • 7.47) 0.001 1.78 (0.37 • 8.59) 0.47 4.20 (1.96 • 9.00) <0.001 2.93 (1.37 • 6.28) 0.006 1.19 (0.24 • 5.78) 0.83 3.60 (1.62 • 8.00) 0.002
Tumor grade
Good 13 8.4% 1 1 1
Moderate 130 83.9% 0.85 (0.30 • 2.39) 0.85 0.74 (0.17 • 3.26) 0.69 1.68 (0.40 • 7.04) 0.48
Poor 9 5.8% 1.70 (0.50 • 5.81) 0.40 1.50 (0.25 • 8.97) 0.66 4.17 (0.89 • 19.66) 0.07
Other^ 3 1.9% - - -
Location - -
Right 79 51.0% 1 1 1
Left 76 49.0% 1.17 (0.65 • 2.12) 0.60 0.88 (0.36 • 2.17) 0.78 0.58 (0.31 • 1.09) 0.09
MSI-statusa
MSI 34 21.9% 1 1 1
MSS 120 77.4% 2.00 (0.79 • 5.08) 0.14 28.64 (0.24 • 3466.30) 0.17 0.64 (0.32 • 1.25) 0.19
Modified signature
low risk 79 51.0% 1 1 1 1 1 1
high risk 76 49.0% 2.12 (1.12 • 4.00) 0.02 5.17 (1.51 • 17.76) 0.009 2.12 (1.12 • 4.00) 0.02 1.81 (0.94 • 3.50) 0.08 5.07 (1.46 • 17.59) 0.011 1.50 (0.76 • 2.96) 0.24
^ there were no events in this subgroup; a n=1 missing
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n % HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value
mRNA expression
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MiR-221 232 100% 1.36 (1.01 • 1.82) 0.041 1.24 (0.79 • 1.94) 0.35 1.02 (0.74 • 1.41) 0.89
MiR-30b 232 100% 1.93 (1.24 • 3.01) 0.004 2.37 (1.20 • 4.66) 0.013 1.35 (0.84 • 2.17) 0.22
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Let-7i 232 100% 0.86 (0.62 • 1.19) 0.36 0.42 (0.27 • 0.64) <0.001 0.92 (0.66 • 1.27) 0.60
Gender
Female 73 47.1% 1 1 1
Male 82 52.9% 1.19 (0.65 • 2.18) 0.57 1.14 (0.46 • 2.82) 0.78 2.23 (1.15 • 4.59) 0.018
Age 232 100% 1.0002 (0.96 • 1.04) 0.99 1.003 (0.95 • 1.06) 0.92 1.06 (1.02 • 1.11) 0.003
Tumor stage
Stage I 57 36.8% 1 1 1
Stage II 98 63.2% 1.51 (.63 • 3.61) 0.36 1.17 (0.35 • 3.90) 0.79 1.08 (0.46 • 2.54) 0.87
Stage III 2.18 (0.92 • 5.18) 0.08 1.40 (0.41 • 4.79) 0.59 1.80 (0.78 • 4.15) 0.17
T status
T2 57 36.8% 1 1 1
T3 98 63.2% 1.97 (0.92 • 4.24) 0.08 1.22 (0.44 • 3.38) 0.71 1.87 (0.86 • 4.07) 0.11
Nodal status
N0 127 81.9% 1 1 1 1 1 1
N0 <10 nodes 28 18.1% 1.20 (0.45 • 3.20) 0.72 3.41 (1.08 • 10.75) 0.036 1.53 (0.6 • 3.88) 0.38 1.16 (0.43 • 3.08) 0.77 3.18 (1.01 • 10.02) 0.049 1.44 (0.56 • 3.68) 0.45
N1 0.99 (0.44 • 2.26) 0.99 1.79 (0.57 • 5.65) 0.32 1.01 (0.42 • 2.45) 0.98 0.90 (0.39 • 2.05) 0.80 1.43 (0.45 • 4.54) 0.54 0.94 (0.39 • 2.29) 0.89
N2 3.57 (1.71 • 7.47) 0.001 1.78 (0.37 • 8.59) 0.47 4.20 (1.96 • 9.00) <0.001 2.93 (1.37 • 6.28) 0.006 1.19 (0.24 • 5.78) 0.83 3.60 (1.62 • 8.00) 0.002
Tumor grade
Good 13 8.4% 1 1 1
Moderate 130 83.9% 0.85 (0.30 • 2.39) 0.85 0.74 (0.17 • 3.26) 0.69 1.68 (0.40 • 7.04) 0.48
Poor 9 5.8% 1.70 (0.50 • 5.81) 0.40 1.50 (0.25 • 8.97) 0.66 4.17 (0.89 • 19.66) 0.07
Other^ 3 1.9% - - -
Location - -
Right 79 51.0% 1 1 1
Left 76 49.0% 1.17 (0.65 • 2.12) 0.60 0.88 (0.36 • 2.17) 0.78 0.58 (0.31 • 1.09) 0.09
MSI-statusa
MSI 34 21.9% 1 1 1
MSS 120 77.4% 2.00 (0.79 • 5.08) 0.14 28.64 (0.24 • 3466.30) 0.17 0.64 (0.32 • 1.25) 0.19
Modified signature
low risk 79 51.0% 1 1 1 1 1 1
high risk 76 49.0% 2.12 (1.12 • 4.00) 0.02 5.17 (1.51 • 17.76) 0.009 2.12 (1.12 • 4.00) 0.02 1.81 (0.94 • 3.50) 0.08 5.07 (1.46 • 17.59) 0.011 1.50 (0.76 • 2.96) 0.24
^ there were no events in this subgroup; a n=1 missing
201748 Robert Coebergh_binnenwerk.indd   197 12-12-17   15:41
CHAPTER 7
198
SUPPLEMENTARY TABLE 4. PATHWAY ANALYSIS RESULTS
LET-7I MIR-30B
P value % of 
predicted 
genes
P value % of 
predicted 
genes
GLYCOSPHINGOLIPID_BIOSYNTHESIS_GANGLIO_SERIES 1.35E-11 -
GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_
SULFATE
1.95E-10 -
AXON_GUIDANCE 3.41E-10 3.9% 3.59E-4 11.6%
FOCAL_ADHESION 7.61E-10 3.6%
ECM_RECEPTOR_INTERACTION 1.33E-9 7.0%
REGULATION_OF_ACTIN_CYTOSKELETON 1.80E-9 2.0%
PATHWAYS_IN_CANCER 2.22E-9 -
HEDGEHOG_SIGNALING_PATHWAY 2.44E-9 0.0%
RENAL_CELL_CARCINOMA 2.72E-9 -
DILATED_CARDIOMYOPATHY 4.69E-9 -
HYPERTROPHIC_CARDIOMYOPATHY_HCM 4.83E-9 -
WNT_SIGNALING_PATHWAY 9.16E-9 2.7%
ARRHYTHMOGENIC_RIGHT_VENTRICULAR_
CARDIOMYOPATHY_ARVC
1.05E-7 -
TGF_BETA_SIGNALING_PATHWAY 2.73E-7 6.0%
MELANOMA 4.10E-7 -
GLYCOSPHINGOLIPID_BIOSYNTHESIS_GLOBO_SERIES 3.05E-6 -
UBIQUITIN_MEDIATED_PROTEOLYSIS 3.90E-4 -
MELANOGENESIS 1.35E-3 -
RNA_POLYMERASE 2.58E-3 -
HOMOLOGOUS_RECOMBINATION 2.69E-3 -
SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT 2.95E-3 -
PRION_DISEASES 4.39E-3 -
EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_
INFECTION
8.69E-3 -
TYROSINE_METABOLISM 1.09E-2 -
FATTY_ACID_METABOLISM 2.08E-2 -
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SUPPLEMENTARY TABLE 5. GENES PER PATHWAY FOR WHICH EXPRESSION DATA WAS AVAILABLE
GLYCOSPHINGOLIPID_BIOSYNTHESIS_GANGLIO_SERIES
B3GALT4 GLB1 HEXB SLC33A1 ST3GAL2 ST6GALNAC3 ST6GALNAC5 ST8SIA1
B4GALNT1 HEXA LCT ST3GAL1 ST3GAL5 ST6GALNAC4 ST6GALNAC6 ST8SIA5
GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE
B3GALT6 B3GAT3 CHPF2 CHST13 CHST3 CHSY3 UST
B3GAT1 B4GALT7 CHST11 CHST14 CHST7 CSGALNACT1 XYLT1
B3GAT2 CHPF CHST12 CHST15 CHSY1 CSGALNACT2 XYLT2
AXON_GUIDANCE
ABL1 EFNA1 EPHB1 LIMK1 NRAS PLXNB2 RHOD SEMA3G SLIT2
ABLIM1 EFNA2 EPHB2 LIMK2 NRP1 PLXNB3 RND1 SEMA4A SLIT3
ABLIM2 EFNA3 EPHB3 LRRC4C NTN1 PLXNC1 ROBO1 SEMA4B SRGAP1
ABLIM3 EFNA4 EPHB4 MAPK1 NTN3 PPP3CA ROBO2 SEMA4C SRGAP2
ARHGEF12 EFNA5 EPHB6 MAPK3 NTN4 PPP3CB ROBO3 SEMA4D SRGAP3
CDC42 EFNB1 FES MET NTNG1 PPP3CC ROCK1 SEMA4F UNC5A
CDK5 EFNB2 FYN MRAS PAK1 PPP3R1 ROCK2 SEMA4G UNC5B
CFL1 EFNB3 GNAI1 NCK1 PAK2 PPP3R2 RRAS SEMA5A UNC5C
CFL2 EPHA1 GNAI2 NCK2 PAK3 PTK2 RRAS2 SEMA5B UNC5D
CHP1 EPHA2 GNAI3 NFAT5 PAK4 RAC1 SEMA3A SEMA6A
CXCL12 EPHA3 GSK3B NFATC1 PAK7 RAC2 SEMA3B SEMA6B
CXCR4 EPHA4 HRAS NFATC2 PLXNA1 RAC3 SEMA3C SEMA6C
DCC EPHA5 ITGB1 NFATC3 PLXNA2 RASA1 SEMA3D SEMA6D
DPYSL2 EPHA7 KRAS NFATC4 PLXNA3 RGS3 SEMA3E SEMA7A
DPYSL5 EPHA8 L1CAM NGEF PLXNB1 RHOA SEMA3F SLIT1
FOCAL_ADHESION
ACTB CCND1 COMP IBSP ITGB8 MYL6 PIK3CD RAP1A TNN
ACTC1 CCND2 CRK IGF1 JUN MYLK PIK3CG RAP1B TNR
ACTG1 CCND3 CRKL IGF1R KDR MYLK2 PIK3R1 RAPGEF1 TNXB
ACTN1 CDC42 CTNNB1 ILK LAMA1 MYLK3 PIK3R2 RELN TTN
ACTN2 CHAD DIAPH1 ITGA10 LAMA2 MYLK4 PIK3R3 RHOA VASP
ACTN3 COL11A1 DOCK1 ITGA11 LAMA3 PAK1 PIK3R5 ROCK1 VAV1
ACTN4 COL11A2 EGF ITGA2 LAMA4 PAK2 PIP5K1C ROCK2 VAV2
AKT1 COL1A1 EGFR ITGA2B LAMA5 PAK3 POTEKP SHC1 VAV3
AKT2 COL1A2 ELK1 ITGA3 LAMB1 PAK4 PPP1CA SHC2 VCL
AKT3 COL2A1 ERBB2 ITGA4 LAMB2 PAK7 PPP1CB SHC3 VEGFA
ARHGAP35 COL3A1 FARP2 ITGA5 LAMB3 PARVA PPP1CC SHC4 VEGFB
ARHGAP5 COL4A1 FIGF ITGA6 LAMB4 PARVB PPP1R12A SOS1 VEGFC
BAD COL4A2 FLNA ITGA7 LAMC1 PARVG PRKCA SOS2 VTN
BCAR1 COL4A4 FLNB ITGA8 LAMC2 PDGFB PRKCB SPP1 VWF
BCL2 COL4A6 FLNC ITGA9 LAMC3 PDGFC PRKCG SRC XIAP
BIRC2 COL5A1 FLT1 ITGAV MAP2K1 PDGFD PTEN THBS1 ZYX
BIRC3 COL5A2 FN1 ITGB1 MAPK1 PDGFRA PTK2 THBS2
BRAF COL5A3 FYN ITGB3 MAPK10 PDGFRB PXN THBS3
CAPN2 COL6A1 GRB2 ITGB4 MAPK3 PDPK1 RAC1 THBS4
CAV1 COL6A2 GSK3B ITGB5 MAPK8 PGF RAC2 TLN1
CAV2 COL6A3 HGF ITGB6 MAPK9 PIK3CA RAC3 TLN2
CAV3 COL6A6 HRAS ITGB7 MET PIK3CB RAF1 TNC
ECM_RECEPTOR_INTERACTION
AGRN COL3A1 COL6A3 GP5 ITGA3 ITGB4 LAMB1 SDC3 TNC
CD36 COL4A1 COL6A6 GP6 ITGA4 ITGB5 LAMB2 SDC4 TNN
CD44 COL4A2 DAG1 GP9 ITGA5 ITGB6 LAMB3 SPP1 TNR
CD47 COL4A4 FN1 HMMR ITGA6 ITGB7 LAMB4 SV2A TNXB
CHAD COL4A6 FNDC1 HSPG2 ITGA7 ITGB8 LAMC1 SV2B VTN
COL11A1 COL5A1 FNDC3A IBSP ITGA8 LAMA1 LAMC2 SV2C VWF
COL11A2 COL5A2 FNDC4 ITGA10 ITGA9 LAMA2 LAMC3 THBS1
COL1A1 COL5A3 FNDC5 ITGA11 ITGAV LAMA3 RELN THBS2
COL1A2 COL6A1 GP1BA ITGA2 ITGB1 LAMA4 SDC1 THBS3
COL2A1 COL6A2 GP1BB ITGA2B ITGB3 LAMA5 SDC2 THBS4
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SUPPLEMENTARY TABLE 5. CONTINUED
REGULATION_OF_ACTIN_CYTOSKELETON
ABI2 BAIAP2 DOCK1 FGF3 ITGA2 KRAS PAK1 PIP4K2C SOS1
ACTB BCAR1 EGF FGF4 ITGA2B LIMK1 PAK2 PIP5K1A SOS2
ACTC1 BDKRB1 EGFR FGF5 ITGA3 LIMK2 PAK3 PIP5K1B SSH1
ACTG1 BDKRB2 EZR FGF6 ITGA4 MAP2K1 PAK4 PIP5K1C SSH2
ACTN1 BRAF F2 FGF7 ITGA5 MAP2K2 PAK7 POTEKP SSH3
ACTN2 BRK1 F2R FGF8 ITGA6 MAPK1 PDGFB PPP1CA TIAM1
ACTN3 CD14 FGD1 FGF9 ITGA7 MAPK3 PDGFRA PPP1CB TIAM2
ACTN4 CDC42 FGD3 FGFR1 ITGA8 MATK PDGFRB PPP1CC TMSB4X
APC CFL1 FGF1 FGFR2 ITGA9 MOS PFN1 PPP1R12A TMSB4XP8
APC2 CFL2 FGF10 FGFR3 ITGAD MRAS PFN2 PPP1R12B TMSB4Y
ARHGAP35 CHRM1 FGF11 FGFR4 ITGAE MSN PFN3 PTK2 TTN
ARHGEF1 CHRM2 FGF12 FN1 ITGAL MYH10 PFN4 PXN VAV1
ARHGEF12 CHRM3 FGF13 GIT1 ITGAM MYH14 PIK3CA RAC1 VAV2
ARHGEF4 CHRM4 FGF14 GNA12 ITGAV MYH9 PIK3CB RAC2 VAV3
ARHGEF6 CHRM5 FGF16 GNA13 ITGAX MYL1 PIK3CD RAC3 VCL
ARHGEF7 CRK FGF17 GNG12 ITGB1 MYL3 PIK3CG RAF1 WAS
ARPC1A CRKL FGF18 GSN ITGB2 MYLK PIK3R1 RDX WASF1
ARPC1B CSK FGF19 HRAS ITGB3 MYLK2 PIK3R2 RHOA WASF2
ARPC2 CYFIP1 FGF2 IQGAP1 ITGB4 MYLK3 PIK3R3 ROCK1 WASL
ARPC3 CYFIP2 FGF20 IQGAP2 ITGB5 MYLK4 PIK3R5 ROCK2
ARPC4 DIAPH1 FGF21 IQGAP3 ITGB6 NCKAP1 PIKFYVE RRAS
ARPC5 DIAPH2 FGF22 ITGA10 ITGB7 NCKAP1L PIP4K2A RRAS2
ARPC5L DIAPH3 FGF23 ITGA11 ITGB8 NRAS PIP4K2B SLC9A1
HEDGEHOG_SIGNALING_PATHWAY
BMP2 BTRC CSNK1G3 GSK3B PRKX STK36 WNT2 WNT6 ZIC2
BMP4 CSNK1A1 DHH HHIP PRKY SUFU WNT2B WNT7A
BMP5 CSNK1A1L FBXW11 IHH PTCH1 WNT1 WNT3 WNT7B
BMP6 CSNK1D GAS1 LRP2 PTCH2 WNT10A WNT3A WNT8A
BMP7 CSNK1E GLI1 PRKACA RAB23 WNT10B WNT4 WNT8B
BMP8A CSNK1G1 GLI2 PRKACB SHH WNT11 WNT5A WNT9A
BMP8B CSNK1G2 GLI3 PRKACG SMO WNT16 WNT5B WNT9B
WNT_SIGNALING_PATHWAY
APC CSNK1A1L DVL2 GSK3B NKD2 PPP3CC RBX1 TBL1XR1 WNT3A
APC2 CSNK1E DVL3 JUN NLK PPP3R1 RHOA TBL1Y WNT4
AXIN1 CSNK2A1 EP300 LEF1 PLCB1 PPP3R2 ROCK1 TCF7 WNT5A
AXIN2 CSNK2A2 FBXW11 LRP5 PLCB2 PRICKLE1 ROCK2 TCF7L1 WNT5B
BTRC CSNK2B FOSL1 LRP6 PLCB3 PRICKLE2 RUVBL1 TCF7L2 WNT6
CACYBP CTBP1 FRAT1 MAP3K7 PLCB4 PRKACA SENP2 TP53 WNT7A
CAMK2A CTBP2 FRAT2 MAPK10 PORCN PRKACB SFRP1 VANGL1 WNT7B
CAMK2B CTNNB1 FZD1 MAPK8 PPARD PRKACG SFRP2 VANGL2 WNT8A
CAMK2D CTNNBIP1 FZD10 MAPK9 PPP2CA PRKCA SFRP4 WIF1 WNT8B
CAMK2G CUL1 FZD2 MMP7 PPP2CB PRKCB SFRP5 WNT1 WNT9A
CCND1 CXXC4 FZD3 MYC PPP2R1A PRKCG SIAH1 WNT10A WNT9B
CCND2 DAAM1 FZD4 NFAT5 PPP2R1B PRKX SKP1 WNT10B
CCND3 DAAM2 FZD5 NFATC1 PPP2R2A PRKY SMAD2 WNT11
CER1 DKK1 FZD6 NFATC2 PPP2R2B PSEN1 SMAD3 WNT16
CHP1 DKK2 FZD7 NFATC3 PPP2R2C RAC1 SMAD4 WNT2
CREBBP DKK4 FZD8 NFATC4 PPP3CA RAC2 SOX17 WNT2B
CSNK1A1 DVL1 FZD9 NKD1 PPP3CB RAC3 TBL1X WNT3
TGF_BETA_SIGNALING_PATHWAY
ACVR1 BMP5 COMP GDF7 LEFTY1 PPP2CB SMAD1 SP1 THBS4
ACVR1B BMP6 CREBBP ID1 LEFTY2 RBL1 SMAD2 TFDP1 TNF
ACVR1C BMP7 CUL1 ID2 LTBP1 RBL2 SMAD3 TGFB1 ZFYVE16
ACVR2A BMP8A DCN ID3 MAPK1 RBX1 SMAD4 TGFB2 ZFYVE9
ACVR2B BMP8B E2F4 ID4 MAPK3 RHOA SMAD5 TGFB3
ACVRL1 BMPR1A E2F5 IFNG MYC ROCK1 SMAD6 TGFBR1
AMH BMPR1B EP300 INHBA NODAL ROCK2 SMAD7 TGFBR2
AMHR2 BMPR2 FST INHBB NOG RPS6KB1 SMAD9 THBS1
BMP2 CDKN2B GDF5 INHBC PITX2 RPS6KB2 SMURF1 THBS2
BMP4 CHRD GDF6 INHBE PPP2CA SKP1 SMURF2 THBS3
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SUPPLEMENTARY TABLE 6. LIST OF GENES THAT WERE PREDICTED AS DIRECT TARGETS BY THE COMBINED USE OF 3 
INDEPENDENT TARGET PREDICTION ALGORITHMS
MIRNA GENE SYMBOL GENE NAME SPEARMAN’S RHO P VALUE
miR-30b ABL1 ABL Proto-Oncogene 1, Non-Receptor 
Tyrosine Kinase
-0.032 0.63
CFL2 Cofilin 2 0.107 0.11
DPYSL2 Dihydropyrimidinase Like 2 0.072 0.28
EFNA3 Ephrin A3 0.121 0.07
GNAI2 G Protein Subunit Alpha I2 -0.030 0.65
NFAT5 Nuclear Factor Of Activated T-Cells 5 -0.286 <0.0001
NFATC2 Nuclear Factor Of Activated T-Cells 2 -0.009 0.90
NFATC3 Nuclear Factor Of Activated T-Cells 3 0.067 0.32
PLXNA2 Plexin A2 -0.077 0.25
PLXNC1 Plexin C1 -0.007 0.92
PPP3R1 Protein Phosphatase 3 Regulatory Subunit B, 
Alpha
-0.331 <0.001
RASA1 RAS P21 Protein Activator 1 -0.083 0.22
SEMA6B Semaphorin 6B -0.198 0.003
SEMA6D Semaphorin 6D 0.178 0.007
SRGAP3 SLIT-ROBO Rho GTPase Activating Protein 3 -0.018 0.79
UNC5C Unc-5 Netrin Receptor C 0.295 <0.0001
let-7i ACVR1C Activin A Receptor Type 1C -0.113 0.09
CHRD Chordin 0.422 <0.0001
COL1A2 Collagen Type I Alpha 2 Chain 0.561 <0.0001
COL3A1 Collagen Type III Alpha 1 Chain 0.576 <0.0001
COL4A6 Collagen Type IV Alpha 6 Chain -0.258 0.000
COL5A2 Collagen Type V Alpha 2 Chain 0.512 <0.0001
E2F5 E2F Transcription Factor 5 0.076 0.25
FNDC3A Fibronectin Type III Domain Containing 3A -0.295 <0.0001
GDF6 Growth Differentiation Factor 6 0.053 0.54
ITGB3 Integrin Subunit Beta 3 0.196 0.003
TGFBR1 Transforming Growth Factor Beta Receptor 1 0.346 <0.0001
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ABSTRACT
BACKGROUND
Systematic evaluation and validation of new prognostic and predictive markers, 
technologies and interventions for colorectal cancer (CRC) is crucial for optimizing 
patients’ outcomes. With only 5-15% of patients participating in clinical trials, 
generalizability of results is poor. Moreover, current trials often lack the capacity for 
post-hoc subgroup analyses. For this purpose, a large observational cohort study, 
serving as a multiple trial and biobanking facility, was set up by the Dutch Colorectal 
Cancer Group (DCCG).
METHODS / DESIGN
The Prospective Dutch ColoRectal Cancer cohort is a prospective multidisciplinary 
nation-wide observational cohort study in The Netherlands (yearly CRC incidence of 
15,500). All CRC patients (stage I-IV) are eligible for inclusion, and longitudinal clinical 
data are registered. Patients give separate consent for the collection of blood and 
tumor tissue, filling out questionnaires, and broad randomization for studies 
according to the innovative cohort multiple randomized controlled trial design 
(cmRCT), serving as an alternative study design for the classic randomized controlled 
trial.
Objectives of the study include 1) systematically collected long-term clinical data, 
patient-reported outcomes and biomaterials from daily CRC practice and 2) to 
facilitate future basic, translational and clinical research including interventional and 
cost-effectiveness studies for both national and international research groups with 
short inclusion periods, even for studies with stringent inclusion criteria. 
RESULTS 
Seven months after initiation 650 patients have been enrolled, 8 centers participate, 
15 centers await IRB approval and 9 embedded cohort- or cmRCT-designed studies 
are currently recruiting patients.
CONCLUSION
This cohort provides a unique multidisciplinary data, biobank, and patient reported 
outcomes collection initiative, serving as an infrastructure for various kinds of 
research aiming to improve treatment outcomes in CRC patients. This comprehensive 
design may serve as an example for other tumor types.
201748 Robert Coebergh_binnenwerk.indd   206 12-12-17   15:41
207
 
BACKGROUND 
Worldwide, colorectal cancer (CRC) is the third most common malignancy in men 
and second in women.1 With a continuously rising incidence, an estimated 1.35 
million new cases are diagnosed yearly, associated with 694,000 annual deaths. In 
the past decades, substantial progress has been made in diagnosis and treatment 
of CRC, resulting in an increasing number of CRC survivors.2-8 The implementation 
of national CRC screening programmes is expected to increase the incidence of CRC.9 
The increasing incidence of CRC, in combination with improved survival rates, has 
led to high numbers of people living with (the consequences of) CRC. In addition to 
treatment parameters and outcomes, also quality of life, workability, and daily 
functioning during and after CRC treatment are becoming increasingly important 
parameters in research.
There is no consensus on the use of prognostic parameters in CRC, and predictive 
factors for treatment are scarce. Also there is a growing availability of new molecular 
markers10-13 and innovative treatment options. This puts increasing pressure on the 
current research system, since large numbers of patients are required to assess 
relevance or superiority before their implementation into clinical practice. This 
warranted large number greatly exceeds the amount of patients that currently 
participate in clinical trials (5%-15%).14-16 Low recruitment-rates may also imply 
selective inclusion of patients in trials rather than representative population 
samples17, which may result in limited external validity of outcomes. The danger of 
the extrapolation of study results to the general population was recently shown. 
Survival outcomes of patients with metastatic CRC (mCRC) treated within the scope 
of a randomized study were significantly better than the survival outcomes in patients 
not fulfilling the study eligibility criteria and treated outside the trial with the same 
drugs during the same period.17,18 Moreover, study designs classically used for 
comparative research often lack the ability to provide sufficient data for subgroup 
treatment effects or post-hoc evaluation. For example, immunotherapy showed to 
be effective in mCRC patients with microsatellite instability (MSI). As MSI is only 
observed in 3-5% of the mCRC patients, the conduction of a large randomized phase 
3 trial will be challenging.19 It is therefore desirable to include all these patients in a 
large representative cohort of CRC patients who are prospectively followed for 
relevant outcomes that enables to study the value of novel prognostic and predictive 
biomarkers in large, but also small subgroups of patients. It would be ideal to use 
data from routine sources such as hospital systems or (cancer) registries, but these 
sources often lack the required detail about (changes in) treatments, doses, toxicity, 
and response, which is paramount for this purpose. As an alternative, a large 
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observational cohort has the advantage that it can provide a standardized data-
collection, dedicated data-monitoring and intensive follow-up, all of which are 
especially valuable for long term research in prognostic or predictive determinants. 
Ideally, all new interventions should be evaluated in Randomized Controlled Trials 
(RCTs) since this is considered the gold standard to prove effectiveness. However, 
this design in itself is often not only complicated by slow recruitment rates and limited 
generalizability15, it is also subject to a considerable delay between conceptualization 
and start, limited long-term follow-up, inadequate collection of patient-reported 
outcomes (PROMs), high non-completion rates and high costs.16 An innovative 
alternative proposed for the classic RCT is the ‘cohort multiple Randomized Controlled 
Trial’ (cmRCT).20 This design was originally developed as an alternative for classic 
pragmatic RCTs, and combines useful features from both classic RCTs (randomization) 
and prospective observational cohort studies. The design is characterized by three 
features: 1) patient-centred informed-consent approach; 2) framework to 
systematically collect long-term clinical follow-up as well as PROMs; and 3) efficient 
recruitment for trials by asking patients to give ‘broad consent for randomization’ in 
future trials. Unique features of the cmRCT design are that it allows to conduct 
multiple randomized trials simultaneously and that patients can participate in 
multiple non-conflicting trials at the same time.20 The design itself and its 
implementation in this study are explained in more detail in Box 2. 
We believe that a prospective observational cohort study can provide a standardized 
and validated collection of long term clinical data, tissue and blood samples and 
PROMs to establish a continuous source for a variety of research purposes. This 
research database can, among others, be used to investigate what (intrinsic and 
environmental) factors are associated with survival and PROMs, to find new predictive 
markers for treatment outcomes and side-effects, and to develop more accurate 
diagnostic tests and efficient follow-up surveillance strategies. 
METHODS / DESIGN
DESIGN AND OBJECTIVES
This is a project of the Dutch Colorectal Cancer Group (DCCG) and was launched as 
the prospective Dutch colorectal cancer cohort (Dutch: ‘Prospectief Landelijk 
ColoRectaal kanker Cohort’ (PLCRC)). The cohort is designed in accordance with the 
‘Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
statement’ guidelines.21 The project aims to collect high quality clinical data, biomaterials 
and PROMs of a large cohort of CRC patients that are prospectively followed from 
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primary diagnosis until death. All data are collected under a broad informed consent 
to facilitate future basic, translational and clinical research (Box 1). Furthermore, the 
cohort aims to serve as an infrastructure to conduct multiple simultaneous (randomized 
controlled) trials (according to the cmRCT design (Box 2)).
STUDY POPULATION
Patients with histologically proven CRC are eligible for participation if they are 18 
years or older and have given written informed consent. Only mentally incompetent 
and non-Dutch speaking patients are withheld from participation. The aim of the 
PLCRC project is to include all eligible patients in The Netherlands, a country with a 
yearly incidence of 15,500.
INFORMED CONSENT
Study information is given by researchers, research assistants, nonphysician clinicians 
and/or physicians during routine hospital visits after initial diagnosis, preferably 
before start of treatment. ‘General’ informed consent is mandatory for participation 
in this study and allows the collection of long term clinical and survival data. 
Subsequently, patients are given the option to consent to 1) filling out questionnaires 
on health-related quality of life, functional outcomes and workability, 2) biobanking 
BOX 1: THE MAIN OBJECTIVES OF THE PROSPECTIVE DUTCH COLORECTAL CANCER COHORT (PLCRC) ARE: 
• To execute a prospective observational cohort study aiming to include all Dutch CRC patients and 
follow them until death.
• To prospectively collect high quality data on medical history, comorbidities, clinical characteristics, 
imaging, pathology results, tumor characteristics, treatment, survival, recurrence, hospitalization, 
adverse events, toxicity and (long-term) outcomes of experimental interventions (table 1).
• To collect, store and make available blood and tumor tissue samples.
• To systematically collect patient-reported outcomes on quality of life, workability and functional 
outcomes.
• To provide detailed data on daily clinical care in the Netherlands.
• To create an infrastructure to facilitate studies of different nature, including:
 A. Prognostic and predictive research
 B. Biological research and (epi-)genetic research
 C.  Studies that compare novel therapies or interventions in a target population according to the 
innovative cohort multiple randomized controlled trial (cmRCT) design serving as a pragmatic 
alternative for classic RCTs.
 D. Cost-effectiveness studies
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of tumor and normal tissue, 3) collection of blood samples, and 4) to be offered 
studies conducted within the infrastructure of the cohort, either in accordance with 
the cmRCT design or not. When participants are offered to participate in a trial or 
intervention, an additional informed consent needs to be signed before patients can 
be enrolled in that trial (Box 2). The PLCRC informed consent procedure is a dynamic 
process since patients can withdraw or alter their consent preferences at any time 
during the study. 
BOX 2: THE COHORT MULTIPLE RANDOMIZED CONTROLLED TRIAL DESIGN
The basis of the cohort multiple Randomized Controlled Trial (cmRCT) design is a prospective 
observational cohort of patients with a certain condition [20], in our case CRC, in which all patients in 
principle undergo standard care. Within this cohort, clinical characteristics and standardized outcome 
measures are collected at baseline and regularly during follow-up. Clinical and self-reported data are 
used to compare effectiveness and safety of trialled interventions.
Practically, when an RCT is conducted within the cmRCT cohort, the first step is to identify a subcohort 
of all patients eligible for the intervention. Some of these patients are randomly selected and offered 
the experimental intervention (intervention group). If patients accept the offer, they are sure to undergo 
the experimental intervention. If they refuse they will undergo standard care. Eligible patients in the 
subcohort not randomly selected (control group), undergo standard treatment and do not receive any 
information on the trial. Outcomes are compared between randomly selected and non-selected patients. 
This process can be repeated for multiple (experimental) interventions simultaneously, offering (more) 
reliable direct comparisons between interventions and standard care. 
In the cmRCT design a patient-centered informed consent procedure is obtained [42] by asking all 
patients to give ‘broad consent for randomization’ after enrolment [42, 43] This allows researchers to 
randomly selected patients from the cohort, and offer them experimental interventions, while patients 
who are not randomly selected serve as controls and undergo standard care without further notification. 
When informing patients about broad consent for randomization, we explicitly state that not all patients 
that consent will be offered an experimental intervention since offers are based on random selection. 
When they got offered an experimental intervention they can either accept the intervention or they 
can refuse and undergo standard care. Also they are told that they may become (temporarily) ineligible 
for future trials if they already participate in a trial which measures interfering endpoints. We ensure 
that patients will never be withheld proven effective care. 
With this consent procedure we aim to mimic clinical practice, where people are usually not told about 
treatments they will not / cannot receive. The patient centered informed consent is expected to prevent 
cross-over and disappointment bias, especially in situations where, regardless of clinical equipoise, a 
new intervention is highly preferred by doctors and patients. Asking broad consent for randomisation 
also deals with the controversial ethical aspect of pre-randomization (as introduced by Zelen [44]) by 
obtaining upfront consent from all patients for randomization and data use in future comparative 
research, thereby not randomizing patients without prior notification and their consent. 
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After inclusion, participants are assigned a unique study identification(ID), which 
remains the only patient identifier throughout all further processes in the cohort’s 
infrastructure. Cohort inclusion does not limit participation in other observational 
studies. However, patients may become temporarily ineligible to participate in clinical 
trials outside the cohort in case they already participate in a cohort-embedded trial 
that has interfering endpoints.
ETHICS
The study was originally initiated as a monocenter study for which it received 
approval of the medical ethical review committee of the University Medical Center 
Utrecht (The Netherlands) in June 2013 (METC 12-510). Subsequently, approval was 
extended by the same IRB for a multicenter set-up, which was implemented in 
September 2015. All new intervention studies trialled within the cohort require 
separate approval from a medical ethical review committee. Study protocols and 
final results of PLCRC trials are available on the website: www.plcrc.nl excluding study 
protocols of cmRCT trials, since this design does not allow patients enrolled in the 
control arm to be informed on these studies (Box 2). PLCRC is registered at 
Clinicaltrials.gov under NCT02070146.
DATA COLLECTION AND ENDPOINTS
OBSERVATIONAL CLINICAL AND SURVIVAL DATA
Extensive observational clinical data (Table 1) are collected from medical charts by 
trained data-managers of the “Netherlands Comprehensive Cancer Organisation” 
(Dutch: Integraal Kankercentrum Nederland (IKNL)22) and does not require additional 
effort from participating hospitals or patients. The collected data is stored in the 
“Netherlands Cancer Registry” (Dutch: Nederlandse Kankerregistratie (NKR) 23) Study 
spe\cific data, not standardly collected in the NKR, is gathered separately by IKNL 
data managers, or by study-personal or researchers. 
BIOBANKING OF BLOOD AND TUMOR TISSUE MATERIALS
Tumor tissues are collected after routine surgery and stored as five snap frozen tissue 
samples, two Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples and two tissue 
sample cores for Tissue Micro Arrays. Blood samples (10ml serum and 10ml EDTA) 
are collected during routine blood withdrawal before treatment. Serum is divided 
over six 0.5ml samples and the EDTA sample is divided over six 0.5ml plasma samples 
and three 0.9ml pellet samples before being frozen and stored. Snap freezing of tumor 
tissue, FFPE processing and blood sample processing are performed locally in 
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TABLE 1. CLINICAL DATA COLLECTION WITHIN THE PROSPECTIVE DUTCH COLORECTAL CANCER COHORT
PART A: PATIENT ID AND DATA SOURCES
Patient identification & demographics
  - Patient-ID code 
  - Birth information (date and city)
  - Gender
Data source
  - Hospital 
  - Patient number within hospital
Data capture
  - ID of person who captures data
Study participation within the cohort
  - Number and name of studies/trials
  - Date(s) of inclusion
  - Date(s) of completed study/trial follow-up
PART B: PRE-TREATMENT RECORD
Medical history
Cancer specific
  -  Date, location, type, treatment,  
   treatment outcome
Comorbidity
  -  Cardiac, pulmonal, vascular, gastro-intestinal, 
neurological, gynecological, urological, muscle/bones, 
endocrine.
Intoxication
  - Smoking at diagnosis
  - Alcohol use at diagnosis
Physical examination
  - BMI (length & weight)
  - WHO performance status
Diagnosis & tumor information
  - Sequential tumor number
  - Date of diagnosis
  - Source/procedure of diagnosis
Laboratory investigations
  - CEA
Diagnostic work-up
Endoscopy
  - Date, hospital, procedure, procedure complete?
  -  Number of tumors/polyps, distance from anal verge
  - Endoscopic treatment
Pathology
  - Type, differentiation, T-stage
Imaging
  - Modalities, date(s), hospital
  - cTNM, MRF involvement, distance from  
    anal verge
Multidisciplinary Tumor Board 
  - Date & final staging
PART C: TREATMENT RECORD
Radiotherapy*
Setting (neo-adjuvant/adjuvant)
Indication for radiotherapy
Treatment
  - Start date first fraction
  - Standard: # fractions, fraction dose,  
   total dose
  - Boost: # fractions, fraction dose,  
   total boost dose
  - Total received dose and fractions
  - Stop/completion date
  - Response (TRG, ycTNM)
  - Adverse events (date, cause,  
   management)
Medical oncology*
Setting (neo-adjuvant/adjuvant)
Indication for systemic therapy
Treatment
  - Start date first cycle
  - Agent, dose, number of cycles
  - Total received dose and cycles
  - Stop/completion date
  - Response (TRG, ycTNM)
  - Adverse events (date, cause,  
   management)
Surgery*
ASA classification
Procedure 
  - Date, hospital
  - Setting (elective/acute)
  - Approach (open/laparoscopic/robot
  - Type ((Sub)Total Colectomy, LAR,  
   APR,Hartmann)
  - Anastomosis (type, stapled/sewn)
  - Date of discharge
Stoma
  - Date, hospital
  - Setting (elective/acute)
  - Temporary/definitive
  - Type (ileostoma, colostoma)
  - Date of stoma reversal 
  - Peri-operative complications  
   (anastomic leakage, abcess, ileus) 
  - Post operative complications  
   (incl. wound complications)
Pathology*
  - pTNM
  - Tumor regression grade 
  - Radicality of resection
  - Circumferential resection margin (CRM) 
  - # lymph nodes & # positive lymph nodes in  
   specimen
  - Angio- and lymphatic invasion
  - Perforation of the bowel
  - Molecular markers (BRAF, RAS, MSI status)
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participating hospitals and transported to regional biobank facilities for long-term 
storage. To provide a sustainable infrastructure for biobanking, we established close 
collaborations with existing national organisations for use of their expertise, and to 
prevent duplicate data entry and unnecessary costs. These initiatives include the 
Dutch Biobanking and BioMolecular resources Research Infrastructure (BBMRI-NL; 
www.bbmri.nl) and the CTMM Translational Research IT (TraIT, www.ctmm-trait.nl).
LONGITUDINAL ASSESSMENT OF PROMS
Nationally and internationally accepted and validated questionnaires are used to 
measure PROMs, which include EORTC QLQ-C3024, -CR2925 and –CIPN2026, Euroqol- 5 
dimensional (EQ-5D)27, Work Ability Index (WAI)28, Low Anterior Resection Syndrome 
(LARS)29, Stoma quality of life scale (SQOLS)30, Short Questionnaire to assess Health-
enhancing physical activity (SQUASH)31, Hospital Anxiety and Depression Score (HADS)32, 
multidimensional fatigue score (MFI-20)33 and the Self-administered Comorbidity 
Questionnaire (SCQ)34. Patients have the option to fill out paper questionnaires, or use 
the digital patient tracking system PROFILES (Patient Reported Outcomes Following Initial 
Long term treatment and Survivor Ship).35 Questionnaires are provided at enrolment 
(baseline) and 3, 6, 12, 18 and 24 months thereafter, followed by an annual questionnaire 
for the remainder of their participation or until death. The comprehensive selection of 
PROM questionnaires which are administered frequently at pre-defined time points 
enable the use of PROM outcomes as consistent endpoints in research. Within PROFILES, 
the option exists to compare PROMs of the PLCRC patient population to those of large 
population-based samples of cancer patients and a normative Dutch cohort.
PART D: POST-TREATMENT / FOLLOW-UP RECORD
Oncological follow-up
Recurrence*
  - Recurrence (date, number, location(s), 
  - Treatment of recurrence (new PART C entry)
  - Setting (curative/palliative)
Metastases*
  - Metachronic metastases (date, number,  
   location(s))
  - Treatment of metastases (new PART C entry)
  - Setting (curative/palliative)
Complications*
  - Grade 3/4 adverse events or complications
Survival
  - Date of last hospital visit
  - Death (including date and cause)
* Multiple entries are allowed within each tumor episode
TABLE 1. CONTINUED
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DATA FOR FUTURE STUDIES
Data collected and stored in the NKR is at all times available to centres where the 
data were originally captured. Additional data required for future research, including 
study specific data not standardly collected in the NKR, PROMs and biomaterials, is 
available upon request. 
SAFETY
The observational nature of this study eliminates the appearance of adverse events 
(AEs) and serious adverse events (SAEs) as a result of participation in this study. 
However, grade 3/4 incidents according to the Common Terminology Criteria for 
Adverse Events (CTCAE) are important outcome parameters in research, and are 
therefore systematically collected. In cohort-embedded trials, reporting of SAEs 
occurs as specified in the separate trial protocols.
PROCEEDINGS
Recruitment of patients initially started in one center in February 2013. At this first 
site, a highly dedicated patient-routine was introduced in which almost all CRC 
patients visiting the radiotherapy department were approached for participation.36 
During the observed period, 90% of all approached patients consented to inclusion, 
of whom 90% additionally consented to receive questionnaires, 83% to the storage 
of biomaterials and 85% to ‘broad consent for randomization’ in future trials. From 
September 2015 onwards, recruitment has been extended to multiple centers 
throughout The Netherlands and more centers expect to start recruitment in the 
(near) future. Currently, 8 hospitals are open for inclusion, 15 hospitals are preparing 
or awaiting IRB approval and 650 patients have been enrolled of which 160 patients 
were included over the last three months. In addition 9 cohort studies that are 
currently recruiting patients have been embedded within the PLCRC infrastructure, 
including 2 RCTs that are designed according to the cmRCT design (Table 2). For both 
RCTs inclusion rates have looked promising so far, with numbers greatly exceeding 
those of other RCTs.16,17,36 PLCRC patients may be eligible for both trials; therefore 
patients that participate in both trials are stratified according to their received neo-
adjuvant treatment as a first step to investigate the feasibility of overlapping trials 
within the cmRCT infrastructure. 
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DISCUSSION 
This multidisciplinary prospective observational cohort study provides a validated 
and standardized collection of high quality clinical data, PROMs and biomaterials of 
a large cohort of CRC patients to facilitate future basic, translational and clinical 
research. By making this collection available to researchers upon request, the cohort 
foresees in the growing need for comprehensive data collection and sharing.37 
Through its broad eligibility the cohort is likely to reach high recruitment rates, 
thereby allowing to conduct highly powered analyses, improve recruitment rates to 
trials and reduce long inclusion periods for studies that use stringent inclusion 
criteria, i.e. aim to include specific subgroups of patients. 
Over the past decades several other cancer registries and prospective observational 
cohort studies have been initiated in The Netherlands.38-41 These initiatives serve 
different purposes, such as providing insight in incidence and prevalence, in the 
effects of nutrition, lifestyle or treatments in current daily practice, or to serve as a 
platform for monitoring quality of care. Often these databases or registries are used 
for various types of research, even though they were originally not intended for this 
(specific type of research) purpose. In addition, most of these existing cohorts are 
closed cohorts, or maintain restricted inclusion criteria that limit the inclusion to 
patients with certain cancer subtypes or to patients that received certain treatment(s). 
The PLCRC initiative differs in respect to these limitations by its dynamic design, its 
unlimited accrual potential, and by allowing the inclusion of CRC patients of all stages, 
independent of their received treatments. Furthermore, some of the registries 
contain data that are provided by healthcare professionals themselves. Therefore, 
these registries may lack adequate validation and monitoring of the included data, 
which likely increases the risk of misclassification and/or underreporting of (adverse) 
outcomes. By harboring independent data managers and monitors for the PLCRC 
cohort, we attempt to limit incorrect data registration, which should improve the 
robustness of outcomes and trial results from our cohort. Finally, the PLCRC cohort 
is unique in the sense that it provides a comprehensive dataset, which includes 
aggregated high quality multidisciplinary clinical information, biomaterials and 
PROMs, and with the possibility of performing studies according to the cmRCT design. 
We acknowledge potential challenges and limitations arise from our cohort’s 
infrastructure. First, by asking informed consent we introduce the risk of selection at 
a patient level (if specific subgroups do not provide consent as much as other 
subgroups), or, in case hospitals decide not to participate, at a hospital level. However, 
since we parallel our data to data from The Netherlands cancer registry (recording 
baseline and clinical data from all histologically confirmed CRC patients in The 
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Netherlands), we are able to obtain insight in the selection that exists in our cohort 
both within and between participating and non-participating centers. Secondly, the 
cmRCT infrastructure is not appropriate for all types of research. Since experimental 
interventions are compared against standard care, the design does not allow placebo-
controlled settings or the use of non-standardly measured outcomes. Nevertheless, 
such trials can still be embedded in the cohort as classic RCTs for which the cohort can 
be used as a recruitment pool. The high participation rates, high levels of consent to 
the additional consent options and the willingness of hospitals to participate in PLCRC 
indicate that this innovative design is feasible in the oncology practice, acceptable for 
patients and healthcare professionals, facilitate research projects and is likely to 
provide generalizable results. Future results are needed to confirm whether the cmRCT 
design indeed provides an acceptable alternative for classic pragmatic RCTs.
In summary, this cohort provides a unique high-quality multidisciplinary data 
collection initiative, including biobanking and PROMs, which serves as an 
infrastructure to perform various kinds of research in the field of CRC. The set-up 
allows evaluation of long-term clinical and PROMs of patients treated in current 
routine care, and that of patients treated by experimental interventions in a 
randomized controlled setting. This comprehensive design may serve as an example 
for research in other tumor types.
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ABSTRACT
BACKGROUND
The increasing sub-classification of cancer patients due to more detailed molecular 
classification of tumors, and limitations of current trial designs, require innovative 
research designs. We present the design, governance and current standing of three 
comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and 
colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, 
tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a 
nationwide coverage, provides the infrastructure for future and novel trial designs 
and facilitates research to improve outcomes of gastrointestinal cancer patients. 
MATERIAL AND METHODS
All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer 
are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) 
biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed 
about relevant newly identified genomic aberrations; (5) collection of longitudinal 
PROs; and (6) to receive information on new interventional studies and possible 
participation in cohort multiple randomized controlled trials (cmRCT) in the future.
RESULTS
In 2015, clinical data of 21,758 newly diagnosed patients were collected in the 
Netherlands Cancer Registry. Additional clinical data on the surgical procedures were 
registered in surgical audits for 13,845 patients. Within the first two years, tumor 
tissue and blood samples were obtained from 1507 patients; during this period, 1180 
patients were included in the PRO registry. Response rate for PROs was 90%. The 
consent rate to receive information on new interventional studies and possible 
participation in cmRCTs in the future was >85%. The number of hospitals participating 
in the cohorts is steadily increasing.
CONCLUSION
A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is 
feasible and surpasses the limitations of classical study designs. With this initiative, 
novel and innovative studies can be performed in an efficient, safe, and 
comprehensive setting.
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BACKGROUND
Patients with gastrointestinal cancer are traditionally treated according to several 
clinical and histopathological characteristics (e.g., tumor location, TNM stage, tumor 
grade). However, patients with similar traditional features, undergoing similar 
treatment, may show important differences in clinical outcome.1-3 The underlying 
biological differences result in an increasing number of disease sub-classifications, 
based on efforts towards more individualized (or tailored) patient treatment.
However, due to the increasing sub-classifications of patients, there is a need for 
novel clinical trial designs and methods for data acquisition and patient recruitment. 
Current clinical trials have important limitations. First, recruitment is extremely 
restricted: only 5–10% of all patients are enrolled in a clinical trial.4 Second, clinical 
trials include only highly selected patient populations, which leads to low inclusion 
rates and further limits their external validity. Third, data collection may be 
inadequate, due to insufficient follow-up or the absence of patient-reported 
outcomes (PROs); this, in turn, results in high costs or premature termination of the 
study. Finally, clinical trials are often underpowered for post hoc subgroup analyses.4,5 
Consequently, the current clinical trial system has been described as ‘broken’, ‘in 
crisis’, and ‘not fit for purpose’.6 However, there is a paucity of data on a population 
level. Current nationwide data initiatives such as the Surveillance, Epidemiology, and 
End Results (SEER) and the Medicare database, contain selected populations and do 
not include biobanking or data on quality of life.7
In an effort to address these issues, three comprehensive nationwide cohorts of 
pancreatic, esophageal/gastric, and colorectal cancer patients were started in the 
Netherlands (the Dutch PAncreatic CAncer Project ‘PACAP’; the Prospective 
Observational Cohort study of Oesophageal-gastric cancer Patients ‘POCOP’; and the 
Prospective Dutch ColoRectal Cancer cohort ‘PLCRC’).
Collaborating as the 3P initiative, these three cohorts collect clinical data, tumor 
tissue, blood samples, and PROs of gastrointestinal cancer patients. The goal is to 
facilitate research by (inter)national research groups to improve the survival and 
quality of life of patients with one of these three cancers. The protocol of PLCRC 
(describing the practical procedures and considerations of the cohort) was previously 
published.8
We present the design, proceedings, governance, opportunities, and pitfalls of the 
three collaborating comprehensive prospective nationwide gastrointestinal cancer 
cohorts.
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MATERIAL  AND METHODS
INCLUSION AND INFORMED CONSENT
All patients aged ≥18 years with pancreatic, esophageal/gastric, or colorectal cancer 
are eligible. Excluded from participation are patients with mental incompetence or 
insufficient understanding of the Dutch language to provide informed consent. 
Patients are asked to sign a multi-source informed consent including the following 
components: (1) reuse of clinical data from all medical files; (2) tissue sampling; (3) 
blood sampling; (4) to be informed about relevant newly identified genomic 
aberrations; (5) PROs; and (6) receiving information on new interventional studies 
and possible participation in cohort multiple randomized controlled trials (cmRCT) 
in the future. Patients can provide written informed consent for each component 
separately, and may alter or retract consent for each component at any point in time. 
As clinical data are crucial to the cohorts for obvious reasons, patients that do not 
give informed consent for this part of the study are considered ineligible.
Patients who want to consent to receiving information on new interventional studies 
in the future are informed in detail about the cmRCT design. They are informed: (i) 
that their data may be (re)used for the evaluation of new interventions offered to 
patients within the cohort; (ii) that they may in future be randomly selected for an 
experimental intervention, which they may accept or refuse at a later stage; and (iii) 
that when enrolled in the cmRCT, they cannot participate in other studies investigating 
the same intervention or outcome. This procedure is identical to current practice for 
classical RCTs. However, patients participating in one of the 3P cohorts, but who are 
not enrolled in a cmRCT, may participate in other studies (e.g., classical RCTs) outside 
of the cohorts.
CLINICAL DATA
Clinical data are obtained from the Netherlands Cancer Registry (NCR), hosted by 
the Netherlands Comprehensive Cancer Organization. The NCR contains clinical data 
from all relevant medical charts registered by trained data managers for every patient 
diagnosed with cancer in the Netherlands.9 In 2015, the item set of the NCR was 
renewed and expanded to meet the requirements of the gastrointestinal cancer 
cohorts and to facilitate research. Items focus on patient, tumor and treatment 
characteristics, adverse events, and survival. Importantly, medical files are revisited 
multiple times to ensure the registration of clinical items from diagnosis until death. 
For every new cancer patient, 200-400 clinical data items are stored in an online 
secured database using Snowmed ontologies. A collaboration between the national 
tumor working groups, research groups, and the NCR has resulted in data sharing 
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initiatives allowing data from the NCR to be merged with other databases, e.g., for 
surgical audits. In these audits, oncologic surgeons collect data for a nationwide 
auditing initiative, supervised by the Dutch Institute for Clinical Auditing (DICA).10 
Participation in these audits is mandatory for each hospital. For each surgical patient, 
an additional set of 100–150 surgical clinical data items is collected.
Importantly, according to Dutch law, collection of clinical data in the NCR and surgical 
audits does not require informed consent; patients sign informed consent for reuse 
of these data (as described above).
TISSUE AND BLOOD SAMPLES
For POCOP and PACAP, tissue and blood sampling is organized in close collaboration 
with the Parelsnoer Institute, an existing national initiative facilitating biobanking for 
17 different diseases, including esophageal/gastric and pancreatic cancer.11,12 Fresh 
frozen tumor and normal tissue samples are taken from the surgical resection 
specimen of the primary tumor. Blood samples are withdrawn before and after 
surgery.
For colorectal cancer, the Parelsnoer Institute facilitates biobanking for hereditary 
cases. Therefore, patients enrolling in PLCRC cohort can consent to tumor and tissue 
collection and biobanking separately, in order to collect biomaterial of all cases of 
colorectal cancer.8 Both fresh frozen and formalin- fixed paraffin embedded tumor 
and normal tissue samples are obtained from the surgical resection specimen of the 
primary tumor. Furthermore, blood samples may be collected as needed for specific 
study protocols. In PLCRC, the informed consent allows for the withdrawal of blood 
samples for future research questions without precisely specifying the time point of 
withdrawal, the patient population studied, and/or the specific tests that will be 
performed. There is a limit of 10 tubes per patient per year, collected only at the time 
of regular blood withdrawals. Details of the biobanking standard operating protocols 
are available in the Supplementary Materials.
PATIENT-REPORTED OUTCOMES
PROs, including health-related quality of life (HRQoL), are increasingly important 
outcomes for patients and physicians, and are also of growing interest to other 
healthcare partners. The PROs that are administered longitudinally were selected in 
close collaboration with national experts, international advisors, patients, and patient 
advocates. A core set of validated questionnaires is used to measure generic and 
disease-specific HRQoL (e.g., the EuroQol and European Organization for Research 
and Treatment of Cancer (EORTC) questionnaires).13,14 In addition, a cohort-specific 
set of questionnaires is used to measure, e.g., self-reported adverse events and work 
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productivity. The composition of questionnaires is flexible and may be altered 
depending on the inclusion of new studies.
To increase patient participation and response rates, patients may complete 
questionnaires on paper, or online (computer, tablet or smartphone). Questionnaires 
are provided by the digital tracking system Patient-Reported Outcomes Following 
Initial treatment and Long-term Evaluation of Survivorship (PROFILES), a 
noncommercial initiative with an online patient management system used to send 
online or paper PROs and automatic reminders.15
DATA ACCESS AND INTEGRATION
As mentioned, the main goal of the 3P initiative is to facilitate (inter)national research 
by collecting and sharing high quality data. Every researcher (national and 
international) can use the data and biomaterial gathered to improve the outcome 
for patients with pancreatic, esophageal/gastric, and colorectal cancer. To ensure a 
sustainable and secure use of the data, a procedure to evaluate requests to access 
the data is in place (see: ‘Governance’ below). Furthermore, participating centers may 
at any time request data of patients enrolled at their own center. Besides the 
evaluation of the request, a generic and easy-to-use information technology (IT) 
infrastructure to facilitate the actual use of data is essential. The IT backbone of the 
three cohorts is based on the FAIR (Findable, Accessible, Interoperable, and Reusable) 
principles16 and has been created in close collaboration with national and international 
research initiatives, such as the Dutch national node of the Biobanking and 
BioMolecular resources Research Infrastructure (BBMRI), Dutch Translational 
Research IT (TraIT), and the AACR (American Association for Cancer Research) project 
‘Genomics, Evidence, Neoplasia, Information, Exchange’ (GENIE). As mentioned, the 
different data types are gathered through existing best practices (e.g., NCR, PROFILES). 
These data are combined using an IT solution in which the data types are matched 
through a unique study registration (USR) number which is assigned to each patient 
at enrollment. A separate enrollment log, only containing USR numbers with 
corresponding patient identifiers (name, date of birth, gender and date of inclusion), 
is stored on a different secured server to secure patients’ identity. Data from the 
different sources are regularly added using data dumps. In the future, the databases 
can and will be enriched with data from other studies. Eventually all clinical, biological, 
and PROs data are integrated and made accessible in a secure way. This allows 
(among other tasks) to scrutinize the data for selection bias of the informed consent 
components, and attrition or responder bias in patients that did respond compared 
with those who did not respond to the PROs.
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STATISTICAL ANALYSIS
Data were analyzed using IBM SPSS statistics version 21 (IBM, Armonk, NY, USA). 
Frequency tables were provided, and categorical data were presented as frequencies 
with percentages. No comparative analyses were performed.
PROSPECTIVE STUDIES
The 3P initiative provides the infrastructure for efficient, safe and comprehensive 
clinical evaluation of new interventions for patients with pancreatic, esophageal/
gastric, and colorectal cancer based on classical observational and interventional 
clinical study designs, or on the cmRCT design (Figure 1).17 Studies based on the 
latter design can be performed because clinical data are collected for all patients 
enrolled in the cohorts, including patients who will be randomized to the standard 
of care arm and do not need to be approached for informed consent at the time of 
a new cmRCT study.
Both cmRCT and multiple simultaneous prospective observational studies can be 
performed within the cohorts, as many variables and endpoints are collected in a 
standardized way. If required, the composition of clinical data and PROs can be 
altered to accommodate prospective studies. Additionally, data from the cohorts 
may be used for studies performed outside the 3P initiative.
Because clinical data are collected for all patients enrolled in the cohorts, the cohorts 
are well suited to serve as the basis for cmRCTs.17 To enable cmRCT studies within 
the cohorts, patients are not only asked for informed consent for data collection and 
to be approached for future clinical trials, but are also specifically asked for future 
randomization according to the cmRCT design. To use the database for cmRCT to 
evaluate a new intervention, eligible patients within the cohort can be identified. A 
randomly selected subgroup will be offered the experimental intervention. The 
outcomes of these patients are compared to the routinely collected outcomes of 
eligible patients who were not randomly selected to receive the intervention (i.e., the 
control group). Patients not receiving the intervention will not be informed that they 
are serving as controls, as is explained at initial enrollment in the cohort. The 
intervention is described in a separate protocol that requires approval of the 
institutional review board. To avoid overlap with other studies, each center can decide 
if it wants to participate in a specific cmRCT. Patients who accept the intervention 
have to sign a separate informed consent.
GOVERNANCE
In order to obtain data, (inter)national researchers can file a study proposal using a 
pre-specified format which will be assessed by the appropriate tumor-specific 
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scientific committee (www.dpcg.nl, www.ducg.nl, and www.plcrc.nl). Submitted 
research proposals are then reviewed to determine feasibility and quality, and to 
ascertain possible duplicate studies. For POCOP and PACAP, study proposals that 
are approved by the scientific committee are subsequently presented to the Dutch 
Upper GI Cancer Group and the Dutch Pancreatic Cancer Group, respectively. 
Participating centers requesting data of patients enrolled at their own center can 
obtain data without following this procedure.
FIGURE 1. FLOWCHART OF THE COHORT MULTIPLE RANDOMIZED CLINICAL TRIAL (CMRCT) DESIGN
At enrollment in one of the three cohorts, patients can consent to be selected and randomized according to 
the cmRCT design. When a patient is eligible to enter a cmRCT trial, the patient is randomized. When a patient 
is randomized to the standard of care arm, no additional steps are undertaken. When a patient is randomized 
to the intervention arm, the patient is approached and offered the intervention, and signs an additional 
informed consent when participating in the trial.
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The scientific committees meet 3–4 times a year and are composed of a 
multidisciplinary team (including basic scientists, social scientists, clinicians, and 
patient advocates), representatives from all participating centers, and representatives 
of the boards of the respective research groups. The scientific committees control 
the release of clinical data, PROs, and blood or tissue samples, to various healthcare 
partners such as government and industry (Supplementary Figure 1).
FUNDING
Financial support of the 3P initiative is based on ad hoc funding and structural 
funding. Ad hoc funding consists of public funds (e.g., the Dutch Cancer Society; The 
Netherlands Organization for Health Research, and Development) and public–private 
partnerships with pharmaceutical companies. These partnerships are increasingly 
popular to create the critical mass of partners in specific areas and allow to combine 
resources, expertise and complementary skills to advance the understanding of the 
factors underlying differences in the clinical outcome. Furthermore, these 
collaborations allow to develop drugs at a (possibly) lower cost and faster rate, and 
to evaluate the cost-effectiveness of new and costly medication.18 Besides the 
financial support, the 3P initiative is also supported through data and knowledge-
sharing, and access to information technology (IT) tools.
ETHICAL CONSIDERATIONS AND PRIVACY
Studies on the three cohorts are conducted in accordance with the principles of the 
Declaration of Helsinki [64th WMA (World Medical Association) General Assembly, 
Fortaleza, Brazil, October 2013] and in accordance with the Dutch Medical Research 
Involving Human Subjects Act.
RESULTS
In 2015, clinical data of all newly diagnosed patients with gastrointestinal cancer 
were collected within the NCR including 2,284 pancreatic, 3,925 esophageal/gastric, 
and 15,549 colorectal cancer patients. Additional clinical data regarding the surgical 
procedure (registered in the surgical audit) were available for patients who underwent 
surgery: 881 (39%) pancreatic, 1244 (32%) esophageal/gastric, and 11,720 (76%) 
colorectal cancer patients. Extensive data on clinical characteristics and data 
completeness are reported elsewhere.8,19
In an increasing number of participating hospitals, the informed consent procedure 
for PACAP, POCOP, and/or PLCRC has been implemented (n = 22, n = 16, and n = 12 
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centers, respectively, as at 1 December 2016). At time of manuscript acceptance, 
informed consent to collect tumor tissue and blood samples was obtained from 538 
pancreatic, 199 esophageal/gastric, and 1,313 colorectal cancer patients. During this 
period, 309 pancreatic, 416 esophageal/gastric, and 1145 colorectal cancer patients 
were included in the PRO registry. Analysis showed that >90% of the patients who 
were informed, provided informed consent for one or more components. Of all 
patients that consented to receiving questionnaires, at baseline the response rate 
was 91%, whereas this decreased to 64% after 3 months and to 31% after 6 months.
Table 1 and Figure 2 provide overviews of patients in the clinical data collection, the 
PROs, and the biobanking initiatives per tumor type. The decrease in response rate 
over time is partly because some patients died or dropped out between the two time 
points, or had not yet reached the 3-month or 6-month time point. Of all patients 
who completed at least one questionnaire, 54% completed the questionnaires online. 
In the first 67 PACAP patients, the median completion time was 40 (IQR 30, range 
15–350) min, which was acceptable to most (70%) of the patients. Over 80% of 
patients were satisfied with the questionnaire and would participate in the cohort 
on a regular basis. In addition, most patients (80%) felt that physicians should pay 
more attention to HRQoL.
Consent to receive information about intervention studies and to participate in 
cmRCT studies in the future were provided by 94% of PACAP, 84% of POCOP, and by 
85% of PLCRC patients.
TABLE 1. NUMBER OF PATIENTS IN THE NETHERLANDS CANCER REGISTRY, SURGICAL AUDITS, PATIENT-REPORTED 
OUTCOMES REGISTRIES, AND BIOBANKING
PACAP PANCREAS POCOP 
ESOPHAGEAL/ 
GASTRIC
PLCRC COLORECTAL TOTAL
Netherlands Cancer Registrya 2,284 3,925 15,549 21,758
Surgical Audita,b 881 1,244 11,720 13,845
Biobank 538 199 1313 2,050
PROs (eligible) 309 (506) 416 (675) 1145 (1575) 2,580 (2,756)
PROs response rate,
t= 0 months
98% 95% 79%c 91%
PROs response rate,
t= 3 months
63% 73% 63%c 64%
Informed consent was obtained from all patients in the patient-reported outcomes registry and biobanking, 
as collection of clinical data does not require informed consent.
a 2015 only.
b Number of registered resections.
c Date of inclusion until 31 August 2016.
PROs: patient-reported outcomes; PACAP: Dutch PAncreatic CAncer Project; POCOP: Prospective Observational 
Cohort study of esophageal-gastric cancer Patients; PLCRC: Prospective Dutch ColoRectal Cancer cohort; 
N/A: not applicable.
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DISCUSSION
The 3P initiative provides a comprehensive, nationwide, multidisciplinary research 
infrastructure that accommodates studies on a national level, providing population-
based data. Extensive and accurate clinical data, tissue samples, blood samples, and 
PROs are collected from diagnosis until the death of patients with pancreatic, 
esophageal/gastric, and colorectal cancer after a broad-based informed consent has 
been given. The participation rate for each informed consent item was >80%, 
including consent to be informed about interventional studies and to participate in 
cmRCT studies in the future. The cohorts overcome many limitations of classical 
study designs and allow the performance of multiple concurrent studies. The 
collaborative nature of the 3P initiative combined with involvement of all relevant 
disciplines and mandated representatives of professional associations ensures a 
broad nationwide support.
Although many other clinical registries and biobank initiatives are available, only a 
few initiatives manage to combine both. The 3P initiative not only contains detailed 
longitudinal clinical data and biomaterial of patients, the PROs are collected and 
patients can easily be approached for future clinical trials. Based on collaboration 
with the NCR, which contains clinical data of all Dutch patients diagnosed with 
(pancreatic, esophageal/gastric, and colorectal) cancer, a nationwide coverage is 
ensured. Completeness of the NCR is reported to be at least 95%.20 For comparison: 
although the SEER program in the USA has greater absolute numbers, coverage is 
FIGURE 2. NUMBER OF SIGNED INFORMED CONSENTS OBTAINED, FOR THE COLLECTION OF BIOMATERIALS AND 
PROMS IN PATIENTS WITH COLORECTAL, ESOPHAGEAL/GASTRIC, AND PANCREATIC CANCER
The number of signed informed consents obtained for collection of biomaterials in patients with esophageal/
gastric cancer was not available per quarter, and is therefore depicted as a total only.
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only 28% of the total US population.7 Regarding the Nordic cancer registries 
(Denmark, Finland, Iceland, Norway, Sweden, and Faroe Islands), their national 
coverage is comparable to the NCR and is reported to be close to 100%.21 Recognizing 
the importance of PROs, Sweden has also started to collect PROs prospectively over 
time and organized by tumor type.22
In the Netherlands, considerable experience has been obtained with surgical auditing, 
leading to case ascertainments of 95%, data completeness of almost 100%, and data 
accuracy of 95–99%.10 The main equivalent for these audits is the American College 
of Surgeons National Surgical Quality Improvement Program (ACS NSQIP)23; although 
the reported completeness and accuracy is lower compared to the Dutch audits24, 
the absence of universal definitions or scoring systems hampers proper comparison. 
Therefore, a generic and easy-to-use IT infrastructure based on the FAIR (Findable, 
Accessible, Interoperable, and Reusable) principles is essential, but not easy to 
achieve.16 Until now, many integration/sharing initiatives in (translational) research 
have failed to achieve full potential. This may be due to either focusing on technology 
push without sufficient user buy-in and content, or on supplying only technical 
solutions for one individual dataset thereby creating information silos instead of 
accessible data. The Handbook for Adequate Natural Data Stewardship (HANDS) 
published by the Netherlands Federation of University Medical Centers, illustrates 
the active attitude to break down these information silos and converge the current 
(inter)national ongoing efforts.25
Continuously evolving ethical and legal changes lead to more stringent criteria, 
lengthier protocols/patient information leaflets, and more informed consents for 
the use and even (retrospective) reuse of patient data and biomaterials. Between 
1987 and 2007, the length of the informed consent documents has doubled, mostly 
due to formal components that aim to inform patients as fully as possible.26 However, 
patients who receive brief/simple documents remember the information provided 
better than those who receive detailed/ lengthy information.27 To maximize 
information retention of the informed consent procedure of the 3P initiative, 
information is provided through multiple sources including: the treating physician, 
a research nurse or physician assistant, study websites, an online patient movie, 
brochures, and small executive summary folders. Cervo et al. studied a similar 
multisource informed consent procedure and showed that these patients retain 
much more information (≥95% of the questions about the informed consent 
answered correctly)28 compared to 56-88% without the provision of multisource 
information.27
In the Netherlands, the cmRCT design complies with the laws on human medical 
research and is becoming increasingly accepted in clinical practice. Nevertheless, the 
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design and the possible future impact on patients have provoked resistance in other 
countries. Patients consenting to randomization following the cmRCT design, may 
be included in an intervention study in the future.17 Patients who consent to be 
approached for future investigations and are later selected for an cmRCT intervention 
arm, will receive additional detailed information and will be asked to sign a separate 
informed consent for the intervention. Patients in the control group previously 
consented at baseline and are fully aware that, when selected for the control group, 
they will not be informed about that particular cmRCT.
Although it remains debatable whether it is ethical not to offer the intervention to 
these (control) patients, this is no different from a classical RCT. A progressive, 
practice-changing agreement in the PLCRC cohort is that a maximum of 10 tubes 
per year may be withdrawn at regular blood withdrawals without the need to amend 
the study protocol to specify the timing, type of tube, and processing steps. This 
avoids multiple informed consents, while the assessment of study proposals from 
researchers or research groups by the tumor-specific scientific committees ensures 
scientific and ethical integrity. Although the 3P initiative has a nationwide coverage, 
intrinsic features of the study population (e.g., the distribution of age/gender/race, 
and what is considered the ‘standard of care’ in the Netherlands) may limit external 
international validity. However, the large number of included patients allows the 
selection of sufficiently large subgroups. Also, the standardized collection of data 
and biomaterials using international guidelines allows researchers to integrate data 
from multiple population-based registries, and to analyze differences in the standard 
of practice and subsequent clinical outcome.
A second limitation is that the clinical data in the NCR are only as accurate as the 
information provided in the relevant medical files. Therefore, synoptic and 
standardized reporting initiatives are ongoing.29 A third limitation (or challenge) is 
the current dependency on ad hoc funding. This may result in additional costs for 
researchers if funding is insufficient to maintain the initiative, which might raise the 
threshold for researchers to make use of the cohorts. However, since the data and 
biomaterials are shared with multiple researchers, the financial contribution per 
research protocol will (if introduced) be lower than the costs for conducting each 
protocol separately. Importantly, retrospective observational studies using the 
available data can be performed without making a financial contribution. 
Nevertheless, structural financial support is preferable to ad hoc funding, which has 
been (in part) realized through public–private partnerships. Ideally, public funds may 
redirect part of their funding towards structural funding of longitudinal research 
initiatives, or the maintenance of longitudinal research initiatives may be considered 
part of daily clinical practice and be reimbursed as such.
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CONCLUSIONS
The 3P initiative provides a comprehensive nationwide multidisciplinary research 
infrastructure to accommodate studies on a national level and complement the 
paucity of population based data. Three nationwide comprehensive cohorts for 
gastrointestinal cancer combine long-term clinical data, biobank material (including 
tissue and blood), and PROs. These are implemented using available best practices, 
internationally accepted standards for data collection, and a broad multi-step 
informed consent. Funding remains a challenge. Data from this initiative are 
accessible for further (inter)national research that aims to improve health outcomes 
for pancreatic, esophageal/gastric, and colorectal cancer patients.
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SUPPLEMENTARY MATERIAL
SAMPLES COLLECTION WITHIN BIOBANKING INITIATIVES
In the Dutch Pancreas Biobank within the Parelsnoer Institute all patients with an 
indication for pancreatic surgery are included. Preoperatively, one 10 ml serum clot 
tube and one 10 EDTA plasma tube are collected. Blood is centrifuged, and serum 
and plasma are stored at -80°C in 0.5 ml aliquots. Moreover, for the purpose of DNA 
isolation, a second EDTA tube is collected preoperatively or the pellet of the first 
EDTA tube is used. At time of surgery the following samples are collected from the 
resection specimen: 2 samples of tumor tissue, 1 sample of normal pancreatic tissue 
and one sample of duodenum or spleen. If possible, also pancreatic (cyst) fluid is 
obtained. Postoperatively, one 10 ml serum clot tube and one 10 EDTA plasma tube 
are collected during the first postoperative visit to the out patients clinic, at 6 months 
and 12 months after resection, and in case of recurrence. All procedures within the 
Dutch Pancreatic and also Esophageal/Gastric Biobank are performed according to 
the Parelsnoer Institute Standard Operating Procedures (SOPs).1
SUPPLEMENTARY FIGURE 1. GOVERNANCE OF CLINICAL DATA, PATIENT-REPORTED OUTCOMES (PROS), AND TISSUE 
AND BLOOD SAMPLES
Ownership of the data remains with each individual center. All data are available to relevant stakeholders 
via an official request filed with the relevant tumor-specific scientific committee. 
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In the Dutch Esophageal/Gastric Biobank within the Parelsnoer Institute patients are 
included who undergo an upper gastrointestinal endoscopy with the taking of 
biopsies to confirm diagnosis and/or an esophagectomy or gastrectomy. During 
endoscopy, six additional biopsies are taken from the tumor for study purposes. 
Three samples are embedded in paraffin and three samples are snap frozen in 
isopentane on dry ice. Similarly, one paraffin and one snap frozen biopsy of normal 
mucosa are collected if possible. Paraffin biopsies are stored at room temperature 
and snap-frozen biopsies at −80°C. Blood samples (serum, EDTA plasma and EDTA 
blood) are preoperatively and postoperatively collected. 10 mL blood is obtained in 
order to take serum and EDTA plasma samples which are stored in 0.5 mL aliquots 
at −80°C. EDTA blood samples (10 mL) for DNA extraction, is stored after quality 
control at 4°C or lower. During surgery, six resection specimens are collected (three 
paraffin and three snap frozen in isopentane). In addition, normal tissue will be taken 
for storage. During follow-up, when biopsies are taken to histopathologically confirm 
recurrent or metastasized disease, two additional biopsies are taken for storage in 
the biobank.2 
For PLCRC, the informed consent allows for the withdrawal of blood samples for 
future research questions without specifying exactly the time point of withdrawal, 
the studied patient population, and the specific tests that will be performed. There 
is a limit of ten tubes per patient per year, collected only at the time of regular blood 
withdrawals. Details on the alliquoting, quality assurance and sampling timing is 
defined per project.
REFERENCES
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GENERAL DISCUSSION
PREVENTION AND THE DETECTION OF EARLY STAGE COLORECTAL CANCER
Over the past decades, the knowledge of the genetic basis of cancer and tumour 
biology has increased exponentially.1 In the metastatic setting, this data has translated 
to advances in patient stratification and the development of targeted therapies.2-4 
However, so far these efforts have not resulted in an effective adjuvant treatment 
of early stage colon cancer. Most recently published adjuvant trials have shown no 
benefit of targeted agents added to standard chemotherapy regimens.5-8 To date, 
the only predictive marker in early stage colon cancer is MSI, which is used to select 
patients who do not benefit from adjuvant chemotherapy.9, 10 The vast majority of 
colon cancer research is focused on metastasized disease, while only a minority is 
directed to early stage cancer. This uneven distribution of efforts may be an important 
factor in the lack of our understanding of early cancers at risk for disease recurrence. 
As an analogy, Bert Vogelstein used the focus of research in heart disease: “In 
cardiology, the focus over the past half century has been on prevention, not treating 
massive infarcts or strokes. In cancer, we’ve taken the opposite approach”.11 
Therefore, beside the current investment to optimize treatment of metastasized 
cancer disease, resources and intellectual energy should be aimed at prevention and 
early detection to detect disease when it is still at a curable stage, and optimization 
of curative treatment of early stage disease. In the Netherlands, the introduction of 
the Dutch bowel cancer screening program in 2014 is an important step towards 
early detection of (pre)malignant colorectal lesions. In the first year of the screening 
program, over 20,000 premalignant lesions and almost 2,500 cancers were detected 
in a cohort of roughly 865,000 individuals.12 The early detection of (pre)malignant 
lesions will increase the proportion of patients who can be treated with curative 
intent using minimally invasive techniques such as endoscopic mucosal resection, 
laparoscopic bowel resection and transanal resection by endoscopic microsurgery. 
PATIENT STRATIFICATION IN EARLY STAGE COLORECTAL CANCER
The expected shift towards earlier stages of colorectal cancer adds to the need for 
reliable criteria to identify which patients are at risk to develop recurrence of disease 
and which patients will benefit from (neo)adjuvant therapy. A deeper understanding 
of the key features of a tumour that define the clinical course of the disease is an 
important step towards the optimization of patient selection. However, the 
interpretation of the numerous biomarkers that are published must be done carefully 
keeping two important things in mind. First, associations between biomarkers and 
endpoints such as the proliferation or apoptotic rate and differentiation grade used 
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in basic research do not directly implicate a clinically relevant difference or effect in 
patients. Second, the use of heterogeneous patient cohorts in terms of clinically 
relevant features such as tumour stage and type of treatment makes it difficult to 
segregate the prognostic value of a biomarker from the prognostic value of known 
clinical/pathological features. Therefore, these kinds of studies should always be 
validated in homogeneous and clinically relevant patient cohorts. The findings in 
Chapter 4 illustrate this important issue, as the prognostic value of the CMS groups 
was less apparent in the homogeneous cohorts of lymph node negative colon cancer 
patients treated with surgery alone than in the heterogeneous cohorts used to posit 
the prognostic value of this gene signature.
Biomarkers should improve the clinical decision model to be clinically relevant. 
Therefore, comprehensive efforts are made to integrate well-defined and frequently 
recurring markers to quantify the added value to currently used decision tools. 
Recently, a multi-institutional effort to optimize prognostic stratification of stage II/
III colon cancer by integrating molecular biomarkers (MSI status and KRAS/BRAF 
mutation) with clinical and pathological features was published.13 Adding molecular 
biomarkers to a model with clinical and pathological features only marginally 
increased the performance of the model to predict overall survival in patients treated 
with adjuvant chemotherapy, while a significant increase in performance was 
observed in patients who were treated with surgery alone. Although these results 
should be interpreted with caution given the retrospective origin of most patients 
in the validation cohorts, this stratification effort has set the stage for similar efforts 
to validate these findings and come to a tailor-made treatment of patients with early 
stage colon cancer. It should be stressed that the differences in outcome underline 
the importance of validation in clinically relevant subgroups. 
It is important to note that biological features occurring even at a low frequency may 
determine the metastatic potential of cancer cells, the response to therapy or the 
prognosis of a single patient, while no effects on population level may be measured. 
For instance, RET kinase inhibitors may be very effective in patients with a tumour 
carrying a RET fusion as these tumours are pan-negative for all other known driver 
mutations (Chapter 5).14 Considerable hurdles must be overcome to implement 
technologies such as RNA sequencing to identify these low frequently occurring 
features in daily clinical practice. These hurdles include lowering the costs to 
sequence a low number of tissues and technical aspects such as sample preparation, 
benchmark standards and reproducibility.15
CONSENSUS MOLECULAR SUBTYPES
The CMS classification is currently the most robust and complete molecular 
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classification system for colorectal cancers with clear biological interpretability.16 
However, before this stratification system can be applied in a clinical setting additional 
information is needed. An important issue that should be addressed is the prognostic 
and predictive value of the CMS classification in clinically relevant subgroups, such 
as stage II and stage III colon cancer. In Chapter 4, we showed that CMS4 (the 
mesenchymal subtype) was more prevalent in advanced stages of colorectal cancer, 
and that it was associated with inadequate lymph node assessment in patients with 
stage II colon cancer. Subsequently, CMS4 only had a worse disease-free survival in 
the subgroup of patients with inadequate lymph node assessment, but did not hold 
significant prognostic value in patients in whom the number of assessed lymph nodes 
was considered adequate. Focusing on the predictive value of CMS, literature 
provides some hints. Patients with a CMS1 tumour (generally MSI and hypermutated) 
are expected not to respond to chemotherapy but may very well benefit from 
immunotherapy, as MSI predicted response to immunotherapy in patients with 
heavily pre-treated metastasised colorectal cancer. 2, 9, 10 Furthermore, patients with 
a CMS2 tumour were shown to be responsive to Oxaliplatin in a multi-agent regimen 
while mesenchymal tumours (CMS4) did not response to chemotherapy.17, 18 However, 
future studies should be conducted to show a solid response monitoring per subtype 
given the retrospective nature of these studies and the fact that differences in 
prognosis and response to therapy are difficult to segregate in these patients. The 
CONNECTION-consortium (a nation-wide Colon Cancer Registry and Stratification 
effort) will initiate such a study on the role of subtypes on therapy response in a 
novel neoadjuvant setting to determine therapy efficacy on the individual subtypes. 
A second essential step towards the clinical application of CMS is the development 
of a ‘CMS test’, which can reliably distinguish the four different subtypes. The current 
gold standard to determine CMS is Affymetrix Array on fresh frozen samples, which 
is impractical, costly and labour intensive. The transition from fresh frozen to 
formalin-fixed paraffin embedded (FFPE) samples poses a real challenge as significant 
differences in Affymetrix array data between the two sample types can be expected 
and thus validation of a FFPE-based test (preferably using Affymetrix array expression 
data generated with the same FFPE sample) can prove to be difficult. Importantly, a 
‘CMS test’ should distinguish each subtype and not one subtype, as each CMS group 
is likely to require a different therapeutic approach. Two techniques that have been 
explored to develop such as test are immunohistochemical staining and polymerase 
chain reactions (PCRs), although these attempts have not yet resulted in a validated 
paraffin-based ‘CMS test’ .19, 20 Still, a ‘CMS test’ based on these techniques is most 
likely be implemented in a clinical setting as these techniques are already used by 
pathologists in daily clinical practice. 
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FUTURE PERSPECTIVES
TUMOUR HETEROGENEITY 
As in most translational research on tumour tissues, this thesis focuses on inter 
tumour heterogeneity using one sample per tumour. However, intratumoral 
heterogeneity caused by the ongoing accumulation of genetic aberrations and 
selective pressure has become increasingly apparent.21 Spatial intratumoral 
heterogeneity (i.e. the existence of multiple genetically distinct clones within one 
tumour) implies that the presence or absence of a biological feature in one sample 
may not reflect the presence or absence of that feature in all clones.21 For instance, 
a recent study showed that lymphatic and distant metastases can arise from 
independent clones within the primary tumour, which may have implication for the 
prediction of the metastatic potential of a tumour.22 In a clinical setting, patients may 
wrongfully be offered or withheld therapy if the decision is based on a single biopsy. 
Furthermore, the extent of intratumoral heterogeneity itself may be a relevant 
feature to take into account when treating and informing a patient.23 In the future, 
multiple biopsies may be needed to determine biological features with acceptable 
accuracy. The evolutionary nature of cancer (temporal intratumoral heterogeneity) 
and the subsequent emerging therapy resistance as a result of selective pressure 
has major consequences for therapy efficacy and strategy.24 The current dogma for 
the systemic treatment of cancer is to maximize cell death. However, this very 
strategy enables the outgrowth of resistant clones after eradication of treatment-
sensitive clones.25 Therefore, alternative strategies should be explored to control this 
mechanism of resistance. A possible alternative strategy is ‘adaptive therapy’, which 
aims to control the disease by allowing treatment-sensitive clones to exist at a stable 
level which in turn keep treatment-resistant clones stable as well.26 Other possibilities 
to overcome therapy-induced resistance may lie in the inhibition of clonal dispersion 
to defer the emergence of resistance and in ‘temporal collateral sensitivity’, a 
transient state of the tumour during the development of resistance in which the 
tumour is (more) vulnerable to therapy.27 
LIQUID BIOPSIES
The above-mentioned tumour heterogeneity encountered when using tumour 
biopsies has pushed research to develop new strategies to gain insight in the 
molecular tumour profile and the concurrent course of the disease. A promising 
source of biomarkers which is thought to be less sensitive to intratumoral 
heterogeneity is blood withdrawal or ‘liquid biopsies’. Since the discovery of cell-free 
DNA in blood in 1948, numerous efforts have tried to harness liquid biopsies focusing 
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on circulating tumour cells, exosomes and circulating tumour DNA (ctDNA).28 An 
important study of stage II colon cancer patients demonstrated that ctDNA analysis 
of blood samples taken after radical surgery can be used to define a population at 
very high risk of recurrence.29 The MEDOCC-project, a collaboration between Dutch 
institutes with the John’s Hopkins hospital aims to validate these findings in a large 
cohort of stage II colon cancer patients. In the future, patients with ctDNA after radical 
surgery for non-metastasised colon cancer may be randomized between follow-up 
or adjuvant chemotherapy to assess the predictive value of ctDNA.  ctDNA analysis 
can also be used to detect recurrence of disease (possibly before a lesion is detectable 
with imaging), to evaluate a patient’s response to therapy, and to guide adaptive 
therapy approaches is also being explored.30, 31
LATERALITY
Laterality as a factor to predict prognosis and response to therapy has gained 
considerable interest. Laterality is defined as the location of the primary tumour in 
the left or right colon with the splenic flexure as the demarcation between left and 
right. Both patients with and without distant metastases and a right sided tumour 
have worse prognosis compared to patients with a left sided tumour, even when the 
primary tumour is resected. Laterality was reported to be predictive in RAS and BRAF 
wild type metastatic colorectal cancer for the response to anti-EGFR therapy.13, 32 
Furthermore, factors such as MSI, BRAF and CMS are unequally distributed between 
left and right sided tumours.16 This suggests that tumours located in the right and 
left hemi colon are two biologically separate entities, although none of the known 
biological features is observed in either left or right sided tumours. An important 
advantage of laterality to most biomarkers is the fact that the location of the primary 
tumour is known based on the preoperative colonoscopy and/or imaging. Laterality 
has been included in the most recent version of treatment guidelines, which will 
likely change the field of biomarker development. This is illustrated by the 
comprehensive analysis mentioned earlier showing that a model including amongst 
others laterality did not improve by the incorporation of MSI, KRAS and BRAF. 
( INTER)NATIONAL COHORTS TO FACILITATE RESEARCH
The progressive understanding of tumour biology will lead to increasingly complex 
sub-classifications of cancer. Novel study designs and methods for data acquisition 
as well as changes in patient recruitment are needed to facilitate basic, translational 
and clinical research in the era of personalized medicine. A single centre approach 
will not solve the problem. Larger well-organized consortia are pivotal to improve 
our insight in tumour biology and improve cancer care. In the Netherlands, the Dutch 
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Prospective ColoRectal Cancer cohort (‘PLCRC’) was initiated to answer to these needs 
in the field of colorectal cancer by gathering clinical data, biomaterial and patient 
reported outcome measures in standardized way under a broad informed consent.33, 
34 A well-built IT infrastructure to store and unlock data according to the FAIR 
principles (Findable, Accessible, Interoperable and Reusable) is key to make these 
kind of initiatives successful.35 Also, rewarding and recognizing the importance of 
data collecting and data sharing itself is important to create an incentive for 
researchers to share data. For instance, contributing ‘data authors’ could be listed 
in the primary publication, a status that should be recognized by all stakeholders 
and should be searchable in relevant sources such as Medline.36 Such an incentive 
is needed to make current efforts on data sharing successful. In the Netherlands, 
the Handbook for Adequate Natural Data Stewardship published by the Netherlands 
Federation of University Medical Centres illustrates the active attitude to break down 
information silos and converge current (inter)national ongoing efforts such as 
PLCRC.37 In the (near) future, intensified collaboration between research initiatives 
such as PLCRC, clinical audits such as the Dutch ColoRectal Audit and government 
driven programs such as the bowel cancer screening programme is key to successfully 
meet the problem of colon cancer. Furthermore, we envision that research and 
clinical practice will become an inseparable unity. Ultimately, research could be 
funded as part of the health care reimbursement system to secure structural research 
funding. With structural funding, hospitals can establish a research agency to lighten 
the load for clinicians. 
To conclude, comprehensive multi-institutional efforts are needed to determine the 
added value of the available prognostic and predictive biomarkers in light of the 
current decision models, and to identify new clinically relevant biomarkers. These 
large-scale collaborations require an open and collaborative research community, 
which in turn requires change in attitude and recognition of currently 
underappreciated efforts such as data collection across all stakeholders. The role of 
tumour heterogeneity in tumour biology and its effect on research involving single 
biopsies will become increasingly important. Biomarkers such as ctDNA analysis in 
liquid biopsies will change the landscape of the detection of early and recurrent 
disease. Finally, molecular diagnostics will help to monitor actual disease burden 
and temporal heterogeneity, leading to a better understanding of the changing face 
of cancer and enabling a more successful approach in personalized cancer treatment. 
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The research described in this thesis focuses on the identification and validation of 
molecular biomarkers to identify patients at risk of recurrence after curative surgery 
for early stage colon cancer. If we could realize to identify these patients at risk, a 
personalized approach would become more successful. 
As many hospitals contribute to the daily care of patients with colorectal cancer it is 
important to develop standard operating procedures that are applicable in all these 
institutes when studying colorectal cancer. In Chapter 2 we show that collecting high 
quality fresh frozen tissue samples of primary colorectal cancer is feasible in a 
multicentre setting. Over 90% of the tissue samples randomly selected from the 
MATCH study could be used for highly demanding techniques such as high-
throughput RNA sequencing.
RNA sequencing data must be processed by several steps including a normalization 
step before any downstream analysis can be performed. Importantly, current 
normalization methods allow either the comparison within samples or between 
samples depending on whether gene length correction is or is not applied, 
respectively. In Chapter 3, we introduce GeTMM (Gene length corrected Trimmed 
Mean of M-values), a new normalization method that combines the individual 
advantages of two normalization methods to enable the execution of comparisons 
within and between samples using the same normalized data set. The analysis 
showed that the performance of GeTMM is not affected by poor RNA quality or GC-
content. GeTMM outperforms the most commonly used normalization methods 
(EgdeR, DESeq2 and TPM) when comparing the normalized data with RT-qPCR mRNA 
expression data. Importantly, gene length correction impacted the prediction of the 
consensus molecular subtypes (CMS), an observation that should be considered 
when predicting CMS based on RNA sequencing data.
In Chapter 4 we showed that CMS4 (the mesenchymal subtype) was found to be 
more prevalent in advanced stages of colorectal cancer, and that the number of 
assessed lymph nodes was often considered too low to reliably distinguish stage II 
from stage III disease. Lymph node assessment impacted the prognostic value of 
the CMS classification in aggregated cohort of patients with stage II colon cancer who 
did not receive adjuvant chemotherapy. CMS4 had a worse DFS in patients with 
inadequate lymph node assessment, but did not hold significant prognostic value in 
patients in whom the number of assessed lymph nodes was considered adequate. 
Combined these observations suggest substantial interconnectivity between tumour 
stage and tumour biology, and suggest that the prognostic value of the CMS 
classification is dependent on the heterogeneity of tumour stage in a patient cohort.
In Chapter 5, we present a systematic analysis of pathogenically relevant oncogenic 
fusions. The analysis yielded two known BRAF fusions and one novel BRAF fusion, 
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which were mutually exclusive with BRAF mutations. The analysis yielded four other 
relevant fusions: an RRBP1-RET fusion, an EML4-NTRK3 fusion, an USP9X-ERAS fusion, 
and an EIF3E-RSPO2 fusion. The tumour that harboured the RET fusion was pan-
negative for the known driver mutations in colorectal cancer, suggesting that 
targeting the RET fusion may be very effective. The ERAS fusion was particularly 
interesting because the fusion was formed through a highly local chromothripsis 
event and because the ERAS protein normally is only expressed in embryogenic cells. 
The low frequency of R-spondin fusions in this well-defined cohort nuances the 
previously reported 10% recurrent R-spondin fusions in a smaller cohort of colorectal 
cancers. All fusions led to increased mRNA expression, and the fusions that were 
introduced in cell lines showed increased oncogenic activity, which both underlined 
the oncogenic potential of these fusions. 
Chapter 6 describes our findings on the prognostic value of SYK and more specifically 
its splice variants SYK(S) and SYK(L). The differential expression of SYK total [SYK(T)] 
and its splice variants between MSI and MSS tumours as well as between tumours 
with or without a BRAF and/or PTEN mutation suggested a different role for SYK in 
hypermutated and non-hypermutated tumours. High SYK(S) was associated with poor 
hepatic metastasis free survival in the patients with stage I-II colon cancer who were 
treated with surgery alone. Notably, the association was not confirmed in two 
independent, clinically less well-defined and smaller cohorts. Further research is 
warranted to elucidate the role of SYK and its splice variants in colorectal cancer.
In Chapter 7 we validated a metastasis-specific microRNA signature, a combination 
of let-7i and miR-10b expression, in a cohort largely identical to the cohort used in 
Chapter 7. Furthermore, we identified miR-30b as an additional prognostic marker 
and showed that adding this microRNA to the signature (modified signature) 
improved the discriminative performance in this cohort to predict metastasis-free 
survival. Additional analysis showed let-7i expression to be mainly associated with 
cell adhesion, migration and motility, and the hedgehog, Wnt and TGF-β signalling 
pathways. MiR-30b expression is associated to axon guidance. Future studies should 
be conducted to further validate the modified signature.
In Chapter 8 the outline of the Prospective Dutch ColoRectal Cancer cohort (PLCRC) 
is described. This national cohort study provides a multidisciplinary data, biobank, 
and patient-reported outcomes collection initiative to serve as an infrastructure for 
basic, translational and clinical research aiming to improve the outcome of patients 
with colorectal cancer. Clinical data are obtained from the Netherlands Cancer 
Registry, which was revisited and expanded to facilitate research. Tissue and blood 
samples are gathered in collaboration with the local pathology and chemistry labs, 
while the questionnaires are sent out and received by PROFILES, a researcher driven 
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national initiative on quality of life. Patients can optionally provide consent to tissue 
sampling and storage, blood withdrawals, receiving questionnaires on quality of life 
and being contacted for interventional studies in the future. This unique initiative 
will allow the selection of homogeneous cohorts of patients to execute studies 
focusing amongst others on the identification and validation of molecular biomarkers 
to identify patients at risk of recurrence after curative surgery for early stage colon 
cancer.
Chapter 9 describes the collaboration between PLCRC and two similar initiatives in 
the field of pancreatic (PACAP) and oesophageal/gastric cancer (POCOP): the 3P 
initiative. We underlined the importance and inevitability of intensive collaboration 
between best practices for data registration, quality of life questionnaires and IT 
research infrastructure to advance cancer research. We discussed the opportunities 
that arise from these cohorts such as the execution of studies according to innovative 
study designs like the cohort multiple randomized controlled trial. We also displayed 
the challenges we encountered when building and maintaining these initiatives such 
as structural funding and the design of a broadly supported governance structure 
that is both agile and robust. Lastly, it highlights some of the progress made in the 
first years of PLCRC such as the agreement with the institutional review board on 
the withdrawal of a maximum of 10 blood tubes for future research questions 
without further specifications to better facilitate observational studies involving, for 
instance, liquid biopsies. By realizing a shorter inclusion period of a large number of 
patients and the collection of standardized data and tissue, studies will be more 
successfully and accelerate the progress of cancer research.
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De studies in dit proefschrift richten zich op de identificatie en validatie van 
moleculaire biomarkers waarmee identificatie mogelijk is van patiënten met een 
vroeg stadium coloncarcinoom die na een curatieve resectie een hoog risico lopen 
op het ontwikkelen van recidief ziekte. Dergelijke biomarkers zullen het mogelijk 
maken om therapie op maat succesvoller toe te passen.
Darmkanker wordt in veel ziekenhuizen behandeld. Bij het doen van onderzoek naar 
darmkanker is het belangrijk om standaardprocedures te ontwikkelen die in ieder 
ziekenhuis kunnen worden toegepast. In Hoofdstuk 2 laten wij zien dat het snel 
invriezen van vers tumormateriaal in veel ziekenhuizen goed mogelijk is met behoud 
van hoogwaardige kwaliteit van het materiaal. Ruim 90% van de willekeurig 
onderzochte biopten uit het MATCH-onderzoek waren van zeer hoge kwaliteit 
waardoor het toepassen van onderzoekstechnieken zoals high throughput RNA 
sequencing mogelijk zijn.
RNA sequencing data moet volgens een aantal stappen inclusief een normalisatiestap 
worden verwerkt voordat verdere analyses kunnen worden verricht. De huidige 
normalisatiemethoden maken het mogelijk om verschillen in genexpressie binnen 
één biopt óf verschillen in genexpressie tussen biopten te onderzoeken afhankelijk 
van het wel of niet corrigeren voor genlengte. In Hoofdstuk 3 introduceren wij 
GeTMM (Gene length corrected Trimmed Mean of M-values), een nieuwe 
normalisatiemethode waarmee beide type analyses kunnen worden uitgevoerd door 
het combineren van de voordelen van twee normalisatiemethoden. De analyses 
lieten zien dat de uitkomsten van GeTMM niet worden beïnvloed door RNA kwaliteit 
of GC-inhoud. Bovendien zijn de uitkomsten beter dan de meest gebruikte 
normalisatiemethoden (EdgeR, DESeq2 en TPM), wanneer de genormaliseerde data 
vergekeken wordt met RT-qPCR expressiedata. Genlengte correctie bleek een 
belangrijke invloed te hebben op het voorspellen van de CMS classificatie, een 
belangrijke bevinding die meegewogen moet worden als CMS groepen worden 
voorspeld op basis van RNA sequencing data.
In Hoofdstuk 4 laten we zien dat  CMS4 (het mesenchymale subtype) vaker voor 
komt in meer gevorderde stadia van het colorectaal carcinoom, en dat het aantal 
onderzochte klieren in de onderzochte patiënten vaak te laag was om betrouwbaar 
stadium II van stadium III te onderscheiden. Het aantal onderzochte lymfklieren 
had invloed op de prognostische waarde van de CMS classificatie in het 
samengesteld cohort van patiënten met stadium II coloncarcinoom die geen 
adjuvante chemotherapie hebben ontvangen. CMS4 was alleen geassocieerd met 
een slechtere overleving in die patiënten waarbij te weinig klieren waren onderzocht, 
en niet in de patiënten waarbij voldoende lymfklieren onderzocht waren. De 
resultaten van dit hoofdstuk suggereren aanzienlijke verwevenheid van 
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tumorstadium en tumorbiologie, en suggereren dat de prognostische waarde van 
CMS afhankelijk is van de heterogeniteit in een patiëntencohort ten aanzien van 
tumorstadium. 
In Hoofdstuk 5 presenteren wij een systematische analyse naar pathogenetisch 
relevante oncogene fusiegenen. Hierbij werden twee bekende BRAF fusies en één 
nieuwe BRAF fusie gevonden in tumoren die geen BRAF-mutatie hadden. Daarnaast 
werden er vier andere relevante fusies gevonden: een RRBP1-RET fusie, een EML4-
NTRK3 fusie, een USP9X-ERAS fusie en een EIF3E-RSPO2 fusie. De tumor die de RET-fusie 
bevatte, had geen andere ‘driver’ mutaties waardoor de fusie een aantrekkelijk 
doelwit voor gerichte therapie is. De ERAS-fusie was interessant, omdat de fusie tot 
stand was gekomen door chromothripsis en omdat het ERAS eiwit normaal alleen 
tot expressie komt in embryonale cellen. De lage frequentie van R-spondin fusies in 
dit goed gedefinieerde patiënten cohort nuanceert de eerder gerapporteerde 
incidentie van 10% in een ander, kleiner cohort van patiënten met darmkanker. Alle 
fusies resulteerden in een verhoogde mRNA expressie, en fusies die werden 
geïntroduceerd in cellijnen lieten een verhoogde oncogene activiteit zien wat het 
oncogene potentieel van de fusies onderstreepte.
Hoofdstuk 6 beschrijft de bevindingen betreffende de prognostische waarde van 
SYK en de SYK splice varianten SYK(S) en SYK(L). De expressieverschillen tussen MSI 
en MSS tumoren, en tussen tumoren met en zonder een BRAF en/of PTEN mutatie 
suggereerde een verschillende rol voor totaal SYK [SYK(T)] en de SYK splice varianten 
in hypergemuteerde en niet-hypergemuteerde tumoren. Verder was hoge expressie 
van SYK(S) geassocieerd met een slechte levermetastasevrije overleving bij patiënten 
met stadium I-II coloncarcinoom die alleen met een operatie werden behandeld. 
Deze associatie werd niet bevestigd in twee kleinere, onafhankelijke, minder goed 
gedefinieerde cohorten. Verder onderzoek naar de rol van SYK en de splice varianten 
bij het colorectaal carcinoom is nodig.
In Hoofdstuk 7 beschrijven wij de validatie van een metastase-specifieke signatuur, 
een combinatie van Let-7i en miR-10b expressie, in een cohort dat vrijwel identiek 
was aan het cohort dat gebruikt werd in hoofdstuk 7. Daarnaast werd miR-30b 
geïdentificeerd als additionele prognostische marker. Het toevoegen van deze marker 
aan de bestaande signatuur (gemodificeerde signatuur) vergrootte het 
onderscheidend vermogen van de signatuur wat betreft de metastasevrije overleving 
in dit cohort. Een additionele analyse liet zien dat Let-7i expressie geassocieerd was 
met celadhesie, celmigratie en celmotiliteit, en met de hedgehog, Wnt en TGF-b 
signaaltransductieroutes. MiR-30b expressie was geassocieerd met axon geleiding. 
Vervolgstudies zullen moeten worden uitgevoerd om de prognostische waarde van 
de gemodificeerde signatuur te valideren.
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In hoofdstuk 8 wordt het studieprotocol van het Prospectief Landelijk ColoRectaal 
Carcinoom cohort (PLCRC) samengevat. Dit landelijke cohortonderzoek is een 
onderzoeksinitiatief dat gestructureerd data, weefsel, en patiëntrapporteerde 
uitkomsten verzameld van patiënten met een colorectaal carcinoom om de 
uitkomsten van patiënten met deze ziekte te verbeteren. De klinische data worden 
opgevraagd bij de Nederlandse kankerregistratie, die werd gereviseerd en uitgebreid 
om onderzoek te kunnen faciliteren. Het verzamelen van weefsel en bloed gebeurd 
in samenwerking met de lokale pathologie- en chemielaboratoria. De vragenlijsten 
worden uitgestuurd en ingenomen door PROFIEL, een nationaal, vanuit onderzoek 
gedreven initiatief op het gebied van kwaliteit van leven. Patiënten kunnen optioneel 
toestemming geven voor de verzameling en opslag van weefsel, bloedafnames, het 
ontvangen van vragenlijsten over kwaliteit van leven en het in de toekomst 
uitgenodigd worden voor interventiestudies. Dit unieke initiatief maakt het mogelijk 
homogene patiëntcohorten te selecteren voor bijvoorbeeld de identificatie en 
validatie van moleculaire biomarkers waarmee patiënten met een vroeg stadium 
coloncarcinoom die recidief ziekte zullen ontwikkelen na curatieve chirurgie kunnen 
worden geïdentificeerd. 
Hoofdstuk 9 beschrijft de samenwerking tussen PLCRC en twee vergelijkbare 
initiatieven op het gebied van het pancreascarcinoom (PACAP), en het slokdarm- en 
maagcarcinoom (POCOP): het 3P initiatief. In dit hoofdstuk gaven wij het belang en 
de onvermijdelijkheid aan van intensieve samenwerking tussen organisaties op het 
gebied van dataregistratie, kwaliteit van leven vragenlijsten en IT onderzoeks-
infrastructuur om kankeronderzoek te bevorderen. We bespraken de mogelijkheden 
die deze cohorten bieden zoals het uitvoeren van een onderzoek volgens innovatieve 
onderzoeksmethoden zoals het ‘cohort multiple randomized controlled trial’. 
Daarnaast bespraken we de uitdagingen zoals het verkrijgen van structurele 
financiering en het ontwerpen van een robuuste, breed ondersteunde bestuurs-
structuur die mee kan evolueren met de zich ontwikkelde platformen. Daarnaast 
werd de progressie besproken die gemaakt is in de eerste jaren van PLCRC zoals de 
overeenkomst met de METC over het afnemen van bloed om observationeel 
onderzoek waarbij bloedafnames worden gebruikt beter te faciliteren. Na het geven 
van toestemming voor PCLRC mogen er per jaar 10 buizen worden afgenomen in 
het kader van onderzoek zonder dat hiervoor opnieuw toestemming moet worden 
gevraagd bij de METC. Het 3P initiatief zal naar verwachting de inclusieperiode voor 
onderzoeken verkorten waardoor snellere resultaten worden behaald en de 
voortgang in het kankeronderzoek wordt versneld. 
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